e10vq

0000950123-11-095253.txt : 20111104 0000950123-11-095253.hdr.sgml : 20111104 20111104143032 ACCESSION NUMBER: 0000950123-11-095253 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 9 CONFORMED PERIOD OF REPORT: 20110930 FILED AS OF DATE: 20111104 DATE AS OF CHANGE: 20111104 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MELA SCIENCES, INC. /NY CENTRAL INDEX KEY: 0001051514 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 133986004 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-51481 FILM NUMBER: 111180644 BUSINESS ADDRESS: STREET 1: 50 SOUTH BUCKHOUT STREET STREET 2: SUITE 1 CITY: IRVINGTON STATE: NY ZIP: 10533 BUSINESS PHONE: 914-591-3783 MAIL ADDRESS: STREET 1: 50 SOUTH BUCKHOUT STREET STREET 2: SUITE 1 CITY: IRVINGTON STATE: NY ZIP: 10533 FORMER COMPANY: FORMER CONFORMED NAME: ELECTRO OPTICAL SCIENCES INC /NY DATE OF NAME CHANGE: 19971216 10-Q 1 y92690e10vq.htm FORM 10-Q e10vq

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q


þ		QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2011


o		TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 000 — 51481

MELA SCIENCES, INC.

(Exact name of Registrant as specified in its charter)


Delaware (State or Other Jurisdiction of Incorporation or Organization)		13-3986004 (I.R.S. Employer Identification No.)


50 South Buckhout Street, Suite 1 Irvington, New York (Address of Principal Executive offices)		10533 (Zip Code)

Registrant’s Telephone Number, including area code:
(914) 591-3783
(Former name if changed since last report)

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes þ No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of “accelerated filer” “large accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):


Large accelerated filer o	Accelerated filer þ	Non-accelerated filer o	Smaller reporting company o
		(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes þ No o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes o No þ

As of October 31, 2011: 25,262,538 shares of the Registrant’s common stock were outstanding.

MELA Sciences, Inc.
Table of Contents


	Page
PART I. FINANCIAL INFORMATION
ITEM 1. Financial Statements
Condensed Balance Sheets as of September 30, 2011 (unaudited) and December 31, 2010		2
Condensed Statements of Operations (unaudited) for the three and nine month periods ended September 30, 2011 and 2010		3
Condensed Statements of Cash Flows (unaudited) for the nine month periods ended September 30, 2011 and 2010		4
Notes to Condensed Financial Statements (unaudited)		5
ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations		14
ITEM 3. Quantitative and Qualitative Disclosures about Market Risk		20
ITEM 4. Controls and Procedures		21
PART II. OTHER INFORMATION
ITEM 1. Legal Proceedings		21
ITEM 1A. Risk Factors		22
ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds		23
ITEM 3. Defaults Upon Senior Securities		23
ITEM 4. [Reserved]		23
ITEM 5. Other Information		23
ITEM 6. Exhibits		24
SIGNATURES		25
EXHIBIT INDEX		26
EX-31.1
EX-31.2
EX-32.1
EX-101 INSTANCE DOCUMENT
EX-101 SCHEMA DOCUMENT
EX-101 CALCULATION LINKBASE DOCUMENT
EX-101 LABELS LINKBASE DOCUMENT
EX-101 PRESENTATION LINKBASE DOCUMENT

MELA SCIENCES, INC.

CONDENSED BALANCE SHEETS


	September 30,			December 31,
	2011			2010
	(unaudited)			*
ASSETS
Current Assets:
Cash and cash equivalents	$	16,999,279		$	30,520,812
Prepaid expenses and other current assets		859,708			523,672

Total Current Assets		17,858,987			31,044,484
Property and equipment, net		1,725,615			2,073,602
Patents and trademarks, net		62,183			71,108
Deferred financing costs		62,391			62,391
Other assets		586,498			337,705

Total Assets	$	20,295,674		$	33,589,290


LIABILITIES AND STOCKHOLDERS’ EQUITY

Current Liabilities:
Accounts payable	$	629,996		$	1,096,505
Accrued expenses (includes related parties of $3,755 as of September 30, 2011)		659,842			559,975
Other current liabilities		28,250			29,538

Total Current Liabilities		1,318,088			1,686,018


Long Term Liabilities:
Deferred rent		129,738			104,304

Total Long Term Liabilities		129,738			104,304

Total Liabilities		1,447,826			1,790,322


COMMITMENTS, CONTINGENCIES and LITIGATION (Note 6)

Stockholders’ Equity
Preferred stock — $.10 par value; authorized 10,000,000 shares; issued and outstanding: none
Common stock — $.001 par value; authorized 45,000,000 shares; issued and outstanding 25,262,538 shares at September 30, 2011 and December 31, 2010		25,263			25,263
Additional paid-in capital		133,827,586			130,916,326
Accumulated deficit		(115,005,001	)		(99,142,621	)

Total Stockholders’ Equity		18,847,848			31,798,968

Total Liabilities and Stockholders’ Equity	$	20,295,674		$	33,589,290


*		Derived from the audited balance sheet as of December 31, 2010

See accompanying notes to the financial statements

MELA SCIENCES, INC.

CONDENSED STATEMENTS OF OPERATIONS
(unaudited)


	Three months ended September 30,						Nine months ended September 30,
	2011			2010			2011			2010
Operating expenses:
Research and development	$	2,437,811		$	2,936,671		$	7,634,493		$	8,276,430
General and administrative		3,689,991			2,033,172			8,291,170			6,352,492

Operating loss		(6,127,802	)		(4,969,843	)		(15,925,663	)		(14,628,922	)
Interest income		10,729			9,741			45,194			13,702
Other income, net		6,419			4,998			18,089			17,521

Net loss	$	(6,110,654	)	$	(4,955,104	)	$	(15,862,380	)	$	(14,597,699	)

Basic and diluted net loss per common share	$	(0.24	)	$	(0.20	)	$	(0.63	)	$	(0.62	)


Basic and diluted weighted average number of common shares outstanding		25,262,538			25,110,970			25,262,538			23,636,446

See accompanying notes to the financial statements

MELA SCIENCES, INC.

CONDENSED STATEMENTS OF CASH FLOWS
(unaudited)


	Nine Months Ended September 30,
	2011			2010
Cash flows from operating activities:
Net loss	$	(15,862,380	)	$	(14,597,699	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		415,592			396,878
Noncash compensation		2,911,260			562,799
Gain on disposal of fixed assets					(27	)
Changes in operating assets and liabilities:
(Increase) decrease in prepaid expenses and other current assets		(336,036	)		271,806
Decrease in accounts payable and accrued expenses		(366,642	)		(1,799	)
Increase in other assets		(248,793	)		(289,705	)
Increase in deferred rent		25,434			78,228
Decrease in other current liabilities		(1,288	)		(3,559	)

Net cash used in operating activities		(13,462,853	)		(13,583,078	)

Cash flows from investing activities:
Purchases of property and equipment		(58,680	)		(1,052,835	)
Proceeds from sale of fixed assets		—			1,500

Net cash used in investing activities		(58,680	)		(1,051,335	)

Cash flows from financing activities:
Proceeds from exercise of stock options		—			26,070
Proceeds from exercise of stock warrants					1,691,633
Proceeds from public offering					16,500,000
Expenses related to public offering		—			(1,244,329	)
Proceeds from Committed Equity Financing Facility		—			3,750,000
Expenses related to Committed Equity Financing Facility		—			(6,717	)

Net cash provided by financing activities		—			20,716,657

Net (decrease) increase in cash and cash equivalents		(13,521,533	)		6,082,244
Cash and cash equivalents at beginning of period		30,520,812			29,673,420

Cash and cash equivalents at end of period	$	16,999,279		$	35,755,664


Supplemental Schedule of Non-cash Investing and Financing Activities
Deferred financing costs charged to additional paid-in capital	$	—		$	23,179

See accompanying notes to the financial statements

MELA SCIENCES, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(In thousands, except for share and per share data)

(unaudited)

1. ORGANIZATION AND BASIS OF PRESENTATION

MELA Sciences, Inc., a Delaware corporation (the “Company”), is a medical device company focused on the design, development and commercialization of a non-invasive, point-of-care (in the doctor’s office) instrument to aid in the detection of early melanoma. The Company’s flagship product, MelaFind^®, features a hand-held imaging device that emits light of multiple wavelengths to capture images of suspicious pigmented skin lesions and extract data. The data are then analyzed utilizing image processing classification algorithms, ‘trained’ on our proprietary database of melanomas and benign lesions, to provide information to assist in the management of the patient’s disease, including information useful in the decision of whether to biopsy the lesion.

The components of the MelaFind^® system include:

•		a hand-held imaging device, which employs high precision optics and multi-spectral illumination (multiple colors of light including near infra-red);

•		a proprietary database of pigmented skin lesions, which we believe to be the largest in the U.S.; and


•		lesion classifiers, which are sophisticated mathematical algorithms that extract lesion feature information and classify lesions.

On November 1, 2011, the Company received written approval from the U.S. Food and Drug Administration (“FDA”) of the Company’s MelaFind^® Pre-Market Approval (“PMA”) application.

The MelaFind^® PMA was submitted to the FDA in June 2009, and had been granted expedited review by the FDA. A pivotal trial conducted to establish the safety and effectiveness of MelaFind^® was performed under the auspices of a binding Protocol Agreement; all study end points were met. The results of the pivotal study were published in the Archives of Dermatology in October 2010 (on-line) and February 2011 (print). The PMA application for MelaFind^® was reviewed by the FDA’s General and Plastic Surgery Devices Panel (“Panel”) in November of 2010. The Panel voted favorably on all three questions posed by the FDA.

In February 2011, the Company submitted a PMA amendment containing a revised ‘indications for use’ statement limiting MelaFind^® to use by dermatologists, based on discussions that ensued during the Panel meeting. In May 2011, the Company filed a second PMA amendment containing a training program for clinicians, an outline of which was presented at the Panel meeting. Also in May 2011, the Company submitted a Citizen’s Petition to the FDA requesting that the Commissioner of the FDA enforce the binding Protocol Agreement, as well as FDA laws and regulations, in completing the review of the MelaFind^{^®}PMA.

The Company received an Approvable Letter from the FDA for the MelaFind^® PMA application on September 22, 2011. Subsequent to September 30, 2011, the Company received an Approval Letter from the FDA on November 1, 2011 approving the MelaFind^® PMA application. Based upon receipt of FDA approval of the MelaFind^® PMA application, the Company withdrew its Citizen’s Petition filed with the FDA in May 2011.

With FDA approval received, the Company plans to launch MelaFind^® commercially in the United States during the first quarter of 2012.

In August of 2011, the Company received the International Organization for Standardization (“ISO”) 13485 certification of the Company’s comprehensive management system for the design

and manufacture of medical devices. On September 6, 2011, the Company received Conformite Europeenne (“CE”) Mark approval for MelaFind^®. With CE Mark approval, the Company has the ability to market MelaFind^® to dermatologists across the European Union and in certain other countries.

The Company plans to launch MelaFind^® commercially in Germany during the first quarter of 2012.

To date the Company has not generated any revenues from MelaFind^®. The Company anticipates that it will continue to incur net losses for the foreseeable future in the development and commercialization of the MelaFind^® device. From inception, the Company financed operations primarily through the sale of convertible preferred stock and subsequently sold common stock as part of an initial public offering in October 2005, two private placements (in November 2006 and August 2007), two registered direct offerings (in August 2008 and July 2009), and pursuant to a Committed Equity Financing Facility (“CEFF”) with Kingsbridge Capital Limited in the second half of 2009 and first quarter of 2010. In addition, the Company received net proceeds of approximately $15.2 million through the sale of common stock pursuant to a public offering which closed July 6, 2010.

The Company faces certain risks and uncertainties which are present in many emerging medical device companies regarding future profitability, ability to obtain future capital, protection of patents and intellectual property rights, competition, rapid technological change, government regulations, changing health care marketplace, recruiting and retaining key personnel, and reliance on third party manufacturing organizations.

As of September 30, 2011, the Company’s total of cash and cash equivalents was approximately $17.0 million. Management believes that with FDA and CE Mark approval this cash balance will be sufficient to fund the Company’s controlled launches in the northeast U.S. and Germany and the anticipated level of operations for at least the next twelve months. However, the Company will require additional funds to achieve significant commercialization of MelaFind^®. There can be no assurances that the Company will be able to raise additional financing in the future. Additional funds may not become available on acceptable terms, and there can be no assurance that any additional funding that the Company does obtain will be sufficient to meet the Company’s needs in the long term. In the event that the Company is unable to raise additional funds, the Company has the ability and intent to reduce certain discretionary expenditures.

The unaudited condensed financial statements included herein have been prepared from the books and records of the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for reporting on Form 10-Q. The information and note disclosures normally included in complete financial statements prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) have been condensed or omitted pursuant to such rules and regulations. The interim financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2010.

The Company’s management is responsible for the financial statements included in this document. The Company’s interim financial statements are unaudited. Interim results may not be indicative of the results that may be expected for the year. However, the Company believes all adjustments considered necessary for a fair presentation of these interim financial statements have been included and are of a normal and recurring nature.

2. USE OF ESTIMATES

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires the use of estimates and assumptions by management that affect reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to stock-based compensation arrangements and accrued expenses. Actual results could differ from these estimates.

With the receipt of the PMA Approvable Letter from the FDA on September 22, 2011, the Company deemed it probable that it would subsequently receive PMA approval from the FDA for the MelaFind^® PMA application. Accordingly, $1,889 in non-cash compensation expense was recorded as of September 30, 2011 representing options on which the performance vesting milestone is related to FDA approval. Those options remain as unvested on all option tables in this report on Form 10-Q, as vesting took place at the time approval was received.

3. RECENT ACCOUNTING PRONOUNCEMENTS

None

4. NET LOSS PER COMMON SHARE

Basic net loss per common share excludes dilution for potentially dilutive securities and is computed by dividing loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share gives effect to dilutive options, warrants and other potential common shares outstanding during the period. Diluted net loss per common share is equal to the basic net loss per common share since all potentially dilutive securities are anti-dilutive for each of the periods presented. Potential common stock equivalents excluded consist of stock options and warrants which are summarized as follows:


	September 30,
	2011		2010
Common stock options		2,126,804		2,171,273
Common stock warrants		546,781		614,906

Total		2,673,585		2,786,179

5. STOCK-BASED COMPENSATION

The Company has one stock-based compensation plan, the 2005 Stock Incentive Plan (“2005 Plan”), under which the Board of Directors may currently grant incentives to employees, consultants, directors, officers and collaborating scientists in the form of incentive stock options, nonqualified stock options and restricted stock awards. The Company also has one other stock-based compensation plan pursuant to which stock options are outstanding but from which no new grants may be made.

Stock awards under the Company’s stock option plans have been granted at prices which are no less than the market value of the stock on the date of the grant. Options granted under the 2005 Plan are generally time-based or performance-based, and vesting varies accordingly. Options under this plan expire in up to a maximum of ten years from the date of grant.

The non-cash compensation expense recognized in the Statement of Operations in the third quarter of 2011 and 2010 for stock options amounted to $2,177 (of which $2,031 relates to performance milestones) and $197 (of which $12 relates to performance milestones), respectively. With the receipt of the PMA Approvable Letter from the FDA on September 22, 2011, approval of the PMA application by the FDA was deemed by the Company to be probable and $1,889 in non-cash compensation expense was recorded in the third quarter of 2011 for options which related to the FDA approval milestone.

For the nine months ended September 2011 and 2010, non-cash compensation expense recognized in the Statement of Operations for stock options amounted to $2,911 (of which $2,059 relates to performance milestones) and $563 (of which $23 relates to performance milestones), respectively. With the receipt of the PMA Approvable Letter from the FDA on September 22, 2011, approval of the PMA application by the FDA was deemed by the Company to be probable and $1,889 in non-cash compensation expense was recorded for the nine months ended September 30, 2011 for options which related to the FDA approval milestone.

There was no cash received from options and warrants exercised under all share-based payment arrangements for the three month periods ended September 30, 2011 and 2010, nor for the nine month period ended September 30, 2011. Cash received from options and warrants exercised under all share-based payment arrangements for the nine months ended September 30, 2010 was $1,718.

The fair value of each option award granted is estimated on the date of grant using the Black-Scholes option valuation model and assumptions as noted in the following table:


	For the Nine Months	For the Nine Months
	Ended September 30, 2011	Ended September 30, 2010
Expected life	6.5 years	5-10 years
Expected volatility	70.54-76.32%	61-67%
Risk-free interest rate	1.38-3.34%	2.26-3.56%
Dividend yield	0%	0%

closing stock price. The risk-free interest rate is based on the continuous rates provided by the U.S. Treasury with a term equal to the expected life of the option. The expected dividend yield is zero as the Company has never paid dividends and does not currently anticipate paying any in the foreseeable future.

At September 30, 2011, stock options to purchase 2,126,804 shares of common stock at exercise prices ranging from $1.00 to $11.11 per share are outstanding and exercisable at various dates through 2021.

During the three months and nine months ended September 30, 2011, the weighted average fair value of options granted, estimated as of the grant date using the Black-Scholes option valuation model, was $1.61 and $2.14, respectively. For the three month and nine month periods ended September 30, 2010, the weighted average fair value of options granted was $5.03 and $4.73, respectively. For the three month and nine month periods ended September 30, 2011 and for the three months ended September 30, 2010 no options were exercised. For the nine months ended September 30, 2010 the total intrinsic value of options exercised was $18.

The status of the Company’s stock option plans at September 30, 2011 is summarized in the following table:


						Weighted
				Weighted		Average
				Average		Remaining
				Exercise		Contractual		Aggregate
	Number of			Price per		Term in		Intrinsic
	Shares			Share		Years		Value
Outstanding at December 31, 2010		2,132,879		$	5.19		5.4
Granted		496,050			3.18		9.6
Exercised		—
Forfeited or expired		(502,125	)		6.59		—

Outstanding at September 30, 2011		2,126,804		$	4.39		6.5	$	1,473


Vested and exercisable at September 30, 2011		874,041		$	4.48		5.6	$	644


			Options Outstanding
			Weighted-			Options Exercisable
			Average	Weighted				Weighted-
			Remaining	Average				Average
	Number		Contractual	Exercise		Number		Exercise
Range of Exercise Prices	Outstanding		Life	Price		Exercisable		Price
$1.00		48,952	1.2 years	$	1.00		48,952	$	1.00
$1.01-$4.50		1,635,202	7.2 years	$	3.63		620,539	$	3.67
$4.51-$11.11		442,650	4.5 years	$	7.56		204,550	$	7.79

$.01-$11.11		2,126,804	6.5 years	$	4.39		874,041	$	4.48

As of September 30, 2011, of the total 2,126,804 options outstanding, 1,252,763 have not vested. Of this total unvested amount, 914,438 options will vest upon the attainment of certain milestones, and the balance will vest over the requisite service period. The weighted average vesting period for the non-milestone, non-vested awards not yet recognized is 1.9 years

As of September 30, 2011, of the $1,046 total unrecognized non-cash compensation cost related to unvested options, $661 is to be recognized over a period to be determined by performance-based milestones, and $385 is to be recognized over the requisite service period through 2015.

As of September 30, 2011, there were 1,629,264 shares available for future grants under the Company’s 2005 Plan.

6. COMMITMENTS, CONTINGENCIES AND LITIGATION

The Company is obligated under a non-cancelable operating lease for office, lab, and assembly space expiring December 2016. The lease is subject to escalations for increases in operating expenses. The approximate aggregate minimum future payments due under this lease at September 30, 2011 are as follows:


2011 Remaining three months	$	95
2012		410
2013		439
2014		456
2015		455
2016		456

	$	2,311

Rental payments are recognized as rent expense on a straight-line basis over the term of the lease.

ASKION GmbH (“ASKION”), located in Gera, Germany, which specializes in precision optics, is an integral member of the MelaFind^® development team and the Company expects to continue to work with ASKION for the foreseeable future. ASKION produced the MelaFind^® hand-held imaging devices used in our pivotal clinical trials and is currently building additional units and performing other developmental activities under production and R&D contracts.

The Company, primarily through ASKION, engages Carl Zeiss Jena GmbH (“Zeiss”) to build the lenses and assemblies, as well as provide certain technical consulting, for the MelaFind^® units used in the Company’s pivotal clinical trials and additional units being manufactured. This work is expected to continue for MelaFind^® units through 2012.

In April, 2011, the Company entered into a “Last Time Buy” supply agreement with Arrow Electronics, Inc. (“Arrow”), a distributor for ON Semiconductors (“ON”), pursuant to which the Company agreed to purchase complementary metal-oxide-semiconductor (“CMOS”) sensors. The CMOS sensor is a critical part of the Company’s MelaFind^® system. The Company believes that these CMOS sensors will be sufficient to meet the Company’s needs until an alternative is found.

The Company has an employment agreement with its President and Chief Executive Officer, Dr. Gulfo, which provides for an annual base salary, stock options and discretionary performance bonuses. The agreement, which provides for automatic one-year renewal terms, currently runs through the end of 2011.

On November 19, 2010, a purported securities class action complaint was filed in the U.S. District Court for the Southern District of New York, naming as defendants the Company and certain of its officers and directors, entitled Randall J. Pederson, Individually and on Behalf of All Others Similarly Situated v. MELA Sciences, Inc., Joseph V. Gulfo, Richard I. Steinhart, and Breaux Castleman, No. 7:10-cv-08774-JFM. Two similar complaints were also filed, one on December 2, 2010 and the other on January 20, 2011, in the same District Court, entitled Amy Steigman, Individually and on Behalf of All Others Similarly Situated v. MELA Sciences, Inc., Joseph V. Gulfo, Richard I. Steinhart, and Breaux Castleman, No. 7:10-cv-09024-JFM; and Martin Slove and Linda Slove, Individually and on Behalf of All Others Similarly Situated v. MELA Sciences, Inc., Joseph V. Gulfo, Richard I. Steinhart, and Breaux Castleman, No. 1:11-cv-00429-JFM. These three securities class actions were consolidated into one action on February 15, 2011, entitled In re MELA Sciences, Inc. Securities Litigation, No. 10-Civ-8774-JFM (“securities class action”). The securities class action plaintiffs assert violations of the Securities Exchange Act of 1934, alleging, among other things, that defendants made misstatements and omissions regarding the Company’s product, MelaFind^®, and its prospects for FDA approval, on behalf of stockholders who purchased the Company’s common stock during the period from February 13, 2009 through November 16, 2010, and seek unspecified damages. On May 2, 2011, the securities class action plaintiffs filed their amended consolidated complaint, alleging similar claims to their prior complaints. On July 29, 2011, defendents filed a motion to dismiss the consolidated amended complaint in its entirety. Plaintiff’s opposition to the motion to dismiss was filed on September 23, 2011. In light of the Company’s receipt of the Approvable Letter from the FDA for the MelaFind^® PMA Application on September 22, 2011, the parties filed a stipulation on October 19, 2011 in which Plaintiff stated its intention to file a motion seeking leave to amend its complaint. Defendants withdrew the outstanding motion to dismiss the current Amended Complaint without prejudice to renew it at a later date.

The Company believes that it has meritorious defenses and intends to vigorously defend against the securities class action; however, as with any litigation, we cannot predict with certainty the eventual outcome of this litigation. An adverse outcome could have a material adverse effect on our business and our business could be materially harmed.

From time to time, we may be a party to certain legal proceedings, incidental to the normal course of our business. These may include controversies relating to contract claims and employment related matters, some of which claims may be material, in which case, we will make separate disclosure as required.

7. STOCKHOLDERS’ EQUITY

On October 31, 2006, the Company entered into securities purchase agreements and a registration rights agreement with certain accredited investors for the private placement of 2,312,384 shares of the Company’s common stock and warrants to purchase up to 346,857 shares of the Company’s common stock for aggregate gross proceeds of approximately $13.2 million and net proceeds of approximately $12.5 million. Pursuant to the securities purchase agreements, for a purchase price of $5.70 each investor received one share of the Company’s common stock and a warrant to purchase 0.15 of a share of the Company’s common stock. The warrants are five-year warrants with an exercise price of $6.70 per share. In accordance with the terms of this warrant, on January 5, 2010 the Company required the holders to exercise their warrants within 30 days. As a result, warrants to purchase 173,963 shares of the Company’s common stock, representing all of the outstanding 2006 warrants, were exercised resulting in gross proceeds to the Company of $1.165 million.

On July 31, 2007, the Company entered into a securities purchase agreement and a registration rights agreement with certain accredited investors for the private placement of 2,000,178 shares of the Company’s common stock and warrants to purchase up to 500,041 shares of the Company’s common stock for aggregate gross proceeds of approximately $11.5 million and net proceeds of approximately $10.7 million. The private placement closed August 3, 2007. Pursuant to the securities purchase agreement, for a purchase price of $5.75 each investor received one share of the Company’s common stock and a warrant to purchase 0.25 of a share of common stock. The warrants are five-year warrants with an exercise price of $8.00 per share.

Pursuant to the terms of the registration rights agreements, the Company filed resale registration statements covering the shares in both private placements, including the shares issuable upon exercise of the warrants, with the SEC. In the event that the Company fails to maintain the effectiveness of these registration statements for the periods described in the registration rights agreements, the holders would be entitled to certain monetary damages.

However, the Company is not obligated to make payments in excess of 10% of the aggregate purchase price of the common shares. The Company has concluded that it is unlikely that the Company would be required to remit any payments to its investors for failing to maintain its effectiveness. The Company’s resale registration statements on Form S-3 were declared effective by the SEC on February 12, 2007 and September 11, 2007, respectively.

In June 2008, the Company filed a Form S-3 shelf registration statement for an indeterminate number of shares of common stock, warrants to purchase shares of common stock and units consisting of a combination thereof having an aggregate initial offering price not to exceed $40 million. Management utilized this shelf registration statement in August 2008 by completing a registered direct offering of 2,088,451 shares of the Company’s common stock for aggregate gross proceeds of $11.9 million ($11 million approximate net proceeds to the Company). In addition, in July 2009, management completed a registered direct offering of 2,400,000 shares of the Company’s common stock for aggregate gross proceeds of $15 million ($13.75 million approximate net proceeds to the Company). The shelf registration statement expired on July 7, 2011.

In May 2009, the Company entered into a committed equity financing facility (“CEFF”) with Kingsbridge Capital Limited, pursuant to which Kingsbridge committed to purchase from time to time at the Company’s sole discretion, up to the lesser of $45 million or 3,327,000 shares of the Company’s common stock, prior to May 7, 2012 subject to various conditions for individual sales, including dollar, timing, and trading volume limitations, a minimum market per share price, and other contractual and regulatory requirements.

There is no assurance that the Company will satisfy all the various conditions for individual sales enabling it to use all of the CEFF. In connection with this CEFF, the Company issued a 5 year warrant, exercisable as of November 7, 2009, to Kingsbridge to purchase up to 200,000 shares of the Company’s common stock at an exercise price of $11.35 per share with a Black Scholes Fair Value of $678. The issuance of this warrant was deemed to be a cost of the offering.

The Company did not sell any stock to Kingsbridge Capital Limited under the CEFF in the nine months ended September 30, 2011. Under the CEFF, during the nine month period ending September 30, 2010, the Company sold 406,744 shares of common stock to Kingsbridge Capital Limited, at an average per share price of approximately $9.22, for gross proceeds of approximately $3.75 million. A proportionate share of the CEFF originating expenses was allocated to these sales from deferred offering costs. Net of expenses, proceeds from the 2010 sales were approximately $3.727 million.

As of September 30, 2011, 1,095,315 shares of common stock remain available for sale under the CEFF, exclusive of the 200,000 outstanding warrants held by Kingsbridge. Legal, accounting, and other costs associated with this agreement approximating $62 have been deferred and will be charged to equity as a reduction of future proceeds from the CEFF or operations should management decide to abandon the CEFF.

In May 2010, the Company filed a Form S-3 shelf registration statement for an indeterminate number of shares of common stock, warrants to purchase shares of common stock and units consisting of a combination thereof having an aggregate initial offering price not to exceed $75 million. The registration statement was declared effective by the SEC on June 1, 2010. On June 30, 2010, the Company entered into an underwriting agreement, relating to the public offering of 2,200,000 shares of the Company’s common stock, at a price to the public of $7.50 per share less underwriting discounts and commissions. The common stock was offered and sold pursuant to the Company’s Prospectus dated June 1, 2010 and the Company’s Prospectus Supplement filed with the SEC on June 30, 2010, in connection with a takedown from the Company’s effective shelf registration statement that closed on July 6, 2010. The gross proceeds to the Company from the sale of the common stock totaled $16.5 million. After deducting the underwriters’ discounts and commissions and other offering expenses, net proceeds were approximately $15.2 million. Approximately $58.5 million remains available under the Company’s 2010 shelf registration statement as of September 30, 2011.

As of September 30, 2011, the Company had 45,000,000 shares of $0.001 par value common stock authorized and 25,262,538 shares issued and outstanding; and 10,000,000 shares of $0.10 par value preferred stock authorized with no preferred shares issued and outstanding.

8. WARRANTS

The status of the Company’s warrants at September 30, 2011 is summarized as follows:


	2007		2009		Total
Outstanding at December 31, 2010		346,781		200,000		546,781
Exercised		—		—		—
Forfeited		—		—		—
Expired		—		—		—

Outstanding at September 30, 2011		346,781		200,000		546,781

As previously discussed in connection with the Company’s private placement in August 2007 the Company issued warrants to purchase up to 500,041 shares of the Company’s common stock. At September 30, 2011, there were 346,781 of the 2007 warrants outstanding. The 2007 outstanding warrants are exercisable for five years at a price of $8.00 per share.

In addition, in connection with the May 7, 2009 CEFF with Kingsbridge Capital, the Company issued a 5 year warrant to Kingsbridge to purchase up to 200,000 shares of the Company’s common stock at an exercise price of $11.35 per share. This 200,000 share warrant is outstanding at September 30, 2011.

No warrants were exercised during the three and nine month periods ended September 30, 2011 and the three month period ended September 30, 2010. During the nine months ended September 30, 2010, warrants for the purchase of 263,549 shares of the Company’s common stock were exercised for total proceeds of approximately $1.7 million.

9. RELATED PARTY CONSULTING AGREEMENTS

The Company has in place the following consulting agreements with related parties:

Consulting Agreement with Breaux Castleman

In June 2003, the Company entered into a consulting agreement with Breaux Castleman, the Chairman of the Company’s Board of Directors, for consulting services related to the FDA approval of MelaFind^®, and the Company’s business and financial strategy. Under this agreement, Mr. Castleman receives compensation for each month of services rendered. The Company incurred and paid, pursuant to this consulting agreement, $6 in each of the three month periods ended September 30, 2011 and 2010 and $18 in each of the nine month periods ended September 30, 2011 and 2010. This consulting agreement is terminable by either party by providing thirty days’ prior written notice.

Consulting Agreement with Gerald Wagner, Ph.D

In January 2007, Dr. Wagner, Ph.D., a member of the Company’s Board of Directors, transitioned out of his role as the Company’s acting Chief Operating Officer and entered into an amended and restated consulting contract with the Company. Under the terms of the amended contract, Dr. Wagner is paid a monthly retainer of $2.5 and will be paid $2.5 for each additional consulting day. This amended agreement will end at the option of Dr. Wagner or the Company at any time, by providing fifteen days’ prior written notice, or immediately upon the mutual agreement of the Company and Dr. Wagner. The Company incurred consulting costs pursuant to this agreement of $7.5 in each of the three month periods ended September 30, 2011 and 2010 and $22.5 in each of the nine month periods ended September 30, 2011 and 2010.

Consulting Agreement with Anne Egger

In March 2009, the Company entered into a consulting agreement with Anne Egger for certain consulting services primarily focusing on physician advocacy. The agreement was for an initial term of three months, and has subsequently been extended to run through September 2012, and may be terminated by either party with 30 days notice. Under the terms of the agreement, Ms. Egger is entitled to receive a consulting fee of $1.6 per day. Ms. Egger was appointed to the Company’s Board of Directors as of June 10, 2009. The Company incurred consulting costs pursuant to this agreement of $2 and $10 in the three month periods ended September 30, 2011 and September 30, 2010, respectively. The Company incurred consulting costs pursuant to this agreement of $8 and $45 in the nine month periods ended September 30, 2011 and September 30, 2010, respectively

10. OTHER INCOME

During April 2005, the Company discontinued all operations associated with its DIFOTI^{^®}product in order to focus its resources and attention on the development and commercialization of MelaFind^®. During December 2006, the Company entered into a sale and exclusive licensing agreement with KaVo Dental GmbH (“KaVo”), a leading dental equipment manufacturer, which provides for KaVo to further develop and commercialize DIFOTI^®. Since July 2008, KaVo has been required to pay to the Company a royalty stream based upon the worldwide aggregate net sales of the licensed product, as defined in the license agreement, or a set minimum. For the three and nine months ended September 30, 2011, the Company earned royalty income of $5 and $15, respectively. For the three and nine months ended September 30, 2010, the Company was paid royalty income of $5 and $15, respectively.

11. COMPREHENSIVE LOSS

For the three and nine month periods ended September 30, 2011 and 2010 respectively, the Company’s comprehensive loss equaled its net loss.

12. SUBSEQUENT EVENTS

On November 1, 2011, the Company received written approval from the U.S. Food and Drug Administration of the Company’s MelaFind^® Pre-Market Approval application.

ITEM 2.

MELA SCIENCES, INC.
MANAGEMENT’S DISCUSSION AND ANALYSIS
OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This management’s discussion and analysis of financial condition and results of operations is intended to provide information to help you better understand and evaluate our financial condition and results of operations. We recommend that you read this section in conjunction with our unaudited condensed financial statements and accompanying notes included under Part I, Item 1 of this Quarterly Report and our financial statements and accompanying notes in our Annual Report on Form 10-K for the year ended December 31, 2010.

This quarterly report on Form 10-Q, including the following discussion and analysis of financial condition and results of operations, contains forward-looking statements that you should read in conjunction with the financial statements and notes to financial statements that we have included elsewhere in this report. These statements are based on our current expectations, assumptions, estimates and projections about our business and our industry, and involve known and unknown risks, uncertainties, and other factors that may cause our or our industry’s results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied in, or contemplated by, the forward-looking statements. Words such as “believe”, “anticipate”, “assuming”, “expect”, “intend”, “plan”, “will”, “may”, “should”, “estimate”, “predict”, “potential”, “continue”, “contemplate” or the negative of such terms or other similar expressions, identify forward-looking statements. Our actual results and the timing of events may differ significantly from the results discussed in the forward-looking statements, and you should not place undue reliance on these statements. Factors that might cause such a difference include those discussed below under the heading “Risk Factors,” as well as those discussed elsewhere in this quarterly report on Form 10-Q and in our annual report on Form 10-K. We disclaim any intent or obligation to update any forward-looking statements as a result of developments occurring after the period covered by this report or otherwise.

Overview

We are a medical device company focused on the design, development and commercialization of a non-invasive, point-of-care instrument to aid in the detection of early melanoma. Our flagship product, MelaFind^®, features a hand-held imaging device that emits light of multiple wavelengths to capture images of suspicious pigmented skin lesions and extract data.

We commenced operations in December 1989 as a New York corporation, re-incorporated as a Delaware corporation in September 1997, and changed our name from Electro-Optical Sciences, Inc. to MELA Sciences, Inc. on April 30, 2010. Since our inception, we have generated significant losses. As of September 30, 2011, we had an accumulated deficit of approximately $115 million. We expect to continue to spend significant amounts on the development and commercialization of MelaFind^®.

On November 1, 2011, the Company received written approval from the U.S. Food and Drug Administration of the Company’s MelaFind^® Pre-Market Approval application.

With FDA approval received, the Company plans to launch MelaFind^® commercially in the United States during the first quarter of 2012.

In August of 2011, the Company received ISO 13485 certification of the Company’s comprehensive management system for the design and manufacture of medical devices. On September 6, 2011, the Company received CE Mark approval for MelaFind^®. With CE Mark approval, the Company has the ability to market MelaFind^® to dermatologists across the European Union and in certain other countries.

The Company plans to launch MelaFind^® commercially in Germany during the first quarter of 2012.

Our revenue for the foreseeable future will depend on the acceptance of MelaFind^® by dermatologists in the U.S. and Europe and the progress of the planned controlled product launch. Revenue may vary substantially from year to year and quarter to quarter.

We believe that period-to-period comparisons of our results of operations may not be meaningful and should not be relied on as indicative of our future performance.

Liquidity and Capital Resources (in thousands)

On June 26, 2008, the Company filed a Form S-3 shelf registration statement for an indeterminate number of shares of common stock, warrants to purchase shares of common stock and units consisting of a combination thereof having an aggregate initial offering price not to exceed $40 million. Management utilized this shelf registration statement in August 2008 by completing a registered direct offering of 2,088,451 shares of the Company’s common stock for aggregate gross proceeds of approximately $11.9 million ($11 million approximate net proceeds to the Company), and in July 2009 by completing a registered direct offering of 2,400,000 shares of the Company’s common stock for aggregate gross proceeds of $15 million ($13.75 million approximate net proceeds to the Company). The shelf registration statement expired on July 7, 2011.

In May 2009, the Company entered into a committed equity financing facility (“CEFF”) with Kingsbridge Capital Limited (“Kingsbridge”), pursuant to which Kingsbridge committed to purchase from time to time at the Company’s sole discretion, up to the lesser of $45 million or 3,327,000 shares of the Company’s common stock, prior to May 7, 2012 subject to various conditions for individual sales, including dollar, timing, and trading volume limitations, a minimum market per share price, and other contractual and regulatory requirements. There is no assurance that the Company will satisfy all the various conditions for individual sales enabling it to use all of the CEFF. In connection with this CEFF, the Company issued a 5 year warrant, exercisable as of November 7, 2009, to Kingsbridge to purchase up to 200,000 shares of the Company’s common stock at an exercise price of $11.35 per share with an aggregate Black Scholes fair value of $678. The issuance of this warrant was deemed to be a cost of the offering.

The Company did not sell any stock to Kingsbridge under the CEFF in the nine months ended September 30, 2011. Under the CEFF, during the nine month period ended September 30, 2010, the Company sold 406,744 shares of common stock to Kingsbridge Capital Limited, at an average per share price of approximately $9.22, for gross proceeds of approximately $3.75 million. A proportionate share of the

CEFF originating expenses was allocated to these sales from deferred offering costs. Net of expenses, proceeds from the 2010 sales were approximately $3.727 million.

Most of our expenditures to date have been for research and development activities and general and administrative expenses. Research and development expenses represent costs incurred for product development, clinical trials, activities related to regulatory filings, and manufacturing development efforts. We expense all of our research and development costs as they are incurred.

To date, we have not borrowed (other than by issuing convertible notes, all of which have been converted into equity) or financed our operations through equipment leases, financing loans or other debt instruments.

As of September 30, 2011, the Company’s total of cash and cash equivalents was approximately $17.0 million. Management believes that with FDA and CE mark approval this cash balance will be sufficient to fund the Company’s controlled launches in the northeast U.S. and Germany and the anticipated level of operations for at least the next twelve months. However, the Company will require additional funds to achieve significant commercialization of MelaFind^®. There can be no assurances that the Company will be able to raise additional financing in the future. Additional funds may not become available on acceptable terms, and there can be no assurance that any additional funding that the Company does obtain will be sufficient to meet the Company’s needs in the long term. In the event that the Company is unable to raise additional funds, the Company has the ability and intent to reduce certain discretionary expenditures.

Our cash and cash equivalents at September 30, 2011 are liquid investments in money market accounts and deposits with commercial banks, which are held in amounts that substantially exceed FDIC limits.

Cash Flows from Operating Activities

Net cash used in operations was $13,463 for the nine months ended September 30, 2011. For the corresponding period in 2010, net cash used in operations was $13,583. In both periods, cash used in operations was attributable to net losses after an adjustment for non-cash charges related to depreciation/amortization and share-based compensation, and other changes in operating assets and liabilities.

Cash Flows from Investing Activities

For the nine months ended September 30, 2011, there was $59 net cash used in our investing activities for the purchase of fixed assets. For the corresponding period in 2010, $1,051 net cash was used in our investing activities for the purchase of fixed assets.

Cash Flows from Financing Activities

For the nine months ended September 30, 2011, no net cash was provided by or used in our financing activities. For the nine months ended September 30, 2010, net cash provided by our financing activities was $20,717, representing proceeds from the July 2010 public offering, the Committed Equity Financing Facility, as well as the exercise of options and warrants.

Operating Capital and Capital Expenditure Requirements

We face certain risks and uncertainties, which are present in many emerging medical device companies. At September 30, 2011, we had an accumulated deficit of $115 million. We have not commercialized our principal product, MelaFind^®. We anticipate that we will continue to incur net losses for the foreseeable future as we continue to develop the MelaFind^{^®}system, expand our corporate infrastructure, and prepare for the commercial launch of MelaFind^{^®}in the first quarter of 2012.

If additional funds are raised through the issuance of debt securities, these securities could have rights senior to those associated with our common stock and could contain covenants that would restrict our operations. If we are unable to obtain additional financing, we may be required to reduce the scope of, delay or eliminate some or all of planned product research and development and commercialization activities, which could harm our business.

Because of the numerous risks and uncertainties associated with the development of medical devices such as MelaFind^®, we are unable to estimate the exact amounts of capital outlays and operating expenditures associated with our current and anticipated clinical trials. Our future funding requirements will depend on many factors, including, but not limited to:

	•		The schedule, costs, and results of our future clinical trials;

	•		The success of our research and development efforts;

	•		The costs associated with maintaining regulatory approval;

	•		Reimbursement amounts for the use of MelaFind^{^®}that we are able to obtain from Medicare and third party payers;

	•		The amount of direct payments we are able to obtain from patients and/or physicians utilizing MelaFind^®;

	•		The cost of commercialization activities, including product marketing and building a domestic direct sales force;

	•		The emergence of competing or complementary technological developments;

	•		The costs of filing, prosecuting, defending and enforcing any patent claims and other rights;

	•		The costs involved in defending any patent infringement actions or other litigation claims brought against us by third parties;

	•		The costs of maintaining or potentially building our inventory and other manufacturing expenses; and

	•		Our ability to establish and maintain any collaborative, licensing or other arrangements, and the terms and timing of any such arrangements.

Contractual Obligations (in thousands)

The following table summarizes our outstanding contractual obligations as of September 30, 2011, and the effect those obligations are expected to have on our liquidity and cash flows in future periods:


			Less than						More than
	Total		1 year		1-3 years		4-5 years		5 years
Operating leases	$	2,311	$	403	$	884	$	910	$	114

Our long-term obligations represent a non-cancelable operating lease for our laboratory, assembly, and office space. The lease on approximately 20,000 square feet of space expires in December 2016.

Purchase Obligations (in thousands)

In April, 2011, the Company entered into a “Last Time Buy” supply agreement with Arrow Electronics, Inc. (“Arrow”), a distributor for ON Semiconductors (“ON”), pursuant to which the Company agreed to purchase complementary metal-oxide-semiconductor (“CMOS”) sensors. As of September 30, 2011, the Company is obligated to pay approximately $65, net per month for the next 12 months.

Results of Operations (in thousands)

Through the first nine months of 2011, the Company actively supported the FDA’s PMA review process leading to the receipt of an approval letter from the FDA on November 1, 2011, continued its efforts in Europe leading to receipt of the CE marking of MelaFind^®, continued to develop procedures and equipment to allow for the efficient manufacture of MelaFind^®, and intensified pre-commercialization activities in preparation for product launch.

Three Months Ended September 30, 2011 Compared to Three Months Ended September 30, 2010

Research and Development Expense

Research and development (“R&D”) expenses experienced an overall decrease of $499 or 17% in the three months ended September 30, 2011, as compared to the corresponding three month period a year earlier. With the receipt of the PMA Approvable Letter from the FDA on September 22, 2011, approval of the PMA application by the FDA was deemed probable by the Company and $355 in non-cash compensation expense was recorded to R&D as of September 30, 2011 for options which related to FDA approval-based performance milestones. Within R&D, offsetting expense decreases were primarily in development costs at Askion which decreased $549 as we move toward commercialization, U.S. research and development with a $95 decrease in design subcontracting and product improvements, clinical studies costs which decreased $97 and software development which had $80 less in compensation costs.

General and Administrative Expense

General and Administrative (“G&A”) expenses experienced an overall increase of $1,657 or 81% for the three months ended September 30, 2011, as compared to the corresponding three month period a year earlier. With the receipt of the PMA Approvable Letter from the FDA on September 22, 2011, approval of the PMA application by the FDA was deemed probable by the Company and $1,534 in non-cash compensation expense was recorded to G&A as of September 30, 2011 for options which related to FDA approval-based performance milestones. Also within G&A, corporate consulting and professional fees increased by $135 from the 2010 level reflecting activity associated with the continued review of the MelaFind^® PMA application along with work associated with legal actions brought against certain officers and directors of the Company.

Interest Income

Interest income for the three months ended September 30, 2011 increased to $11from $10 in the comparable period of 2010. Interest income increased as a reflection of the improvement in interest rates obtained on our cash balances.

Other Income

Other income remained essentially the same in 2011 from a year earlier.

Nine Months Ended September 30, 2011 Compared to Nine Months Ended September 30, 2010

Research and Development Expense

Research and development expenses experienced an overall decrease of $642 or 8% in the nine months ended September 30, 2011, as compared to the corresponding nine month period a year earlier. With the receipt of the PMA Approvable Letter from the FDA on September 22, 2011, approval of the PMA application by the FDA was deemed probable by the Company and $355 in non-cash compensation expense was recorded to R&D as of September 30, 2011 for options which related to FDA approval-based performance milestones. Within R&D, offsetting expense decreases were primarily in development costs at Askion which decreased $678 and U.S. research

and development with a $150 decrease in design sub-contracting and a $143 decrease in product improvement materials.

General and Administrative Expense

General and Administrative (“G&A”) expenses experienced an overall increase of $1,939 or 31% for the nine months ended September 30, 2011, as compared to the corresponding nine month period a year earlier. With the receipt of the PMA Approvable Letter from the FDA on September 22, 2011, approval of the PMA application by the FDA was deemed probable by the Company and $1,534 in non-cash compenstion expense was recorded as of September 30, 2011 for options which related to FDA approval-based performance milestones. Also within G&A, corporate consulting, professional fees and investor relations increased by $656 and legal fees increased by $196 from the 2010 level reflecting activity associated with the continued review of the MelaFind^® PMA application along with work associated with legal actions brought against certain officers and directors of the Company. These increases were partially offset by a $254 decrease in market research and reimbursement consulting and a $191 decrease in office and computer supplies and maintenance costs.

Interest Income

Interest income for the nine months ended September 30, 2011 increased to $45 from $14 in the comparable period of 2010. Interest income increased as a reflection of the improvement in interest rates obtained on our cash balances.

Other Income

Other income remained essentially the same in 2011 from a year earlier.

Critical Accounting Policies and Significant Judgments and Estimates

Our management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with generally accepted accounting principles (“GAAP”). The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate our judgments related to accounting estimates. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

We believe that the following accounting policies and significant judgments and estimates relating to revenue recognition, stock-based compensation charges, and accrued expenses are most critical to aid you in fully understanding and evaluating our reported financial results.

Revenue Recognition

We currently have not launched any commercialized products or have any significant source of revenue.

Stock-Based Compensation

The Company records compensation expense associated with stock options and other forms of equity compensation.

The Company grants to certain employees stock options that vest over a requisite service period or with the attainment of performance milestones over which the Company has control of the timing required to satisfy. A compensation charge is recorded over the service period or the probable period estimated to satisfy the performance condition. The probability of vesting is updated at each reporting period and compensation is adjusted prospectively.

The Company also grants to certain employees stock options that vest with the attainment of performance milestones over which the Company has no control of the timing required to satisfy. Upon the attainment of these performance milestones, there will be a significant compensation charge based on the fair value of such options on the date granted. With the receipt of the PMA Approvable Letter from the FDA on September 22, 2011, the Company deemed it probable that it would subsequently receive PMA approval from the FDA. Accordingly, $1,889 in non-cash compensation expense was recorded as of September 30, 2011 representing options on which the performance vesting milestone is related to FDA approval.

The Company accounts for non-employee stock-based awards in which goods or services are the consideration received for the equity instruments issued based on the fair value of the equity instruments issued.

Accrued Expenses

As part of the process of preparing financial statements, we are required to estimate accrued expenses. This process involves identifying services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for such service where we have not been invoiced or otherwise notified of the actual cost. Examples of estimated accrued expenses include:

	•		professional service fees;

	•		contract clinical service fees;

	•		fees paid to contract manufacturers in conjunction with the production of clinical components or materials; and

	•		fees paid to third party data collection organizations and investigators in conjunction with clinical trials.

In connection with such service fees, our estimates are most affected by our projections of the timing of services provided relative to the actual level of services incurred by such service providers. The majority of our service providers invoice us monthly in arrears for services performed. In the event that we do not identify certain costs that have begun to be incurred or we are under or over our estimate of the level of services performed or the costs of such services, our actual expenses could differ from such estimates. The date on which certain services commence, the level of services performed on or before a given date, and the cost of such services are often subjective determinations. We make these judgments based upon the facts and circumstances known to us in accordance with GAAP. This is done as of each balance sheet date in our financial statements.

Off-Balance Sheet Arrangements

We do not currently have, nor have we ever had, any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. In addition, we do not engage in trading activities involving non-exchange traded contracts. As such, we are not materially exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in these relationships.

Recent Accounting Pronouncements

None

ITEM 3.

Quantitative and Qualitative Disclosures about Market Risk

Our exposure to market risk is confined to our cash, cash equivalents, and short-term investments. We invest in high-quality financial instruments, primarily money market funds, with the average effective

duration of the portfolio within one year which we believe are subject to limited credit risk. We currently do not hedge interest rate exposure. Due to the short-term nature of our investments, we do not believe that we have any material exposure to interest rate risk arising from our investments. The Company is exposed to credit risks in the event of default by the financial institutions or issuers of investments in excess of FDIC insured limits. The Company performs periodic evaluations of the relative credit standing of these financial institutions and limits the amount of credit exposure with any institution.

ITEM 4.

Controls and Procedures

Evaluation of disclosure controls and procedures

Based on their evaluation as of September 30, 2011, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended, were effective to ensure that the information required to be disclosed by us in this Quarterly Report on Form 10-Q was recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and Form l0-Q, and that such information was accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Change in internal control over financial reporting

There were no changes in our internal control over financial reporting during the quarter ended September 30, 2011 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Limitations on the effectiveness of controls

Our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure control system are met. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within a company have been detected.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

Item 1A. Risk Factors

Our business and operations entail a variety of serious risks and uncertainties, including those described in Item 1A of our Form 10-K for the year ended December 31, 2010. In addition, the following risk factors have materially changed during the nine months ended September 30, 2011:

We have incurred losses for a number of years, and anticipate that we will incur continued losses for the foreseeable future.

We began operations in December 1989. At that time, we provided research services, mostly to US government agencies, on classified projects. We have financed our operations since 1999 primarily through the sale of our equity securities and have devoted substantially all of our resources to research and development relating to MelaFind^®. Our net loss for the nine months ended September 30, 2011 was approximately $15.9 million and as of September 30, 2011, we had an accumulated deficit of approximately $115 million. Our research and development expenses may continue to increase in connection with our clinical trials and other development activities related to MelaFind^®. In the process of fully commercializing MelaFind^{^®}, we expect to incur significant sales, marketing, and manufacturing expenses, which will require additional funding. As a result, we expect to continue to incur significant and increasing operating losses for the foreseeable future. These losses, among other things, have had and will continue to have an adverse effect on our stockholders’ equity.

We will not be able to achieve significant commercialization of MelaFind^® without additional funding, and may be unable to complete the development and commence commercialization of other products without additional funding.

As of September 30, 2011 we had approximately $17.0 million in cash and cash equivalents. Our operations have consumed substantial amounts of cash for each of the last nine years. We expect to continue to spend substantial amounts on research and development and we expect that our cash used by operations will increase significantly in each of the next several years. We will need additional funds to achieve significant commercialization of MelaFind^®, including development of a direct sales force and expansion of manufacturing capacity. Any additional equity financing may be dilutive to stockholders, or may require us to grant a lender a security interest in our assets. The amount of funding we will need will depend on many factors, including:

• the schedule, costs, and results of our future clinical trials;

• the success of our research and development efforts;

• the costs of maintaining regulatory approval;

• reimbursement amounts for the use of MelaFind^® that we are able to obtain from Medicare and third party payers;

• the cost of commercialization activities, including product marketing and building a domestic direct sales force;

• the amount of direct payments we are able to obtain from patients or physicians utilizing MelaFind^®;

• the emergence of competing or complementary technological developments;

• the costs of filing, prosecuting, defending and enforcing any patent claims and other rights;

• the costs involved in defending any patent infringement actions or other litigation claims brought against us by third parties;

• the costs of maintaining inventory and other manufacturing expenses; and

• our ability to establish and maintain any collaborative, licensing or other arrangements, and the terms and timing of any such arrangements.

Additional financing may not be available to us when we need it, or it may not be available on favorable terms.

If we are unable to obtain adequate financing on a timely basis, we may be required to significantly curtail or cease one or more of our development and marketing programs. We could be required to seek funds through arrangements with collaborators or others that may require us to relinquish rights to some of our technologies, product candidates or products that we would otherwise pursue on our own. We also may have to reduce marketing, customer support and other resources devoted to our products. If we raise additional funds by issuing equity securities, our then-existing stockholders will experience ownership dilution, could experience declines in our share price and the terms of any new equity securities may have preferences over our common stock

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None

Item 3. Defaults Upon Senior Securities

Not applicable.

Item 4. [Reserved]

Item 5. Other Information

(a) Not applicable

(b) Not applicable

Item 6. Exhibits


Exhibit
Number		Exhibit Title
31.1#		Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended.

31.2#		Certification of Chief Financial Officer Pursuant to Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended.

32.1#		Certification of Chief Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.1#		Interactive Data File

#		Filed herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


	MELA SCIENCES, INC.
	By:	/s/ Richard I. Steinhart
		Richard I. Steinhart
		Vice President and Chief Financial Officer (Principal Accounting and Financial Officer)

Date: November 4, 2011

EXHIBIT INDEX


Exhibit No.		Description
31.1		Certification by the Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended.

31.2		Certification by the Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) under the Securities Exchange Act of 1934, as amended.

32.1		Certification Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101.1		Interactive Data File

EX-31.1 2 y92690exv31w1.htm EX-31.1 exv31w1

Exhibit 31.1

CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER PURSUANT TO RULE 13A-14(A) or
RULE 15D-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

I, Joseph V. Gulfo, certify that:

1.		I have reviewed this report on Form 10-Q of MELA Sciences, Inc.;

2.		Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.		Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.		The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a)		designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b)		designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the financial statements for external purposes in accordance with generally accepted accounting principles;

	c)		evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d)		disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):

	a)		all significant deficiencies and material weaknesses in the design or operations of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b)		any fraud whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 4, 2011

/s/ Joseph V. Gulfo, M.D.

Joseph V. Gulfo, M.D.
President and Chief Executive Officer
(Principal Executive Officer)

EX-31.2 3 y92690exv31w2.htm EX-31.2 exv31w2

Exhibit 31.2

CERTIFICATION BY THE CHIEF FINANCIAL OFFICER PURSUANT TO RULE 13A-14(A) or
RULE 15D-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

I, Richard I. Steinhart, certify that:

1.		I have reviewed this report on Form 10-Q of MELA Sciences, Inc.;

2.		Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.		Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.		The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a)		designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b)		designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the financial statements for external purposes in accordance with generally accepted accounting principles;

	c)		evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d)		disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

	a)		all significant deficiencies and material weaknesses in the design or operations of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b)		any fraud whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 4, 2011

/s/ Richard I. Steinhart

Richard I. Steinhart
Vice President and Chief Financial Officer
(Principal Accounting and Financial Officer)

EX-32.1 4 y92690exv32w1.htm EX-32.1 exv32w1

Exhibit 32.1

MELA SCIENCES, INC.
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Each of the undersigned officers of MELA Sciences, Inc. (the “Company”) hereby certifies to his knowledge that the Company’s quarterly report on Form 10-Q for the period ended September 30, 2011 (the “Report”), as filed with the Securities and Exchange Commission on the date hereof, fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended, and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Joseph V. Gulfo

Joseph V. Gulfo
President and Chief Executive Officer
(Principal Executive Officer)

November 4,, 2011

/s/ Richard I. Steinhart

Richard I. Steinhart
Vice President & Chief Financial Officer
(Principal Accounting and Financial Officer)

November 4, 2011


*		A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to MELA Sciences, Inc. and will be retained by MELA Sciences, Inc. and furnished to the Securities and Exchange Commission or its staff upon request. This written statement accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission, and will not be incorporated by reference into any filing of MELA Sciences, Inc. under the Securities Act of 1933 or the Securities Exchange Act of 1934, irrespective of any general incorporation language contained in such filing.

EX-101.INS 5 mela-20110930.xml EX-101 INSTANCE DOCUMENT 0001051514 2011-10-31 0001051514 2010-06-30 0001051514 2011-09-30 0001051514 2010-12-31 0001051514 2011-07-01 2011-09-30 0001051514 2010-07-01 2010-09-30 0001051514 2011-01-01 2011-09-30 0001051514 2010-01-01 2010-09-30 0001051514 2009-12-31 0001051514 2010-09-30 iso4217:USD xbrli:shares xbrli:shares iso4217:USD MELA SCIENCES, INC. /NY 0001051514 --12-31 No No Yes Accelerated Filer 10-Q false 2011-09-30 Q3 2011 163015258 25262538

16999279

30520812

859708

523672

17858987

31044484

1725615

2073602

62183

71108

62391

586498

337705

20295674

33589290

629996

1096505

659842

559975

3755

28250

29538

1318088

1686018

129738

104304

129738

104304

1447826

1790322

.10

10000000

25263

.001

45000000

25262538

133827586

130916326

-115005001

-99142621

18847848

31798968

20295674

33589290

2437811

2936671

7634493

8276430

3689991

2033172

8291170

6352492

-6127802

-4969843

-15925663

-14628922

10729

9741

45194

13702

6419

4998

18089

17521

-6110654

-4955104

-15862380

-14597699

-0.24

-0.20

-0.63

-0.62

25262538 25110970 25262538 23636446

415592

396878

2911260

562799

336036

-271806

-366642

-1799

248793

289705

25434

78228

-1288

-3559

-13462853

-13583078

58680

1052835

1500

-58680

-1051335

26070

1691633

16500000

1244329

-3750000

6717

20716657

-13521533

6082244

29673420

35755664

23179

<div align="left" style="font-family: 'Times New Roman',Times,serif">   <div align="center" style="font-size: 10pt; margin-top: 0pt"><b></b> </div> <div align="left"> </div> <div align="center" style="font-size: 10pt"><b></b></div> <div align="center" style="font-size: 10pt"><b></b></div> <div align="center" style="font-size: 10pt"><b></b></div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>1. ORGANIZATION AND BASIS OF PRESENTATION</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">MELA Sciences, Inc., a Delaware corporation (the “Company”), is a medical device company focused on the design, development and commercialization of a non-invasive, point-of-care (in the doctor’s office) instrument to aid in the detection of early melanoma. The Company’s flagship product, MelaFind<sup style="font-size: 85%; vertical-align: text-top">®</sup>, features a hand-held imaging device that emits light of multiple wavelengths to capture images of suspicious pigmented skin lesions and extract data. The data are then analyzed utilizing image processing classification algorithms, ‘trained’ on our proprietary database of melanomas and benign lesions, to provide information to assist in the management of the patient’s disease, including information useful in the decision of whether to biopsy the lesion. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The components of the MelaFind<sup style="font-size: 85%; vertical-align: text-top">®</sup> system include: </div> <div style="margin-top: 6pt"> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"> <td width="2%" nowrap="nowrap" align="left"><b>•</b></td> <td width="1%"> </td> <td>a <i>hand-held imaging device</i>, which employs high precision optics and multi-spectral illumination (multiple colors of light including near infra-red);</td> </tr> <tr> <td style="font-size: 6pt"> </td> </tr> <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"> <td width="2%" nowrap="nowrap" align="left"><b>•</b></td> <td width="1%"> </td> <td>a <i>proprietary database </i>of pigmented skin lesions, which we believe to be the largest in the U.S.; and</td> </tr> </table> </div> <div style="margin-top: 6pt"> <table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; text-align: left"> <tr> <td style="font-size: 6pt"> </td> </tr> <tr valign="top" style="font-size: 10pt; color: #000000; background: transparent"> <td width="2%" nowrap="nowrap" align="left"><b>•</b></td> <td width="1%"> </td> <td><i>lesion classifiers</i>, which are sophisticated mathematical algorithms that extract lesion feature information and classify lesions. </td> </tr> </table> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">On November 1, 2011, the Company received written approval from the U.S. Food and Drug Administration (“FDA”) of the Company’s MelaFind<sup style="font-size: 85%; vertical-align: text-top">®</sup> Pre-Market Approval (“PMA”) application. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The MelaFind<sup style="font-size: 85%; vertical-align: text-top">®</sup> PMA was submitted to the FDA in June 2009, and had been granted expedited review by the FDA. A pivotal trial conducted to establish the safety and effectiveness of MelaFind<sup style="font-size: 85%; vertical-align: text-top">®</sup> was performed under the auspices of a binding Protocol Agreement; all study end points were met. The results of the pivotal study were published in the <i>Archives of Dermatology </i>in October 2010 (on-line) and February 2011 (print). The PMA application for MelaFind<sup style="font-size: 85%; vertical-align: text-top">®</sup> was reviewed by the FDA’s General and Plastic Surgery Devices Panel (“Panel”) in November of 2010. The Panel voted favorably on all three questions posed by the FDA. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">In February 2011, the Company submitted a PMA amendment containing a revised ‘indications for use’ statement limiting MelaFind<sup style="font-size: 85%; vertical-align: text-top">®</sup> to use by dermatologists, based on discussions that ensued during the Panel meeting. In May 2011, the Company filed a second PMA amendment containing a training program for clinicians, an outline of which was presented at the Panel meeting. Also in May 2011, the Company submitted a Citizen’s Petition to the FDA requesting that the Commissioner of the FDA enforce the binding Protocol Agreement, as well as FDA laws and regulations, in completing the review of the MelaFind<sup style="font-size: 85%; vertical-align: text-top"><sup style="font-size: 85%; vertical-align: text-top">®</sup> </sup>PMA. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The Company received an Approvable Letter from the FDA for the MelaFind<sup style="font-size: 85%; vertical-align: text-top">®</sup> PMA application on September 22, 2011. Subsequent to September 30, 2011, the Company received an Approval Letter from the FDA on November 1, 2011 approving the MelaFind<sup style="font-size: 85%; vertical-align: text-top">®</sup> PMA application. Based upon receipt of FDA approval of the MelaFind<sup style="font-size: 85%; vertical-align: text-top">®</sup> PMA application, the Company withdrew its Citizen’s Petition filed with the FDA in May 2011. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">With FDA approval received, the Company plans to launch MelaFind<sup style="font-size: 85%; vertical-align: text-top">®</sup> commercially in the United States during the first quarter of 2012. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">In August of 2011, the Company received the International Organization for Standardization (“ISO”) 13485 certification of the Company’s comprehensive management system for the design and manufacture of medical devices. On September 6, 2011, the Company received Conformite Europeenne (“CE”) Mark approval for MelaFind<sup style="font-size: 85%; vertical-align: text-top">®</sup>. With CE Mark approval, the Company has the ability to market MelaFind<sup style="font-size: 85%; vertical-align: text-top">®</sup> to dermatologists across the European Union and in certain other countries. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The Company plans to launch MelaFind<sup style="font-size: 85%; vertical-align: text-top">®</sup> commercially in Germany during the first quarter of 2012. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">To date the Company has not generated any revenues from MelaFind<sup style="font-size: 85%; vertical-align: text-top">®</sup>. The Company anticipates that it will continue to incur net losses for the foreseeable future in the development and commercialization of the MelaFind<sup style="font-size: 85%; vertical-align: text-top">®</sup> device. From inception, the Company financed operations primarily through the sale of convertible preferred stock and subsequently sold common stock as part of an initial public offering in October 2005, two private placements (in November 2006 and August 2007), two registered direct offerings (in August 2008 and July 2009), and pursuant to a Committed Equity Financing Facility (“CEFF”) with Kingsbridge Capital Limited in the second half of 2009 and first quarter of 2010. In addition, the Company received net proceeds of approximately $15.2 million through the sale of common stock pursuant to a public offering which closed July 6, 2010. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The Company faces certain risks and uncertainties which are present in many emerging medical device companies regarding future profitability, ability to obtain future capital, protection of patents and intellectual property rights, competition, rapid technological change, government regulations, changing health care marketplace, recruiting and retaining key personnel, and reliance on third party manufacturing organizations. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">As of September 30, 2011, the Company’s total of cash and cash equivalents was approximately $17.0 million. Management believes that with FDA and CE Mark approval this cash balance will be sufficient to fund the Company’s controlled launches in the northeast U.S. and Germany and the anticipated level of operations for at least the next twelve months. However, the Company will require additional funds to achieve significant commercialization of MelaFind<sup style="font-size: 85%; vertical-align: text-top">®</sup>. There can be no assurances that the Company will be able to raise additional financing in the future. Additional funds may not become available on acceptable terms, and there can be no assurance that any additional funding that the Company does obtain will be sufficient to meet the Company’s needs in the long term. In the event that the Company is unable to raise additional funds, the Company has the ability and intent to reduce certain discretionary expenditures. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The unaudited condensed financial statements included herein have been prepared from the books and records of the Company pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for reporting on Form 10-Q. The information and note disclosures normally included in complete financial statements prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) have been condensed or omitted pursuant to such rules and regulations. The interim financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2010. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The Company’s management is responsible for the financial statements included in this document. The Company’s interim financial statements are unaudited. Interim results may not be indicative of the results that may be expected for the year. However, the Company believes all adjustments considered necessary for a fair presentation of these interim financial statements have been included and are of a normal and recurring nature. </div> </div>

<div align="left" style="font-family: 'Times New Roman',Times,serif"> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>2. USE OF ESTIMATES</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires the use of estimates and assumptions by management that affect reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to stock-based compensation arrangements and accrued expenses. Actual results could differ from these estimates. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">With the receipt of the PMA Approvable Letter from the FDA on September 22, 2011, the Company deemed it probable that it would subsequently receive PMA approval from the FDA for the MelaFind<sup style="font-size: 85%; vertical-align: text-top">®</sup> PMA application. Accordingly, $1,889 in non-cash compensation expense was recorded as of September 30, 2011 representing options on which the performance vesting milestone is related to FDA approval. Those options remain as unvested on all option tables in this report on Form 10-Q, as vesting took place at the time approval was received. </div>   </div>  <div style="font-family: 'Times New Roman',Times,serif"> </div>

<div style="font-family: 'Times New Roman',Times,serif"> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>3. RECENT ACCOUNTING PRONOUNCEMENTS</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">None </div> </div>

<div style="font-family: 'Times New Roman',Times,serif"> <div align="left" style="font-size: 10pt; margin-top: 12pt">4<b>. NET LOSS PER COMMON SHARE</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">Basic net loss per common share excludes dilution for potentially dilutive securities and is computed by dividing loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share gives effect to dilutive options, warrants and other potential common shares outstanding during the period. Diluted net loss per common share is equal to the basic net loss per common share since all potentially dilutive securities are anti-dilutive for each of the periods presented. Potential common stock equivalents excluded consist of stock options and warrants which are summarized as follows: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">  <tr valign="bottom"> <td width="76%"> </td> <td width="5%"> </td> <td width="1%"> </td> <td width="5%"> </td> <td width="1%"> </td> <td width="5%"> </td> <td width="1%"> </td> <td width="5%"> </td> <td width="1%"> </td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td> </td> <td> </td> <td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"><b>September 30,</b></td> <td> </td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td> </td> <td> </td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2011</b></td> <td> </td> <td> </td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2010</b></td> <td> </td> </tr>   <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Common stock options </div></td> <td> </td> <td> </td> <td align="right">2,126,804</td> <td> </td> <td> </td> <td> </td> <td align="right">2,171,273</td> <td> </td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Common stock warrants </div></td> <td> </td> <td> </td> <td align="right">546,781</td> <td> </td> <td> </td> <td> </td> <td align="right">614,906</td> <td> </td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">  </div></td> <td> </td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"> </td> <td> </td> <td> </td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"> </td> <td> </td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Total </div></td> <td> </td> <td> </td> <td align="right">2,673,585</td> <td> </td> <td> </td> <td> </td> <td align="right">2,786,179</td> <td> </td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">  </div></td> <td> </td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"> </td> <td> </td> <td> </td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"> </td> <td> </td> </tr>  </table> </div> </div>

<div style="font-family: 'Times New Roman',Times,serif"> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>5. STOCK-BASED COMPENSATION</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The Company has one stock-based compensation plan, the 2005 Stock Incentive Plan (“2005 Plan”), under which the Board of Directors may currently grant incentives to employees, consultants, directors, officers and collaborating scientists in the form of incentive stock options, nonqualified stock options and restricted stock awards. The Company also has one other stock-based compensation plan pursuant to which stock options are outstanding but from which no new grants may be made. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">Stock awards under the Company’s stock option plans have been granted at prices which are no less than the market value of the stock on the date of the grant. Options granted under the 2005 Plan are generally time-based or performance-based, and vesting varies accordingly. Options under this plan expire in up to a maximum of ten years from the date of grant. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt"> The non-cash compensation expense recognized in the Statement of Operations in the third quarter of 2011 and 2010 for stock options amounted to $2,177 (of which $2,031 relates to performance milestones) and $197 (of which $12 relates to performance milestones), respectively. With the receipt of the PMA Approvable Letter from the FDA on September 22, 2011, approval of the PMA application by the FDA was deemed by the Company to be probable and $1,889 in non-cash compensation expense was recorded in the third quarter of 2011 for options which related to the FDA approval milestone. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt"> For the nine months ended September 2011 and 2010, non-cash compensation expense recognized in the Statement of Operations for stock options amounted to $2,911 (of which $2,059 relates to performance milestones) and $563 (of which $23 relates to performance milestones), respectively. With the receipt of the PMA Approvable Letter from the FDA on September 22, 2011, approval of the PMA application by the FDA was deemed by the Company to be probable and $1,889 in non-cash compensation expense was recorded for the nine months ended September 30, 2011 for options which related to the FDA approval milestone. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt"> There was no cash received from options and warrants exercised under all share-based payment arrangements for the three month periods ended September 30, 2011 and 2010, nor for the nine month period ended September 30, 2011. Cash received from options and warrants exercised under all share-based payment arrangements for the nine months ended September 30, 2010 was $1,718. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The fair value of each option award granted is estimated on the date of grant using the Black-Scholes option valuation model and assumptions as noted in the following table: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">  <tr valign="bottom"> <td width="76%"> </td> <td width="5%"> </td> <td width="1%"> </td> <td width="5%"> </td> <td width="1%"> </td> <td width="5%"> </td> <td width="1%"> </td> <td width="5%"> </td> <td width="1%"> </td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td> </td> <td> </td> <td nowrap="nowrap" align="center" colspan="2"><b>For the Nine Months</b></td> <td> </td> <td> </td> <td nowrap="nowrap" align="center" colspan="2"><b>For the Nine Months</b></td> <td> </td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td> </td> <td> </td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Ended September 30,</b> <b>2011</b></td> <td> </td> <td> </td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Ended September 30, 2010</b></td> <td> </td> </tr>   <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Expected life </div></td> <td> </td> <td colspan="3" align="center">6.5 years</td> <td> </td> <td colspan="3" align="center">5-10 years</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Expected volatility </div></td> <td> </td> <td colspan="3" align="center">70.54-76.32%</td> <td> </td> <td colspan="3" align="center">61-67%</td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Risk-free interest rate </div></td> <td> </td> <td colspan="3" align="center">1.38-3.34%</td> <td> </td> <td colspan="3" align="center">2.26-3.56%</td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Dividend yield </div></td> <td> </td> <td colspan="3" align="center">0%</td> <td> </td> <td colspan="3" align="center">0%</td> </tr>  </table> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The expected life of the options is based upon the expected time to full-vesting and term of the options. The expected volatility assumptions are determined based upon the historical volatility of the Company’s daily closing stock price. The risk-free interest rate is based on the continuous rates provided by the U.S. Treasury with a term equal to the expected life of the option. The expected dividend yield is zero as the Company has never paid dividends and does not currently anticipate paying any in the foreseeable future. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">At September 30, 2011, stock options to purchase 2,126,804 shares of common stock at exercise prices ranging from $1.00 to $11.11 per share are outstanding and exercisable at various dates through 2021. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">During the three months and nine months ended September 30, 2011, the weighted average fair value of options granted, estimated as of the grant date using the Black-Scholes option valuation model, was $1.61 and $2.14, respectively. For the three month and nine month periods ended September 30, 2010, the weighted average fair value of options granted was $5.03 and $4.73, respectively. For the three month and nine month periods ended September 30, 2011 and for the three months ended September 30, 2010 no options were exercised. For the nine months ended September 30, 2010 the total intrinsic value of options exercised was $18. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The status of the Company’s stock option plans at September 30, 2011 is summarized in the following table: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">  <tr valign="bottom"> <td width="52%"> </td> <td width="5%"> </td> <td width="1%"> </td> <td width="5%"> </td> <td width="1%"> </td> <td width="5%"> </td> <td width="1%"> </td> <td width="5%"> </td> <td width="1%"> </td> <td width="5%"> </td> <td width="1%"> </td> <td width="5%"> </td> <td width="1%"> </td> <td width="5%"> </td> <td width="1%"> </td> <td width="5%"> </td> <td width="1%"> </td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td nowrap="nowrap" align="center" colspan="2"><b>Weighted</b></td> <td> </td> <td> </td> <td nowrap="nowrap" align="center" colspan="2"> </td> <td> </td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td nowrap="nowrap" align="center" colspan="2"><b>Weighted</b></td> <td> </td> <td> </td> <td nowrap="nowrap" align="center" colspan="2"><b>Average</b></td> <td> </td> <td> </td> <td nowrap="nowrap" align="center" colspan="2"> </td> <td> </td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td nowrap="nowrap" align="center" colspan="2"><b>Average</b></td> <td> </td> <td> </td> <td nowrap="nowrap" align="center" colspan="2"><b>Remaining</b></td> <td> </td> <td> </td> <td nowrap="nowrap" align="center" colspan="2"> </td> <td> </td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td nowrap="nowrap" align="center" colspan="2"><b>Exercise</b></td> <td> </td> <td> </td> <td nowrap="nowrap" align="center" colspan="2"><b>Contractual</b></td> <td> </td> <td> </td> <td nowrap="nowrap" align="center" colspan="2"><b>Aggregate</b></td> <td> </td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td> </td> <td> </td> <td nowrap="nowrap" align="center" colspan="2"><b>Number of</b></td> <td> </td> <td> </td> <td nowrap="nowrap" align="center" colspan="2"><b>Price per</b></td> <td> </td> <td> </td> <td nowrap="nowrap" align="center" colspan="2"><b>Term in</b></td> <td> </td> <td> </td> <td nowrap="nowrap" align="center" colspan="2"><b>Intrinsic</b></td> <td> </td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td> </td> <td> </td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Shares</b></td> <td> </td> <td> </td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Share</b></td> <td> </td> <td> </td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Years</b></td> <td> </td> <td> </td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Value</b></td> <td> </td> </tr>   <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Outstanding at December 31, 2010 </div></td> <td> </td> <td> </td> <td align="right">2,132,879</td> <td> </td> <td> </td> <td align="left">$</td> <td align="right">5.19</td> <td> </td> <td> </td> <td> </td> <td align="right">5.4</td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Granted </div></td> <td> </td> <td> </td> <td align="right">496,050</td> <td> </td> <td> </td> <td> </td> <td align="right">3.18</td> <td> </td> <td> </td> <td> </td> <td align="right">9.6</td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Exercised </div></td> <td> </td> <td> </td> <td align="right">—</td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Forfeited or expired </div></td> <td> </td> <td nowrap="nowrap" align="left"> </td> <td align="right">(502,125</td> <td nowrap="nowrap">)</td> <td> </td> <td> </td> <td align="right">6.59</td> <td> </td> <td> </td> <td> </td> <td align="right">—</td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">  </div></td> <td> </td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Outstanding at September 30, 2011 </div></td> <td> </td> <td> </td> <td align="right">2,126,804</td> <td> </td> <td> </td> <td align="left">$</td> <td align="right">4.39</td> <td> </td> <td> </td> <td> </td> <td align="right">6.5</td> <td> </td> <td> </td> <td align="left">$</td> <td align="right">1,473</td> <td> </td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">  </div></td> <td> </td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">  </div></td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Vested and exercisable at September 30, 2011 </div></td> <td> </td> <td> </td> <td align="right">874,041</td> <td> </td> <td> </td> <td align="left">$</td> <td align="right">4.48</td> <td> </td> <td> </td> <td> </td> <td align="right">5.6</td> <td> </td> <td> </td> <td align="left">$</td> <td align="right">644</td> <td> </td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">  </div></td> <td> </td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr>  </table> </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">  <tr valign="bottom"> <td width="40%"> </td> <td width="5%"> </td> <td width="1%"> </td> <td width="5%"> </td> <td width="1%"> </td> <td width="5%"> </td> <td width="1%"> </td> <td width="5%"> </td> <td width="1%"> </td> <td width="5%"> </td> <td width="1%"> </td> <td width="5%"> </td> <td width="1%"> </td> <td width="5%"> </td> <td width="1%"> </td> <td width="5%"> </td> <td width="1%"> </td> <td width="5%"> </td> <td width="1%"> </td> <td width="5%"> </td> <td width="1%"> </td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td nowrap="nowrap" align="center" colspan="2"><b>Options Outstanding</b></td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td nowrap="nowrap" align="center" colspan="6"> </td> <td> </td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 0px solid #000000"><b>Weighted-</b></td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td nowrap="nowrap" align="center" colspan="6" style="border-bottom: 1px solid #000000"><b>Options Exercisable</b></td> <td> </td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td nowrap="nowrap" align="center" colspan="2"><b>Average</b></td> <td> </td> <td> </td> <td nowrap="nowrap" align="center" colspan="2"><b>Weighted</b></td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td nowrap="nowrap" align="center" colspan="2"><b>Weighted-</b></td> <td> </td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td nowrap="nowrap" align="center" colspan="2"><b>Remaining</b></td> <td> </td> <td> </td> <td nowrap="nowrap" align="center" colspan="2"><b>Average</b></td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td nowrap="nowrap" align="center" colspan="2"><b>Average</b></td> <td> </td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td> </td> <td> </td> <td nowrap="nowrap" align="center" colspan="2"><b>Number</b></td> <td> </td> <td> </td> <td nowrap="nowrap" align="center" colspan="2"><b>Contractual</b></td> <td> </td> <td> </td> <td nowrap="nowrap" align="center" colspan="2"><b>Exercise</b></td> <td> </td> <td> </td> <td nowrap="nowrap" align="center" colspan="2"><b>Number</b></td> <td> </td> <td> </td> <td nowrap="nowrap" align="center" colspan="2"><b>Exercise</b></td> <td> </td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td nowrap="nowrap" align="left" style="border-bottom: 1px solid #000000"><b>Range of Exercise Prices</b></td> <td> </td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Outstanding</b></td> <td> </td> <td> </td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Life</b></td> <td> </td> <td> </td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Price</b></td> <td> </td> <td> </td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Exercisable</b></td> <td> </td> <td> </td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Price</b></td> <td> </td> </tr>   <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">$1.00 </div></td> <td> </td> <td> </td> <td align="right">48,952</td> <td> </td> <td> </td> <td colspan="3" align="center">1.2 years</td> <td> </td> <td align="left">$</td> <td align="right">1.00</td> <td> </td> <td> </td> <td> </td> <td align="right">48,952</td> <td> </td> <td> </td> <td align="left">$</td> <td align="right">1.00</td> <td> </td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">$1.01-$4.50 </div></td> <td> </td> <td> </td> <td align="right">1,635,202</td> <td> </td> <td> </td> <td colspan="3" align="center">7.2 years</td> <td> </td> <td align="left">$</td> <td align="right">3.63</td> <td> </td> <td> </td> <td> </td> <td align="right">620,539</td> <td> </td> <td> </td> <td align="left">$</td> <td align="right">3.67</td> <td> </td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">$4.51-$11.11 </div></td> <td> </td> <td> </td> <td align="right">442,650</td> <td> </td> <td> </td> <td colspan="3" align="center">4.5 years</td> <td> </td> <td align="left">$</td> <td align="right">7.56</td> <td> </td> <td> </td> <td> </td> <td align="right">204,550</td> <td> </td> <td> </td> <td align="left">$</td> <td align="right">7.79</td> <td> </td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">  </div></td> <td> </td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">$.01-$11.11 </div></td> <td> </td> <td> </td> <td align="right">2,126,804</td> <td> </td> <td> </td> <td colspan="3" align="center">6.5 years</td> <td> </td> <td align="left">$</td> <td align="right">4.39</td> <td> </td> <td> </td> <td> </td> <td align="right">874,041</td> <td> </td> <td> </td> <td align="left">$</td> <td align="right">4.48</td> <td> </td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">  </div></td> <td> </td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> </tr>  </table> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">As of September 30, 2011, of the total 2,126,804 options outstanding, 1,252,763 have not vested. Of this total unvested amount, 914,438 options will vest upon the attainment of certain milestones, and the balance will vest over the requisite service period. The weighted average vesting period for the non-milestone, non-vested awards not yet recognized is 1.9 years </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">As of September 30, 2011, of the $1,046 total unrecognized non-cash compensation cost related to unvested options, $661 is to be recognized over a period to be determined by performance-based milestones, and $385 is to be recognized over the requisite service period through 2015. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">As of September 30, 2011, there were 1,629,264 shares available for future grants under the Company’s 2005 Plan. </div>   </div>  <div style="font-family: 'Times New Roman',Times,serif"> </div>

<div style="font-family: 'Times New Roman',Times,serif"> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>6. COMMITMENTS, CONTINGENCIES AND LITIGATION</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The Company is obligated under a non-cancelable operating lease for office, lab, and assembly space expiring December 2016. The lease is subject to escalations for increases in operating expenses. The approximate aggregate minimum future payments due under this lease at September 30, 2011 are as follows: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">  <tr valign="bottom"> <td width="88%"> </td> <td width="5%"> </td> <td width="1%"> </td> <td width="5%"> </td> <td width="1%"> </td> </tr>   <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">2011 Remaining three months </div></td> <td> </td> <td align="left">$</td> <td align="right">95</td> <td> </td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">2012 </div></td> <td> </td> <td> </td> <td align="right">410</td> <td> </td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">2013 </div></td> <td> </td> <td> </td> <td align="right">439</td> <td> </td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">2014 </div></td> <td> </td> <td> </td> <td align="right">456</td> <td> </td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">2015 </div></td> <td> </td> <td> </td> <td align="right">455</td> <td> </td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">2016 </div></td> <td> </td> <td> </td> <td align="right">456</td> <td> </td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">  </div></td> <td> </td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"> </td> <td> </td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">  </div></td> <td> </td> <td align="left">$</td> <td align="right">2,311</td> <td> </td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">  </div></td> <td> </td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"> </td> <td> </td> </tr>  </table> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">Rental payments are recognized as rent expense on a straight-line basis over the term of the lease. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">ASKION GmbH (“ASKION”), located in Gera, Germany, which specializes in precision optics, is an integral member of the MelaFind<sup style="font-size: 85%; vertical-align: text-top">®</sup> development team and the Company expects to continue to work with ASKION for the foreseeable future. ASKION produced the MelaFind<sup style="font-size: 85%; vertical-align: text-top">®</sup> hand-held imaging devices used in our pivotal clinical trials and is currently building additional units and performing other developmental activities under production and R&D contracts. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The Company, primarily through ASKION, engages Carl Zeiss Jena GmbH (“Zeiss”) to build the lenses and assemblies, as well as provide certain technical consulting, for the MelaFind<sup style="font-size: 85%; vertical-align: text-top">®</sup> units used in the Company’s pivotal clinical trials and additional units being manufactured. This work is expected to continue for MelaFind<sup style="font-size: 85%; vertical-align: text-top">®</sup> units through 2012. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">In April, 2011, the Company entered into a “Last Time Buy” supply agreement with Arrow Electronics, Inc. (“Arrow”), a distributor for ON Semiconductors (“ON”), pursuant to which the Company agreed to purchase complementary metal-oxide-semiconductor (“CMOS”) sensors. The CMOS sensor is a critical part of the Company’s MelaFind<sup style="font-size: 85%; vertical-align: text-top">®</sup> system. The Company believes that these CMOS sensors will be sufficient to meet the Company’s needs until an alternative is found. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The Company has an employment agreement with its President and Chief Executive Officer, Dr. Gulfo, which provides for an annual base salary, stock options and discretionary performance bonuses. The agreement, which provides for automatic one-year renewal terms, currently runs through the end of 2011. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">On November 19, 2010, a purported securities class action complaint was filed in the U.S. District Court for the Southern District of New York, naming as defendants the Company and certain of its officers and directors, entitled <i>Randall J. Pederson, Individually and on Behalf of All Others Similarly Situated v. MELA Sciences, Inc., Joseph V. Gulfo, Richard I. Steinhart, and Breaux Castleman, </i>No. 7:10-cv-08774-JFM. Two similar complaints were also filed, one on December 2, 2010 and the other on January 20, 2011, in the same District Court, entitled <i>Amy Steigman, Individually and on Behalf of All Others Similarly Situated v. MELA Sciences, Inc., Joseph V. Gulfo, Richard I. Steinhart, and Breaux Castleman</i>, No. 7:10-cv-09024-JFM; and <i>Martin Slove and Linda Slove, Individually and on Behalf of All Others Similarly Situated v. MELA Sciences, Inc., Joseph V. Gulfo, Richard I. Steinhart, and Breaux Castleman, </i>No. 1:11-cv-00429-JFM. These three securities class actions were consolidated into one action on February 15, 2011, entitled <i>In re MELA Sciences, Inc. Securities Litigation</i>, No. 10-Civ-8774-JFM (“securities class action”). The securities class action plaintiffs assert violations of the Securities Exchange Act of 1934, alleging, among other things, that defendants made misstatements and omissions regarding the Company’s product, MelaFind<sup style="font-size: 85%; vertical-align: text-top">®</sup>, and its prospects for FDA approval, on behalf of stockholders who purchased the Company’s common stock during the period from February 13, 2009 through November 16, 2010, and seek unspecified damages. On May 2, 2011, the securities class action plaintiffs filed their amended consolidated complaint, alleging similar claims to their prior complaints. On July 29, 2011, defendents filed a motion to dismiss the consolidated amended complaint in its entirety. Plaintiff’s opposition to the motion to dismiss was filed on September 23, 2011. In light of the Company’s receipt of the Approvable Letter from the FDA for the MelaFind<sup style="font-size: 85%; vertical-align: text-top">®</sup> PMA Application on September 22, 2011, the parties filed a stipulation on October 19, 2011 in which Plaintiff stated its intention to file a motion seeking leave to amend its complaint. Defendants withdrew the outstanding motion to dismiss the current Amended Complaint without prejudice to renew it at a later date. </div>   </div>  <div style="font-family: 'Times New Roman',Times,serif"> <div align="left" style="font-size: 10pt; margin-top: 6pt">The Company believes that it has meritorious defenses and intends to vigorously defend against the securities class action; however, as with any litigation, we cannot predict with certainty the eventual outcome of this litigation. An adverse outcome could have a material adverse effect on our business and our business could be materially harmed. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">From time to time, we may be a party to certain legal proceedings, incidental to the normal course of our business. These may include controversies relating to contract claims and employment related matters, some of which claims may be material, in which case, we will make separate disclosure as required. </div> </div>

<div style="font-family: 'Times New Roman',Times,serif"> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>7. STOCKHOLDERS’ EQUITY</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">On October 31, 2006, the Company entered into securities purchase agreements and a registration rights agreement with certain accredited investors for the private placement of 2,312,384 shares of the Company’s common stock and warrants to purchase up to 346,857 shares of the Company’s common stock for aggregate gross proceeds of approximately $13.2 million and net proceeds of approximately $12.5 million. Pursuant to the securities purchase agreements, for a purchase price of $5.70 each investor received one share of the Company’s common stock and a warrant to purchase 0.15 of a share of the Company’s common stock. The warrants are five-year warrants with an exercise price of $6.70 per share. In accordance with the terms of this warrant, on January 5, 2010 the Company required the holders to exercise their warrants within 30 days. As a result, warrants to purchase 173,963 shares of the Company’s common stock, representing all of the outstanding 2006 warrants, were exercised resulting in gross proceeds to the Company of $1.165 million. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">On July 31, 2007, the Company entered into a securities purchase agreement and a registration rights agreement with certain accredited investors for the private placement of 2,000,178 shares of the Company’s common stock and warrants to purchase up to 500,041 shares of the Company’s common stock for aggregate gross proceeds of approximately $11.5 million and net proceeds of approximately $10.7 million. The private placement closed August 3, 2007. Pursuant to the securities purchase agreement, for a purchase price of $5.75 each investor received one share of the Company’s common stock and a warrant to purchase 0.25 of a share of common stock. The warrants are five-year warrants with an exercise price of $8.00 per share. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">Pursuant to the terms of the registration rights agreements, the Company filed resale registration statements covering the shares in both private placements, including the shares issuable upon exercise of the warrants, with the SEC. In the event that the Company fails to maintain the effectiveness of these registration statements for the periods described in the registration rights agreements, the holders would be entitled to certain monetary damages. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">However, the Company is not obligated to make payments in excess of 10% of the aggregate purchase price of the common shares. The Company has concluded that it is unlikely that the Company would be required to remit any payments to its investors for failing to maintain its effectiveness. The Company’s resale registration statements on Form S-3 were declared effective by the SEC on February 12, 2007 and September 11, 2007, respectively. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">In June 2008, the Company filed a Form S-3 shelf registration statement for an indeterminate number of shares of common stock, warrants to purchase shares of common stock and units consisting of a combination thereof having an aggregate initial offering price not to exceed $40 million. Management utilized this shelf registration statement in August 2008 by completing a registered direct offering of 2,088,451 shares of the Company’s common stock for aggregate gross proceeds of $11.9 million ($11 million approximate net proceeds to the Company). In addition, in July 2009, management completed a registered direct offering of 2,400,000 shares of the Company’s common stock for aggregate gross proceeds of $15 million ($13.75 million approximate net proceeds to the Company). The shelf registration statement expired on July 7, 2011. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">In May 2009, the Company entered into a committed equity financing facility (“CEFF”) with Kingsbridge Capital Limited, pursuant to which Kingsbridge committed to purchase from time to time at the Company’s sole discretion, up to the lesser of $45 million or 3,327,000 shares of the Company’s common stock, prior to May 7, 2012 subject to various conditions for individual sales, including dollar, timing, and trading volume limitations, a minimum market per share price, and other contractual and regulatory requirements. </div>   </div>  <div style="font-family: 'Times New Roman',Times,serif"> <div align="left" style="font-size: 10pt; margin-top: 6pt">There is no assurance that the Company will satisfy all the various conditions for individual sales enabling it to use all of the CEFF. In connection with this CEFF, the Company issued a 5 year warrant, exercisable as of November 7, 2009, to Kingsbridge to purchase up to 200,000 shares of the Company’s common stock at an exercise price of $11.35 per share with a Black Scholes Fair Value of $678. The issuance of this warrant was deemed to be a cost of the offering. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The Company did not sell any stock to Kingsbridge Capital Limited under the CEFF in the nine months ended September 30, 2011. Under the CEFF, during the nine month period ending September 30, 2010, the Company sold 406,744 shares of common stock to Kingsbridge Capital Limited, at an average per share price of approximately $9.22, for gross proceeds of approximately $3.75 million. A proportionate share of the CEFF originating expenses was allocated to these sales from deferred offering costs. Net of expenses, proceeds from the 2010 sales were approximately $3.727 million. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">As of September 30, 2011, 1,095,315 shares of common stock remain available for sale under the CEFF, exclusive of the 200,000 outstanding warrants held by Kingsbridge. Legal, accounting, and other costs associated with this agreement approximating $62 have been deferred and will be charged to equity as a reduction of future proceeds from the CEFF or operations should management decide to abandon the CEFF. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">In May 2010, the Company filed a Form S-3 shelf registration statement for an indeterminate number of shares of common stock, warrants to purchase shares of common stock and units consisting of a combination thereof having an aggregate initial offering price not to exceed $75 million. The registration statement was declared effective by the SEC on June 1, 2010. On June 30, 2010, the Company entered into an underwriting agreement, relating to the public offering of 2,200,000 shares of the Company’s common stock, at a price to the public of $7.50 per share less underwriting discounts and commissions. The common stock was offered and sold pursuant to the Company’s Prospectus dated June 1, 2010 and the Company’s Prospectus Supplement filed with the SEC on June 30, 2010, in connection with a takedown from the Company’s effective shelf registration statement that closed on July 6, 2010. The gross proceeds to the Company from the sale of the common stock totaled $16.5 million. After deducting the underwriters’ discounts and commissions and other offering expenses, net proceeds were approximately $15.2 million. Approximately $58.5 million remains available under the Company’s 2010 shelf registration statement as of September 30, 2011. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">As of September 30, 2011, the Company had 45,000,000 shares of $0.001 par value common stock authorized and 25,262,538 shares issued and outstanding; and 10,000,000 shares of $0.10 par value preferred stock authorized with no preferred shares issued and outstanding. </div> </div>

<div style="font-family: 'Times New Roman',Times,serif"> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>8. WARRANTS</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The status of the Company’s warrants at September 30, 2011 is summarized as follows: </div> <div align="center"> <table style="font-size: 10pt; text-align: left" cellspacing="0" border="0" cellpadding="0" width="100%">  <tr valign="bottom"> <td width="64%"> </td> <td width="5%"> </td> <td width="1%"> </td> <td width="5%"> </td> <td width="1%"> </td> <td width="5%"> </td> <td width="1%"> </td> <td width="5%"> </td> <td width="1%"> </td> <td width="5%"> </td> <td width="1%"> </td> <td width="5%"> </td> <td width="1%"> </td> </tr> <tr style="font-size: 8pt" valign="bottom"> <td> </td> <td> </td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2007</b></td> <td> </td> <td> </td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>2009</b></td> <td> </td> <td> </td> <td nowrap="nowrap" align="center" colspan="2" style="border-bottom: 1px solid #000000"><b>Total</b></td> <td> </td> </tr>   <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Outstanding at December 31, 2010 </div></td> <td> </td> <td> </td> <td align="right">346,781</td> <td> </td> <td> </td> <td> </td> <td align="right">200,000</td> <td> </td> <td> </td> <td> </td> <td align="right">546,781</td> <td> </td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Exercised </div></td> <td> </td> <td> </td> <td align="right">—</td> <td> </td> <td> </td> <td> </td> <td align="right">—</td> <td> </td> <td> </td> <td> </td> <td align="right">—</td> <td> </td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Forfeited </div></td> <td> </td> <td> </td> <td align="right">—</td> <td> </td> <td> </td> <td> </td> <td align="right">—</td> <td> </td> <td> </td> <td> </td> <td align="right">—</td> <td> </td> </tr> <tr valign="bottom"> <td> <div style="margin-left:15px; text-indent:-15px">Expired </div></td> <td> </td> <td> </td> <td align="right">—</td> <td> </td> <td> </td> <td> </td> <td align="right">—</td> <td> </td> <td> </td> <td> </td> <td align="right">—</td> <td> </td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">  </div></td> <td> </td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"> </td> <td> </td> <td> </td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"> </td> <td> </td> <td> </td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 1px solid #000000"> </td> <td> </td> </tr> <tr valign="bottom" style="background: #cceeff"> <td> <div style="margin-left:15px; text-indent:-15px">Outstanding at September 30, 2011 </div></td> <td> </td> <td> </td> <td align="right">346,781</td> <td> </td> <td> </td> <td> </td> <td align="right">200,000</td> <td> </td> <td> </td> <td> </td> <td align="right">546,781</td> <td> </td> </tr> <tr style="font-size: 1px"> <td> <div style="margin-left:15px; text-indent:-15px">  </div></td> <td> </td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"> </td> <td> </td> <td> </td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"> </td> <td> </td> <td> </td> <td nowrap="nowrap" colspan="2" align="right" style="border-top: 3px double #000000"> </td> <td> </td> </tr>  </table> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">As previously discussed in connection with the Company’s private placement in August 2007 the Company issued warrants to purchase up to 500,041 shares of the Company’s common stock. At September 30, 2011, there were 346,781 of the 2007 warrants outstanding. The 2007 outstanding warrants are exercisable for five years at a price of $8.00 per share. </div>   </div>  <div style="font-family: 'Times New Roman',Times,serif"> <div align="left" style="font-size: 10pt; margin-top: 6pt">In addition, in connection with the May 7, 2009 CEFF with Kingsbridge Capital, the Company issued a 5 year warrant to Kingsbridge to purchase up to 200,000 shares of the Company’s common stock at an exercise price of $11.35 per share. This 200,000 share warrant is outstanding at September 30, 2011. </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">No warrants were exercised during the three and nine month periods ended September 30, 2011 and the three month period ended September 30, 2010. During the nine months ended September 30, 2010, warrants for the purchase of 263,549 shares of the Company’s common stock were exercised for total proceeds of approximately $1.7 million. </div> </div>

<div style="font-family: 'Times New Roman',Times,serif"> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>9. RELATED PARTY CONSULTING AGREEMENTS</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">The Company has in place the following consulting agreements with related parties: </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>Consulting Agreement with Breaux Castleman</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">In June 2003, the Company entered into a consulting agreement with Breaux Castleman, the Chairman of the Company’s Board of Directors, for consulting services related to the FDA approval of MelaFind<sup style="font-size: 85%; vertical-align: text-top">®</sup>, and the Company’s business and financial strategy. Under this agreement, Mr. Castleman receives compensation for each month of services rendered. The Company incurred and paid, pursuant to this consulting agreement, $6 in each of the three month periods ended September 30, 2011 and 2010 and $18 in each of the nine month periods ended September 30, 2011 and 2010. This consulting agreement is terminable by either party by providing thirty days’ prior written notice. </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>Consulting Agreement with Gerald Wagner, Ph.D</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">In January 2007, Dr. Wagner, Ph.D., a member of the Company’s Board of Directors, transitioned out of his role as the Company’s acting Chief Operating Officer and entered into an amended and restated consulting contract with the Company. Under the terms of the amended contract, Dr. Wagner is paid a monthly retainer of $2.5 and will be paid $2.5 for each additional consulting day. This amended agreement will end at the option of Dr. Wagner or the Company at any time, by providing fifteen days’ prior written notice, or immediately upon the mutual agreement of the Company and Dr. Wagner. The Company incurred consulting costs pursuant to this agreement of $7.5 in each of the three month periods ended September 30, 2011 and 2010 and $22.5 in each of the nine month periods ended September 30, 2011 and 2010. </div> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>Consulting Agreement with Anne Egger</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">     In March 2009, the Company entered into a consulting agreement with Anne Egger for certain consulting services primarily focusing on physician advocacy. The agreement was for an initial term of three months, and has subsequently been extended to run through September 2012, and may be terminated by either party with 30 days notice. Under the terms of the agreement, Ms. Egger is entitled to receive a consulting fee of $1.6 per day. Ms. Egger was appointed to the Company’s Board of Directors as of June 10, 2009. The Company incurred consulting costs pursuant to this agreement of $2 and $10 in the three month periods ended September 30, 2011 and September 30, 2010, respectively. The Company incurred consulting costs pursuant to this agreement of $8 and $45 in the nine month periods ended September 30, 2011 and September 30, 2010, respectively </div> </div>

<div style="font-family: 'Times New Roman',Times,serif"> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>10. OTHER INCOME</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">During April 2005, the Company discontinued all operations associated with its DIFOTI<sup style="font-size: 85%; vertical-align: text-top"><sup style="font-size: 85%; vertical-align: text-top">®</sup> </sup>product in order to focus its resources and attention on the development and commercialization of MelaFind<sup style="font-size: 85%; vertical-align: text-top">®</sup>. During December 2006, the Company entered into a sale and exclusive licensing agreement with KaVo Dental GmbH (“KaVo”), a leading dental equipment manufacturer, which provides for KaVo to further develop and commercialize DIFOTI<sup style="font-size: 85%; vertical-align: text-top">®</sup>. Since July 2008, KaVo has been required to pay to the Company a royalty stream based upon the worldwide aggregate net sales of the licensed product, as defined in the license agreement, or a set minimum. For the three and nine months ended September 30, 2011, the Company earned royalty income of $5 and $15, respectively. For the three and nine months ended September 30, 2010, the Company was paid royalty income of $5 and $15, respectively. </div>   </div>  <div style="font-family: 'Times New Roman',Times,serif"> </div>

<div style="font-family: 'Times New Roman',Times,serif"> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>11. COMPREHENSIVE LOSS</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">For the three and nine month periods ended September 30, 2011 and 2010 respectively, the Company’s comprehensive loss equaled its net loss. </div> </div>

<div style="font-family: 'Times New Roman',Times,serif"> <div align="left" style="font-size: 10pt; margin-top: 12pt"><b>12. SUBSEQUENT EVENTS</b> </div> <div align="left" style="font-size: 10pt; margin-top: 6pt">On November 1, 2011, the Company received written approval from the U.S. Food and Drug Administration of the Company’s MelaFind<sup style="font-size: 85%; vertical-align: text-top">®</sup> Pre-Market Approval application<b>.</b> </div> </div>

Derived from the audited balance sheet as of December 31, 2010

EX-101.SCH 6 mela-20110930.xsd EX-101 SCHEMA DOCUMENT 00 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 01 - Statement - Condensed Balance Sheets link:presentationLink link:definitionLink link:calculationLink 011 - Statement - Condensed Balance Sheets (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 02 - Statement - Condensed Statements of Operations (Unaudited) link:presentationLink link:definitionLink link:calculationLink 03 - Statement - Condensed Statements of Cash Flows (Unaudited) link:presentationLink link:definitionLink link:calculationLink 06001 - Disclosure - Organization and Basis Of Presentation link:presentationLink link:definitionLink link:calculationLink 06002 - Disclosure - Use of Estimates link:presentationLink link:definitionLink link:calculationLink 06003 - Disclosure - Recent Accounting Pronouncements link:presentationLink link:definitionLink link:calculationLink 06004 - Disclosure - Net Loss Per Common Share link:presentationLink link:definitionLink link:calculationLink 06005 - Disclosure - Stock-based Compensation link:presentationLink link:definitionLink link:calculationLink 06006 - Disclosure - Commitments, Contingencies And Litigation link:presentationLink link:definitionLink link:calculationLink 06007 - Disclosure - Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 06008 - Disclosure - Warrants link:presentationLink link:definitionLink link:calculationLink 06009 - Disclosure - Related Party Consulting Agreements link:presentationLink link:definitionLink link:calculationLink 06010 - Disclosure - Other Income link:presentationLink link:definitionLink link:calculationLink 06011 - Disclosure - Comprehensive Loss link:presentationLink link:definitionLink link:calculationLink 06012 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 7 mela-20110930_cal.xml EX-101 CALCULATION LINKBASE DOCUMENT EX-101.LAB 8 mela-20110930_lab.xml EX-101 LABELS LINKBASE DOCUMENT Document and Entity Information [Abstract] ASSETS Assets [Abstract] Current Assets: Assets, Current [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Total Current Assets Assets, Current, Total Total Current Assets Property and equipment, net Property, Plant and Equipment, Net Patents and trademarks, net Intangible Assets, Net (Excluding Goodwill) Deferred financing costs Deferred Finance Costs, Noncurrent, Net Other assets Other Assets, Noncurrent Other assets Total Assets Assets, Total Total Assets LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] Current Liabilities: Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Accrued expenses (includes related parties of $3,755 as of September 30, 2011) Accrued Liabilities, Current Accrued expenses due to related parties Due to Affiliate, Current Other current liabilities Other Liabilities, Current Other current liabilities Total Current Liabilities Liabilities, Current, Total Total Current Liabilities Long Term Liabilities: Liabilities, Noncurrent [Abstract] Deferred rent Deferred Rent Credit, Noncurrent Deferred rent Total Long Term Liabilities Liabilities, Noncurrent, Total Total Long Term Liabilities Total Liabilities Liabilities, Total Total Liabilities COMMITMENTS, CONTINGENCIES and LITIGATION (Note 6) Commitments and Contingencies Stockholders' Equity Stockholders' Equity Attributable to Parent [Abstract] Preferred stock - $.10 par value; authorized 10,000,000 shares; issued and outstanding: none Preferred Stock, Value, Issued Preferred stock, par value Preferred Stock, Par or Stated Value Per Share Preferred stock, shares authorized Preferred Stock, Shares Authorized Preferred stock, shares issued Preferred Stock, Shares Issued Preferred stock, shares outstanding Preferred Stock, Shares Outstanding Common stock - $.001 par value; authorized 45,000,000 shares; issued and outstanding 25,262,538 shares at September 30, 2011 and December 31, 2010 Common Stock, Value, Issued Common stock, par value Common Stock, Par or Stated Value Per Share Common stock, shares authorized Common Stock, Shares Authorized Common stock, shares issued Common Stock, Shares, Issued Common stock, shares outstanding Common Stock, Shares, Outstanding Additional paid-in capital Additional Paid in Capital, Common Stock Accumulated deficit Retained Earnings (Accumulated Deficit) Accumulated deficit Total Stockholders' Equity Stockholders' Equity Attributable to Parent, Total Total Stockholders' Equity Total Liabilities and Stockholders' Equity Liabilities and Equity, Total Total Liabilities and Stockholders' Equity Operating expenses: Operating Expenses [Abstract] Research and development Research and Development Expense General and administrative General and Administrative Expense General and administrative Operating loss Operating Income (Loss) Operating loss Interest income Investment Income, Interest Other income, net Other Nonoperating Income (Expense) Net loss Net Income (Loss) Attributable to Parent Net loss Basic and diluted net loss per common share Earnings Per Share, Basic and Diluted Basic and Diluted Weighted Average Number of Shares Outstanding Basic and diluted weighted average number of common shares outstanding Basic and diluted weighted average number of common shares outstanding Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Net loss Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Noncash compensation Share-based Compensation Gain on disposal of fixed assets Gain (Loss) on Disposition of Assets Gain on disposal of fixed assets Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] (Increase) decrease in prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets (Increase) decrease in prepaid expenses and other current assets Decrease in accounts payable and accrued expenses Increase (Decrease) in Accounts Payable and Accrued Liabilities Increase in other assets Increase (Decrease) in Other Operating Assets Increase in other assets Increase in deferred rent Increase (Decrease) in Deferred Liabilities Decrease in other current liabilities Increase (Decrease) in Other Operating Liabilities Decrease in other current liabilities Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment Proceeds from sale of fixed assets Proceeds from Sale of Productive Assets Proceeds from sale of fixed assets Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Net cash used in investing activities Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Proceeds from exercise of stock options Proceeds from Stock Options Exercised Proceeds from Exercise of Stock Warrants Proceeds from exercise of stock warrants Proceeds from exercise of stock warrants Proceeds from public offering Proceeds from Issuance Initial Public Offering Expenses related to public offering Payments of Stock Issuance Costs Expenses related to public offering Proceeds from Committed Equity Financing Facility Proceeds from Committed Equity Financing Facility Proceeds from Committed Equity Financing Facility Proceeds from Committed Equity Financing Facility Expenses related to Committed Equity Financing Facility Payments of Financing Costs Expenses related to Committed Equity Financing Facility Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Net cash provided by financing activities Net (decrease) increase in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Net (decrease) increase in cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Supplemental Schedule of Non-cash Investing and Financing Activities Supplemental Cash Flow Information [Abstract] Deferred Financing Costs Charged to Additional Paid in Capital Deferred financing costs charged to additional paid-in capital Deferred financing costs charged to additional paid-in capital ORGANIZATION AND BASIS OF PRESENTATION Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Organization and Basis of Presentation [Abstract] Organization and Basis of Presentation [Abstract] Use of Estimates [Text Block] USE OF ESTIMATES USE OF ESTIMATES Use of Estimates [Abstract] Use of Estimates [Abstract] USE OF ESTIMATES RECENT ACCOUNTING PRONOUNCEMENTS Accounting Changes and Error Corrections [Text Block] Recent Accounting Pronouncements [Abstract] Recent Accounting Pronouncements [Abstract] NET LOSS PER COMMON SHARE Earnings Per Share [Text Block] Net Loss Per Common Share [Abstract] Net Loss Per Common Share [Abstract] STOCK-BASED COMPENSATION Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stock-based Compensation [Abstract] Stock-based Compensation [Abstract] COMMITMENTS, CONTINGENCIES AND LITIGATION Commitments and Contingencies Disclosure [Text Block] Commitments, Contingencies and Litigation [Abstract] Commitments, Contingencies and Litigation [Abstract] STOCKHOLDERS' EQUITY Stockholders' Equity Note Disclosure [Text Block] Stockholders' Equity/Comprehensive Loss [Abstract] Stockholders' Equity/Comprehensive Loss [Abstract] Schedule of Stockholders Equity Note Warrants [Text Block] WARRANTS WARRANTS Warrants [Abstract] Warrants [Abstract] RELATED PARTY CONSULTING AGREEMENTS Related Party Transactions Disclosure [Text Block] Related Party Consulting Agreements [Abstract] Related Party Consulting Agreements [Abstract] OTHER INCOME Other Income and Other Expense Disclosure [Text Block] Other Income [Abstract] Other Income [Abstract] COMPREHENSIVE LOSS Comprehensive Income (Loss) Note [Text Block] SUBSEQUENT EVENTS Subsequent Events [Text Block] Subsequent Events [Abstract] Subsequent Events [Abstract] Amendment Flag Current Fiscal Year End Date Document Period End Date Document Type Entity Central Index Key Entity Common Stock, Shares Outstanding Entity Current Reporting Status Entity Filer Category Entity Registrant Name Entity Voluntary Filers Entity Well-known Seasoned Issuer Entity Public Float Document Fiscal Period Focus Document Fiscal Year Focus Condensed Balance Sheets[Abstract] Condensed Statements of Operations [Abstract] Condensed Statements of Cash Flows [Abstract] EX-101.PRE 9 mela-20110930_pre.xml EX-101 PRESENTATION LINKBASE DOCUMENT XML 10 R3.htm IDEA: XBRL DOCUMENT

Condensed Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2011	Dec. 31, 2010
Current Liabilities:
Accrued expenses due to related parties	$ 3,755
Stockholders' Equity
Preferred stock, par value	$ 0.10	$ 0.10
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	45,000,000	45,000,000
Common stock, shares issued	25,262,538	25,262,538
Common stock, shares outstanding	25,262,538	25,262,538

XML 11 R4.htm IDEA: XBRL DOCUMENT

Condensed Statements of Operations (Unaudited) (USD $)	3 Months Ended		9 Months Ended
Condensed Statements of Operations (Unaudited) (USD $)	Sep. 30, 2011	Sep. 30, 2010	Sep. 30, 2011	Sep. 30, 2010
Operating expenses:
Research and development	$ 2,437,811	$ 2,936,671	$ 7,634,493	$ 8,276,430
General and administrative	3,689,991	2,033,172	8,291,170	6,352,492
Operating loss	(6,127,802)	(4,969,843)	(15,925,663)	(14,628,922)
Interest income	10,729	9,741	45,194	13,702
Other income, net	6,419	4,998	18,089	17,521
Net loss	$ (6,110,654)	$ (4,955,104)	$ (15,862,380)	$ (14,597,699)
Basic and diluted net loss per common share	$ (0.24)	$ (0.20)	$ (0.63)	$ (0.62)
Basic and diluted weighted average number of common shares outstanding	25,262,538	25,110,970	25,262,538	23,636,446

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e565-108580

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A7

-Appendix A

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 10, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 87-21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 03

-Paragraph 19

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28, 29, 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References+ Details

XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information (USD $)	9 Months Ended
Document and Entity Information (USD $)	Sep. 30, 2011	Oct. 31, 2011	Jun. 30, 2010
Document and Entity Information [Abstract]
Entity Registrant Name	MELA SCIENCES, INC. /NY
Entity Central Index Key	0001051514
Document Type	10-Q
Document Period End Date	Sep. 30, 2011
Amendment Flag	false
Document Fiscal Year Focus	2011
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Public Float			$ 163,015,258
Entity Common Stock, Shares Outstanding		25,262,538

XML 13 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "

"+ text.join( "

\n" ) +"

"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "

" + text[p] + "

\n"; } } }else{ formatted = '

' + raw + '

'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'

'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'

'+ "\n"+' '+ "\n"+'

'+ "\n"+'

'+raw+'

'+ "\n"+'

'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } } XML 14 R12.htm IDEA: XBRL DOCUMENT

Stockholders' Equity	9 Months Ended
Stockholders' Equity	Sep. 30, 2011
Stockholders' Equity/Comprehensive Loss [Abstract]
STOCKHOLDERS' EQUITY	7. STOCKHOLDERS’ EQUITY On October 31, 2006, the Company entered into securities purchase agreements and a registration rights agreement with certain accredited investors for the private placement of 2,312,384 shares of the Company’s common stock and warrants to purchase up to 346,857 shares of the Company’s common stock for aggregate gross proceeds of approximately $13.2 million and net proceeds of approximately $12.5 million. Pursuant to the securities purchase agreements, for a purchase price of $5.70 each investor received one share of the Company’s common stock and a warrant to purchase 0.15 of a share of the Company’s common stock. The warrants are five-year warrants with an exercise price of $6.70 per share. In accordance with the terms of this warrant, on January 5, 2010 the Company required the holders to exercise their warrants within 30 days. As a result, warrants to purchase 173,963 shares of the Company’s common stock, representing all of the outstanding 2006 warrants, were exercised resulting in gross proceeds to the Company of $1.165 million. On July 31, 2007, the Company entered into a securities purchase agreement and a registration rights agreement with certain accredited investors for the private placement of 2,000,178 shares of the Company’s common stock and warrants to purchase up to 500,041 shares of the Company’s common stock for aggregate gross proceeds of approximately $11.5 million and net proceeds of approximately $10.7 million. The private placement closed August 3, 2007. Pursuant to the securities purchase agreement, for a purchase price of $5.75 each investor received one share of the Company’s common stock and a warrant to purchase 0.25 of a share of common stock. The warrants are five-year warrants with an exercise price of $8.00 per share. Pursuant to the terms of the registration rights agreements, the Company filed resale registration statements covering the shares in both private placements, including the shares issuable upon exercise of the warrants, with the SEC. In the event that the Company fails to maintain the effectiveness of these registration statements for the periods described in the registration rights agreements, the holders would be entitled to certain monetary damages. However, the Company is not obligated to make payments in excess of 10% of the aggregate purchase price of the common shares. The Company has concluded that it is unlikely that the Company would be required to remit any payments to its investors for failing to maintain its effectiveness. The Company’s resale registration statements on Form S-3 were declared effective by the SEC on February 12, 2007 and September 11, 2007, respectively. In June 2008, the Company filed a Form S-3 shelf registration statement for an indeterminate number of shares of common stock, warrants to purchase shares of common stock and units consisting of a combination thereof having an aggregate initial offering price not to exceed $40 million. Management utilized this shelf registration statement in August 2008 by completing a registered direct offering of 2,088,451 shares of the Company’s common stock for aggregate gross proceeds of $11.9 million ($11 million approximate net proceeds to the Company). In addition, in July 2009, management completed a registered direct offering of 2,400,000 shares of the Company’s common stock for aggregate gross proceeds of $15 million ($13.75 million approximate net proceeds to the Company). The shelf registration statement expired on July 7, 2011. In May 2009, the Company entered into a committed equity financing facility (“CEFF”) with Kingsbridge Capital Limited, pursuant to which Kingsbridge committed to purchase from time to time at the Company’s sole discretion, up to the lesser of $45 million or 3,327,000 shares of the Company’s common stock, prior to May 7, 2012 subject to various conditions for individual sales, including dollar, timing, and trading volume limitations, a minimum market per share price, and other contractual and regulatory requirements. There is no assurance that the Company will satisfy all the various conditions for individual sales enabling it to use all of the CEFF. In connection with this CEFF, the Company issued a 5 year warrant, exercisable as of November 7, 2009, to Kingsbridge to purchase up to 200,000 shares of the Company’s common stock at an exercise price of $11.35 per share with a Black Scholes Fair Value of $678. The issuance of this warrant was deemed to be a cost of the offering. The Company did not sell any stock to Kingsbridge Capital Limited under the CEFF in the nine months ended September 30, 2011. Under the CEFF, during the nine month period ending September 30, 2010, the Company sold 406,744 shares of common stock to Kingsbridge Capital Limited, at an average per share price of approximately $9.22, for gross proceeds of approximately $3.75 million. A proportionate share of the CEFF originating expenses was allocated to these sales from deferred offering costs. Net of expenses, proceeds from the 2010 sales were approximately $3.727 million. As of September 30, 2011, 1,095,315 shares of common stock remain available for sale under the CEFF, exclusive of the 200,000 outstanding warrants held by Kingsbridge. Legal, accounting, and other costs associated with this agreement approximating $62 have been deferred and will be charged to equity as a reduction of future proceeds from the CEFF or operations should management decide to abandon the CEFF. In May 2010, the Company filed a Form S-3 shelf registration statement for an indeterminate number of shares of common stock, warrants to purchase shares of common stock and units consisting of a combination thereof having an aggregate initial offering price not to exceed $75 million. The registration statement was declared effective by the SEC on June 1, 2010. On June 30, 2010, the Company entered into an underwriting agreement, relating to the public offering of 2,200,000 shares of the Company’s common stock, at a price to the public of $7.50 per share less underwriting discounts and commissions. The common stock was offered and sold pursuant to the Company’s Prospectus dated June 1, 2010 and the Company’s Prospectus Supplement filed with the SEC on June 30, 2010, in connection with a takedown from the Company’s effective shelf registration statement that closed on July 6, 2010. The gross proceeds to the Company from the sale of the common stock totaled $16.5 million. After deducting the underwriters’ discounts and commissions and other offering expenses, net proceeds were approximately $15.2 million. Approximately $58.5 million remains available under the Company’s 2010 shelf registration statement as of September 30, 2011. As of September 30, 2011, the Company had 45,000,000 shares of $0.001 par value common stock authorized and 25,262,538 shares issued and outstanding; and 10,000,000 shares of $0.10 par value preferred stock authorized with no preferred shares issued and outstanding.

- Definition

The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable). Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187143-122770

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Article 4

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 4

-Section 08

-Paragraph d

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Chapter 1

-Section B

-Paragraph 7, 11A

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 20: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 21: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 22: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 23: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

XML 15 R17.htm IDEA: XBRL DOCUMENT

Subsequent Events	9 Months Ended
Subsequent Events	Sep. 30, 2011
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	12. SUBSEQUENT EVENTS On November 1, 2011, the Company received written approval from the U.S. Food and Drug Administration of the Company’s MelaFind^® Pre-Market Approval application.

XML 16 R8.htm IDEA: XBRL DOCUMENT

Recent Accounting Pronouncements	9 Months Ended
Recent Accounting Pronouncements	Sep. 30, 2011
Recent Accounting Pronouncements [Abstract]
RECENT ACCOUNTING PRONOUNCEMENTS	3. RECENT ACCOUNTING PRONOUNCEMENTS None

- Definition

The entire disclosure for reporting accounting changes and error corrections. It includes the conveyance of information necessary for a user of the Company's financial information to understand all aspects and required disclosure information concerning all changes and error corrections reported in the Company's financial statements for the period.

+ References+ Details

XML 17 R14.htm IDEA: XBRL DOCUMENT

Related Party Consulting Agreements	9 Months Ended
Related Party Consulting Agreements	Sep. 30, 2011
Related Party Consulting Agreements [Abstract]
RELATED PARTY CONSULTING AGREEMENTS	9. RELATED PARTY CONSULTING AGREEMENTS The Company has in place the following consulting agreements with related parties: Consulting Agreement with Breaux Castleman In June 2003, the Company entered into a consulting agreement with Breaux Castleman, the Chairman of the Company’s Board of Directors, for consulting services related to the FDA approval of MelaFind^®, and the Company’s business and financial strategy. Under this agreement, Mr. Castleman receives compensation for each month of services rendered. The Company incurred and paid, pursuant to this consulting agreement, $6 in each of the three month periods ended September 30, 2011 and 2010 and $18 in each of the nine month periods ended September 30, 2011 and 2010. This consulting agreement is terminable by either party by providing thirty days’ prior written notice. Consulting Agreement with Gerald Wagner, Ph.D In January 2007, Dr. Wagner, Ph.D., a member of the Company’s Board of Directors, transitioned out of his role as the Company’s acting Chief Operating Officer and entered into an amended and restated consulting contract with the Company. Under the terms of the amended contract, Dr. Wagner is paid a monthly retainer of $2.5 and will be paid $2.5 for each additional consulting day. This amended agreement will end at the option of Dr. Wagner or the Company at any time, by providing fifteen days’ prior written notice, or immediately upon the mutual agreement of the Company and Dr. Wagner. The Company incurred consulting costs pursuant to this agreement of $7.5 in each of the three month periods ended September 30, 2011 and 2010 and $22.5 in each of the nine month periods ended September 30, 2011 and 2010. Consulting Agreement with Anne Egger In March 2009, the Company entered into a consulting agreement with Anne Egger for certain consulting services primarily focusing on physician advocacy. The agreement was for an initial term of three months, and has subsequently been extended to run through September 2012, and may be terminated by either party with 30 days notice. Under the terms of the agreement, Ms. Egger is entitled to receive a consulting fee of $1.6 per day. Ms. Egger was appointed to the Company’s Board of Directors as of June 10, 2009. The Company incurred consulting costs pursuant to this agreement of $2 and $10 in the three month periods ended September 30, 2011 and September 30, 2010, respectively. The Company incurred consulting costs pursuant to this agreement of $8 and $45 in the nine month periods ended September 30, 2011 and September 30, 2010, respectively

- Definition

The entire disclosure for related party transactions, including the nature of the relationship(s), a description of the transactions, the amount of the transactions, the effects of any change in the method of establishing the terms of the transaction from the previous period, stated interest rate, expiration date, terms and manner of settlement per the agreement with the related party, and amounts due to or from related parties. If the entity and one or more other entities are under common ownership or management control and this control affects the operating results or financial position, disclosure includes the nature of the control relationship even if there are no transactions between the entities. Disclosure may also include the aggregate amount of current and deferred tax expense for each statement of earnings presented where the entity is a member of a group that files a consolidated tax return, the amount of any tax related balances due to or from affiliates as of the date of each statement of financial position presented, the principal provisions of the method by which the consolidated amount of current and deferred tax expense is allocated to the members of the group and the nature and effect of any changes in that method. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 3A

-Section 04

-Paragraph b

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 57

-Paragraph 1-4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 4

-Section 08

-Paragraph k

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

+ Details

XML 18 R15.htm IDEA: XBRL DOCUMENT

Other Income	9 Months Ended
Other Income	Sep. 30, 2011
Other Income [Abstract]
OTHER INCOME	10. OTHER INCOME During April 2005, the Company discontinued all operations associated with its DIFOTI^{^®}product in order to focus its resources and attention on the development and commercialization of MelaFind^®. During December 2006, the Company entered into a sale and exclusive licensing agreement with KaVo Dental GmbH (“KaVo”), a leading dental equipment manufacturer, which provides for KaVo to further develop and commercialize DIFOTI^®. Since July 2008, KaVo has been required to pay to the Company a royalty stream based upon the worldwide aggregate net sales of the licensed product, as defined in the license agreement, or a set minimum. For the three and nine months ended September 30, 2011, the Company earned royalty income of $5 and $15, respectively. For the three and nine months ended September 30, 2010, the Company was paid royalty income of $5 and $15, respectively.

XML 19 R13.htm IDEA: XBRL DOCUMENT

Warrants

9 Months Ended

Sep. 30, 2011

Warrants [Abstract]

WARRANTS

8. WARRANTS

The status of the Company’s warrants at September 30, 2011 is summarized as follows:


	2007		2009		Total
Outstanding at December 31, 2010		346,781		200,000		546,781
Exercised		—		—		—
Forfeited		—		—		—
Expired		—		—		—

Outstanding at September 30, 2011		346,781		200,000		546,781

XML 20 R6.htm IDEA: XBRL DOCUMENT

Organization and Basis Of Presentation

9 Months Ended

Sep. 30, 2011

Organization and Basis of Presentation [Abstract]

ORGANIZATION AND BASIS OF PRESENTATION

1. ORGANIZATION AND BASIS OF PRESENTATION

The components of the MelaFind^® system include:

•		a hand-held imaging device, which employs high precision optics and multi-spectral illumination (multiple colors of light including near infra-red);

•		a proprietary database of pigmented skin lesions, which we believe to be the largest in the U.S.; and


•		lesion classifiers, which are sophisticated mathematical algorithms that extract lesion feature information and classify lesions.

On November 1, 2011, the Company received written approval from the U.S. Food and Drug Administration (“FDA”) of the Company’s MelaFind^® Pre-Market Approval (“PMA”) application.

With FDA approval received, the Company plans to launch MelaFind^® commercially in the United States during the first quarter of 2012.

In August of 2011, the Company received the International Organization for Standardization (“ISO”) 13485 certification of the Company’s comprehensive management system for the design and manufacture of medical devices. On September 6, 2011, the Company received Conformite Europeenne (“CE”) Mark approval for MelaFind^®. With CE Mark approval, the Company has the ability to market MelaFind^® to dermatologists across the European Union and in certain other countries.

The Company plans to launch MelaFind^® commercially in Germany during the first quarter of 2012.

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 720

-SubTopic 15

-URI http://asc.fasb.org/subtopic&trid=2122524

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6921930&loc=d3e5614-111684

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6970148&loc=SL6228881-111685

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Name Statement of Position (SOP)

-Publisher AICPA

-Number 94-6

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 272

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Staff Position (FSP)

-Number FAS140-4/FIN46(R)-8

-Paragraph 8, C1, C7

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Name FASB Interpretation (FIN)

-Publisher FASB

-Number 46R

-Paragraph 4, 14, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 852

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2209116

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2134480

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 2-6

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 235

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2122150

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6359553&loc=d3e288-107754

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2197480

+ Details

XML 21 R9.htm IDEA: XBRL DOCUMENT

Net Loss Per Common Share

9 Months Ended

Sep. 30, 2011

Net Loss Per Common Share [Abstract]

NET LOSS PER COMMON SHARE

4. NET LOSS PER COMMON SHARE


	September 30,
	2011		2010
Common stock options		2,126,804		2,171,273
Common stock warrants		546,781		614,906

Total		2,673,585		2,786,179

XML 22 R10.htm IDEA: XBRL DOCUMENT

Stock-based Compensation

9 Months Ended

Sep. 30, 2011

Stock-based Compensation [Abstract]

STOCK-BASED COMPENSATION

5. STOCK-BASED COMPENSATION

The fair value of each option award granted is estimated on the date of grant using the Black-Scholes option valuation model and assumptions as noted in the following table:


	For the Nine Months	For the Nine Months
	Ended September 30, 2011	Ended September 30, 2010
Expected life	6.5 years	5-10 years
Expected volatility	70.54-76.32%	61-67%
Risk-free interest rate	1.38-3.34%	2.26-3.56%
Dividend yield	0%	0%

The expected life of the options is based upon the expected time to full-vesting and term of the options. The expected volatility assumptions are determined based upon the historical volatility of the Company’s daily closing stock price. The risk-free interest rate is based on the continuous rates provided by the U.S. Treasury with a term equal to the expected life of the option. The expected dividend yield is zero as the Company has never paid dividends and does not currently anticipate paying any in the foreseeable future.

The status of the Company’s stock option plans at September 30, 2011 is summarized in the following table:


						Weighted
				Weighted		Average
				Average		Remaining
				Exercise		Contractual		Aggregate
	Number of			Price per		Term in		Intrinsic
	Shares			Share		Years		Value
Outstanding at December 31, 2010		2,132,879		$	5.19		5.4
Granted		496,050			3.18		9.6
Exercised		—
Forfeited or expired		(502,125	)		6.59		—

Outstanding at September 30, 2011		2,126,804		$	4.39		6.5	$	1,473


Vested and exercisable at September 30, 2011		874,041		$	4.48		5.6	$	644


			Options Outstanding
			Weighted-			Options Exercisable
			Average	Weighted				Weighted-
			Remaining	Average				Average
	Number		Contractual	Exercise		Number		Exercise
Range of Exercise Prices	Outstanding		Life	Price		Exercisable		Price
$1.00		48,952	1.2 years	$	1.00		48,952	$	1.00
$1.01-$4.50		1,635,202	7.2 years	$	3.63		620,539	$	3.67
$4.51-$11.11		442,650	4.5 years	$	7.56		204,550	$	7.79

$.01-$11.11		2,126,804	6.5 years	$	4.39		874,041	$	4.48

As of September 30, 2011, there were 1,629,264 shares available for future grants under the Company’s 2005 Plan.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Statement of Position (SOP)

-Number 93-6

-Paragraph 53

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 64, 65, A240

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 40

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

XML 23 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 24 R11.htm IDEA: XBRL DOCUMENT

Commitments, Contingencies And Litigation

9 Months Ended

Sep. 30, 2011

Commitments, Contingencies and Litigation [Abstract]

COMMITMENTS, CONTINGENCIES AND LITIGATION

6. COMMITMENTS, CONTINGENCIES AND LITIGATION


2011 Remaining three months	$	95
2012		410
2013		439
2014		456
2015		455
2016		456

	$	2,311

Rental payments are recognized as rent expense on a straight-line basis over the term of the lease.

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Interpretation (FIN)

-Number 14

-Paragraph 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 9, 10, 11, 12

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

+ Details

XML 25 R5.htm IDEA: XBRL DOCUMENT

Condensed Statements of Cash Flows (Unaudited) (USD $)

9 Months Ended

Sep. 30, 2011

Sep. 30, 2010

Cash flows from operating activities:

Net loss

$ (15,862,380)

$ (14,597,699)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation and amortization

415,592

396,878

Noncash compensation

2,911,260

562,799

Gain on disposal of fixed assets

(27)

Changes in operating assets and liabilities:

(Increase) decrease in prepaid expenses and other current assets

(336,036)

271,806

Decrease in accounts payable and accrued expenses

(366,642)

(1,799)

Increase in other assets

(248,793)

(289,705)

Increase in deferred rent

25,434

78,228

Decrease in other current liabilities

(1,288)

(3,559)

Net cash used in operating activities

(13,462,853)

(13,583,078)

Cash flows from investing activities:

Purchases of property and equipment

(58,680)

(1,052,835)

Proceeds from sale of fixed assets

1,500

Net cash used in investing activities

(58,680)

(1,051,335)

Cash flows from financing activities:

Proceeds from exercise of stock options

26,070

Proceeds from exercise of stock warrants

1,691,633

Proceeds from public offering

16,500,000

Expenses related to public offering

(1,244,329)

Proceeds from Committed Equity Financing Facility

3,750,000

(6,717)

Net cash provided by financing activities

20,716,657

Net (decrease) increase in cash and cash equivalents

(13,521,533)

6,082,244

Cash and cash equivalents at beginning of period

30,520,812

^[1]

29,673,420

Cash and cash equivalents at end of period

16,999,279

35,755,664

Supplemental Schedule of Non-cash Investing and Financing Activities

Deferred financing costs charged to additional paid-in capital

$ 23,179

[1]	Derived from the audited balance sheet as of December 31, 2010

XML 26 R7.htm IDEA: XBRL DOCUMENT

Use of Estimates	9 Months Ended
Use of Estimates	Sep. 30, 2011
Use of Estimates [Abstract]
USE OF ESTIMATES	2. USE OF ESTIMATES The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires the use of estimates and assumptions by management that affect reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The most significant estimates relate to stock-based compensation arrangements and accrued expenses. Actual results could differ from these estimates. With the receipt of the PMA Approvable Letter from the FDA on September 22, 2011, the Company deemed it probable that it would subsequently receive PMA approval from the FDA for the MelaFind^® PMA application. Accordingly, $1,889 in non-cash compensation expense was recorded as of September 30, 2011 representing options on which the performance vesting milestone is related to FDA approval. Those options remain as unvested on all option tables in this report on Form 10-Q, as vesting took place at the time approval was received.

XML 27 R16.htm IDEA: XBRL DOCUMENT

Comprehensive Loss	9 Months Ended
Comprehensive Loss	Sep. 30, 2011
Stockholders' Equity/Comprehensive Loss [Abstract]
COMPREHENSIVE LOSS	11. COMPREHENSIVE LOSS For the three and nine month periods ended September 30, 2011 and 2010 respectively, the Company’s comprehensive loss equaled its net loss.

- Definition

The entire disclosure for comprehensive income. Includes, but is not limited to, the following: 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income. Components of comprehensive income include: (1) foreign currency translation adjustments; (2) gains (losses) on foreign currency transactions that are designated as, and are effective as, economic hedges of a net investment in a foreign entity; (3) gains (losses) on intercompany foreign currency transactions that are of a long-term-investment nature, when the entities to the transaction are consolidated, combined, or accounted for by the equity method in the reporting enterprise's financial statements; (4) change in the market value of a futures contract that qualifies as a hedge of an asset reported at fair value; (5) unrealized holding gains (losses) on available-for-sale securities and that resulting from transfers of debt securities from the held-to-maturity category to the available-for-sale category; (6) a net loss recognized as an additional pension liability not yet recognized as net periodic pension cost; and (7) the net gain (loss) and net prior service cost or credit for pension plans and other postretirement benefit plans.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 55

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6920433&loc=d3e998-108581

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e689-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e637-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 17

-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e716-108580

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14

-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e681-108580

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Reclassification Adjustments

-URI http://asc.fasb.org/extlink&oid=6522872

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 14-26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e640-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e653-108580

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e709-108580

+ Details

XML 28 R2.htm IDEA: XBRL DOCUMENT

Condensed Balance Sheets (USD $)

Sep. 30, 2011

Dec. 31, 2010

Current Assets:

Cash and cash equivalents

$ 16,999,279

$ 30,520,812

^[1]

Prepaid expenses and other current assets

859,708

523,672

^[1]

Total Current Assets

17,858,987

31,044,484

^[1]

Property and equipment, net

1,725,615

2,073,602

^[1]

Patents and trademarks, net

62,183

71,108

^[1]

Deferred financing costs

62,391

^[1]

Other assets

586,498

337,705

^[1]

Total Assets

20,295,674

33,589,290

^[1]

Current Liabilities:

Accounts payable

629,996

1,096,505

^[1]

Accrued expenses (includes related parties of $3,755 as of September 30, 2011)

659,842

559,975

^[1]

Other current liabilities

28,250

29,538

^[1]

Total Current Liabilities

1,318,088

1,686,018

^[1]

Long Term Liabilities:

Deferred rent

129,738

104,304

^[1]

Total Long Term Liabilities

129,738

104,304

^[1]

Total Liabilities

1,447,826

1,790,322

^[1]

COMMITMENTS, CONTINGENCIES and LITIGATION (Note 6)

^[1]

Stockholders' Equity

Preferred stock - $.10 par value; authorized 10,000,000 shares; issued and outstanding: none

^[1]

Common stock - $.001 par value; authorized 45,000,000 shares; issued and outstanding 25,262,538 shares at September 30, 2011 and December 31, 2010

25,263

^[1]

Additional paid-in capital

133,827,586

130,916,326

^[1]

Accumulated deficit

(115,005,001)

(99,142,621)

^[1]

Total Stockholders' Equity

18,847,848

31,798,968

^[1]

Total Liabilities and Stockholders' Equity

$ 20,295,674

$ 33,589,290

^[1]

[1]	Derived from the audited balance sheet as of December 31, 2010

XML 29 FilingSummary.xml IDEA: XBRL DOCUMENT 2.3.0.15 Html 10 86 1 true 0 0 false 3 true false R1.htm 00 - Document - Document and Entity Information Sheet http://melasciences.com/role/DocumentAndEntityInformation Document and Entity Information false false R2.htm 01 - Statement - Condensed Balance Sheets Sheet http://melasciences.com/role/BalanceSheets Condensed Balance Sheets false false R3.htm 011 - Statement - Condensed Balance Sheets (Parenthetical) Sheet http://melasciences.com/role/BalanceSheetsParenthetical Condensed Balance Sheets (Parenthetical) false false R4.htm 02 - Statement - Condensed Statements of Operations (Unaudited) Sheet http://melasciences.com/role/StatementsOfOperations Condensed Statements of Operations (Unaudited) false false R5.htm 03 - Statement - Condensed Statements of Cash Flows (Unaudited) Sheet http://melasciences.com/role/StatementsOfCashFlows Condensed Statements of Cash Flows (Unaudited) false false R6.htm 06001 - Disclosure - Organization and Basis Of Presentation Sheet http://melasciences.com/role/OrganizationAndBasisOfPresentation Organization and Basis Of Presentation false false R7.htm 06002 - Disclosure - Use of Estimates Sheet http://melasciences.com/role/UseOfEstimates Use of Estimates false false R8.htm 06003 - Disclosure - Recent Accounting Pronouncements Sheet http://melasciences.com/role/RecentAccountingPronouncements Recent Accounting Pronouncements false false R9.htm 06004 - Disclosure - Net Loss Per Common Share Sheet http://melasciences.com/role/NetLossPerCommonShare Net Loss Per Common Share false false R10.htm 06005 - Disclosure - Stock-based Compensation Sheet http://melasciences.com/role/StockBasedCompensation Stock-based Compensation false false R11.htm 06006 - Disclosure - Commitments, Contingencies And Litigation Sheet http://melasciences.com/role/CommitmentsContingenciesAndLitigation Commitments, Contingencies And Litigation false false R12.htm 06007 - Disclosure - Stockholders' Equity Sheet http://melasciences.com/role/StockholdersEquity Stockholders' Equity false false R13.htm 06008 - Disclosure - Warrants Sheet http://melasciences.com/role/Warrants Warrants false false R14.htm 06009 - Disclosure - Related Party Consulting Agreements Sheet http://melasciences.com/role/RelatedPartyConsultingAgreements Related Party Consulting Agreements false false R15.htm 06010 - Disclosure - Other Income Sheet http://melasciences.com/role/OtherIncome Other Income false false R16.htm 06011 - Disclosure - Comprehensive Loss Sheet http://melasciences.com/role/ComprehensiveLoss Comprehensive Loss false false R17.htm 06012 - Disclosure - Subsequent Events Sheet http://melasciences.com/role/SubsequentEvents Subsequent Events false false All Reports Book All Reports Process Flow-Through: 01 - Statement - Condensed Balance Sheets Process Flow-Through: Removing column 'Sep. 30, 2010' Process Flow-Through: Removing column 'Dec. 31, 2009' Process Flow-Through: 011 - Statement - Condensed Balance Sheets (Parenthetical) Process Flow-Through: 02 - Statement - Condensed Statements of Operations (Unaudited) Process Flow-Through: 03 - Statement - Condensed Statements of Cash Flows (Unaudited) mela-20110930.xml mela-20110930.xsd mela-20110930_cal.xml mela-20110930_lab.xml mela-20110930_pre.xml true true EXCEL 30 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%]C,C1E-S,P,U\V969E7S1C-V9?.35D9E\S939D M.69E8S8Y8V4B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I% M>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=OF%T:6]N M7V%N9%]"87-I#I%>&-E;%=O#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/E)E8V5N=%]!8V-O=6YT:6YG7U!R;VYO M=6YC96UE;CPO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE M/DYE=%],;W-S7U!E#I7 M;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-T;V-K:&]L9&5R#I7;W)K#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E)E;&%T961?4&%R='E? M0V]N#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D]T:&5R7TEN8V]M93PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O;7!R96AE;G-I=F5?3&]S#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/E-U8G-E<75E;G1?179E;G1S M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I!8W1I=F53 M:&5E=#XP/"]X.D%C=&EV95-H965T/@T*("`\>#I0#I%>&-E;%=O7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA'0^345,02!30TE%3D-%4RP@24Y#+B`O3ED\2!# M96YT3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^,#`P,3`U,34Q-#QS<&%N/CPO'0^,3`M43QS<&%N/CPO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^3F\\2!#=7)R96YT(%)E<&]R=&EN M9R!3=&%T=7,\+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^ M#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C,C1E M-S,P,U\V969E7S1C-V9?.35D9E\S939D.69E8S8Y8V4-"D-O;G1E;G0M3&]C M871I;VXZ(&9I;&4Z+R\O0SHO8S(T93'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'!E;G-E6%B;&4\+W1D M/@T*("`@("`@("`\=&0@8VQA'!E;G-EF5D(#$P+#`P,"PP,#`@F5D(#0U+#`P,"PP,#`@3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%]C,C1E-S,P,U\V969E7S1C-V9?.35D9E\S939D.69E8S8Y8V4-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8S(T93'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$F5D M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-2PP,#`L,#`P/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C,C1E-S,P,U\V M969E7S1C-V9?.35D9E\S939D.69E8S8Y8V4-"D-O;G1E;G0M3&]C871I;VXZ M(&9I;&4Z+R\O0SHO8S(T93'0O:'1M;#L@8VAA3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%]C,C1E-S,P,U\V969E7S1C-V9?.35D9E\S939D.69E M8S8Y8V4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8S(T93'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6%B;&4@86YD(&%C8W)U960@97AP96YS97,\+W1D M/@T*("`@("`@("`\=&0@8VQA2!A;F0@97%U:7!M96YT/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@U."PV.#`I/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S&5D(&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'!E;G-E'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S3PO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'!E;G-E2!F:6YA;F-I M;F<@86-T:79I=&EE'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQAF%T:6]N(&%N9"!"87-IF%T M:6]N0V]N6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N M)RQ4:6UE6QE/3-$ M)V9O;G0M6QE/3-$)V9O;G0MF4Z(#$P<'0G/CQB/CPO8CX\+V1I=CX-"B`@(#QD:78@ M86QI9VX],T1C96YT97(@F4Z(#$P<'0[(&UAF4Z(#$P M<'0[(&UA2!F;V-U28C.#(Q-SMS(&9L86=S:&EP('!R;V1U8W0L#0H@("!-96QA1FEN9#QS=7`@ MFEN9R!I;6%G92!P6QE/3-$)V9O;G0M6QE/3-$ M)V9O;G0M7-T96T@:6YC;'5D93H-"B`@(#PO9&EV/@T*("`@/&1I M=B!S='EL93TS1"=M87)G:6XM=&]P.B`V<'0G/@T*("`@/'1A8FQE('=I9'1H M/3-$,3`P)2!B;W)D97(],T0P(&-E;&QP861D:6YG/3-$,"!C96QL6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M6QE/3-$ M)V9O;G0M6QE/3-$)V9O;G0M2!R96-E:79E9"!W M28C.#(Q-SMS(`T*("`@365L849I;F0\6QE/3-$)V9O M;G0M6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M2!T:&4@ M1D1!+B!!('!I=F]T86P@=')I86P@8V]N9'5C=&5D('1O(&5S=&%B;&ES:"!T M:&4@6QE/3-$)V9O;G0M2!O;B!A;&P@=&AR964@<75E M2!T:&4@1D1!+@T*("`@/"]D:78^#0H@("`\ M9&EV(&%L:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA M2!S=6)M:71T960@82!034$@86UE;F1M96YT(&-O;G1A:6YI;F<@82!R M979IF4Z(#@U)3L@=F5R=&EC86PM86QI9VXZ('1E>'0M=&]P)SXF(S$W-#L\ M+W-U<#X@=&\@=7-E(&)Y(&1E2!F:6QE9"!A('-E M8V]N9"!034$@86UE;F1M96YT(&-O;G1A:6YI;F<@80T*("`@=')A:6YI;F<@ M<')O9W)A;2!F;W(@8VQI;FEC:6%N0T*("`@,C`Q,2P@=&AE($-O;7!A;GD@6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M2!R96-E:79E9"!A;B!!<'!R;W9A8FQE($QE='1E M'0M=&]P M)SXF(S$W-#L\+W-U<#X-"B`@("!034$@87!P;&EC871I;VX@;VX@4V5P=&5M M8F5R(#(R+"`R,#$Q+B!3=6)S97%U96YT('1O(%-E<'1E;6)E2!R96-E:79E9"!A;B!!<'!R;W9A;"!,971T M97(@9G)O;2!T:&4@1D1!(&]N($YO=F5M8F5R(#$L(#(P,3$@87!P6QE/3-$)V9O;G0MF5N)B,X,C$W.W,@4&5T:71I;VX@9FEL960@=VET:"!T:&4@1D1!(&EN($UA M>2`R,#$Q+@T*("`@/"]D:78^#0H@("`\9&EV(&%L:6=N/3-$;&5F="!S='EL M93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA2!I;B!T:&4@56YI=&5D(%-T871E6QE/3-$)V9O;G0MF%T:6]N(&9O6QE/3-$)V9O;G0M2!H87,@=&AE(&%B:6QI='D@=&\@ M;6%R:V5T#0H@("!-96QA1FEN9#QS=7`@F4Z(#$P<'0[(&UA M'0M=&]P)SXF(S$W-#L\+W-U<#X@8V]M;65R8VEA;&QY(&EN M($=E6QE/3-$)V9O;G0M M2!R979E;G5E2!A M;G1I8VEP871E'0M=&]P)SXF(S$W-#L\+W-U<#X@9&5V:6-E+B!&F4Z(#$P M<'0[(&UAF%T:6]N28C M.#(Q-SMS('1O=&%L(&]F(&-A&EM871E;'D@)FYB28C.#(Q-SMS(&-O;G1R;VQL960@;&%U;F-H97,@ M:6X@=&AE(&YO2!W:6QL#0H@("!R97%U:7)E(&%D9&ET:6]N86P@9G5N9',@=&\@86-H:65V M92!S:6=N:69I8V%N="!C;VUM97)C:6%L:7IA=&EO;B!O9@T*("`@365L849I M;F0\6QE/3-$)V9O;G0M2!W:6QL(&)E(&%B;&4@=&\@2!A9&1I=&EO;F%L(&9U;F1I;F<@=&AA="!T:&4@0V]M M<&%N>2!D;V5S(&]B=&%I;B!W:6QL(&)E#0H@("!S=69F:6-I96YT('1O(&UE M970@=&AE($-O;7!A;GDF(S@R,3<[2!I2!A;F0@:6YT96YT('1O(')E9'5C92!C97)T86EN(&1I0T*("`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`\(2TM($)E9VEN($)L;V-K(%1A9V=E9"!.;W1E(#(@ M+2!M96QA.E5S94]F17-T:6UA=&5S5&5X=$)L;V-K+2T^#0H@("`\9&EV(&%L M:6=N/3-$;&5F="!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2 M;VUA;BF4Z(#$P<'0[(&UA'0M=&]P)SXF(S$W-#L\+W-U<#X@4$U!(&%P<&QI8V%T M:6]N+B`@06-C;W)D:6YG;'DL("9N8G-P.R0Q+#@X.2!I;B!N;VXM8V%S:"!C M;VUP96YS871I;VX@97AP96YS92!W87,@3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%]C,C1E-S,P,U\V969E7S1C-V9?.35D9E\S939D.69E8S8Y M8V4-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8S(T93'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U&AT M;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^#0H@("`\(2TM M($)E9VEN($)L;V-K(%1A9V=E9"!.;W1E(#,@+2!U'1";&]C:RTM/@T*("`@ M/&1I=B!S='EL93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;B'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'1";&]C:RTM/@T*("`@/&1I=B!S='EL M93TS1"=F;VYT+69A;6EL>3H@)U1I;65S($YE=R!2;VUA;BF4Z(#$P<'0[(&UA6QE/3-$)V9O;G0M6QE/3-$)V)O"!S;VQI M9"`C,#`P,#`P)SX\8CXR,#$Q/"]B/CPO=&0^#0H@("`@("`@/'1D/B8C,38P M.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO M=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E6QE/3-$ M)V)A8VMG#L@=&5X="UI;F1E;G0Z+3$U<'@G M/D-O;6UO;B!S=&]C:R!O<'1I;VYS#0H@("`\+V1I=CX\+W1D/@T*("`@("`@ M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@ M("`@(#QT9"!A;&EG;CTS1')I9VAT/C(L,3(V+#@P-#PO=&0^#0H@("`@("`@ M/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@ M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$#L@=&5X="UI;F1E;G0Z M+3$U<'@G/D-O;6UO;B!S=&]C:R!W87)R86YT#L@ M=&5X="UI;F1E;G0Z+3$U<'@G/B8C,38P.PT*("`@/"]D:78^/"]T9#X-"B`@ M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W6QE/3-$)V)O"!S;VQI9"`C,#`P,#`P)SXF M(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T"<^5&]T86P-"B`@(#PO M9&EV/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$"<^)B,Q-C`[#0H@("`\ M+V1I=CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@("`@ M("`\=&0@;F]W7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&AT;6PQ+71R86YS:71I;VYA;"YD=&0B("TM/@T*("`@ M/"$M+2!"96=I;B!";&]C:R!486=G960@3F]T92`U("T@=7,M9V%A<#I$:7-C M;&]S=7)E3V9#;VUP96YS871I;VY296QA=&5D0V]S='-3:&%R94)A6QE/3-$)V9O;G0MF4Z(#$P<'0[(&UA2!G65E6QE/3-$)V9O;G0M65A'!E;G-E(')E8V]G M;FEZ960@:6X@=&AE(%-T871E;65N="!O9B!/<&5R871I;VYS(&EN('1H92!T M:&ER9"!Q=6%R=&5R(&]F(#(P,3$@86YD(#(P,3`@9F]R('-T;V-K(&]P=&EO M;G,@#0H@("!A;6]U;G1E9"!T;R`F;F)S<#LD,BPQ-S<@*&]F('=H:6-H("9N M8G-P.R0R+#`S,2!R96QA=&5S('1O('!E6QE/3-$)V9O;G0M'!E;G-E(')E8V]G M;FEZ960@:6X@=&AE(%-T871E;65N="!O9B!/<&5R871I;VYS(&9O2!T:&4@0V]M<&%N>2!T;R!B92!P'!E M;G-E('=A&5R8VES960@ M=6YD97(@86QL('-H87)E+6)A6UE;G0@87)R86YG96UE;G1S(&9O MF4Z(#$P<'0[(&UA6QE/3-$)V9O;G0M6QE M/3-$)V9O;G0M6QE/3-$)V)A8VMG M#L@=&5X="UI;F1E;G0Z+3$U<'@G/D5X<&5C M=&5D(&QI9F4-"B`@(#PO9&EV/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO M=&0^#0H@("`@("`@/'1D(&-O;'-P86X],T0S(&%L:6=N/3-$8V5N=&5R/C8N M-2!Y96%R65A"<^17AP96-T960@=F]L871I;&ET>0T*("`@/"]D:78^ M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@8V]L M6QE/3-$)V)A8VMG#L@=&5X="UI;F1E;G0Z+3$U<'@G/E)I6QE/3-$)VUA'0M:6YD M96YT.BTQ-7!X)SY$:79I9&5N9"!Y:65L9`T*("`@/"]D:78^/"]T9#X-"B`@ M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@8V]L2`M+3X-"B`@ M(#PO=&%B;&4^#0H@("`\+V1I=CX-"B`@(#QD:78@86QI9VX],T1L969T('-T M>6QE/3-$)V9O;G0M'!E8W1E9"!T:6UE('1O(&9U;&PM=F5S=&EN9R!A;F0@=&5R;2!O9B!T M:&4-"B`@(&]P=&EO;G,N(%1H92!E>'!E8W1E9"!V;VQA=&EL:71Y(&%S2!O9@T*("`@=&AE($-O;7!A;GDF(S@R,3<[0T*("`@8VQO2!T:&4@52Y3+B!42!W:71H(&$@=&5R;2!E M<75A;"!T;R!T:&4@97AP96-T960@;&EF92!O9B!T:&4@;W!T:6]N+B!4:&4@ M97AP96-T960@9&EV:61E;F0@>6EE;&0@:7,@>F5R;PT*("`@87,@=&AE($-O M;7!A;GD@:&%S(&YE=F5R('!A:60@9&EV:61E;F1S(&%N9"!D;V5S(&YO="!C M=7)R96YT;'D@86YT:6-I<&%T92!P87EI;F<@86YY(&EN('1H90T*("`@9F]R M97-E96%B;&4@9G5T=7)E+@T*("`@/"]D:78^#0H@("`\9&EV(&%L:6=N/3-$ M;&5F="!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[(&UA2X@1F]R('1H92!T:')E92!M;VYT:"!A M;F0@;FEN92!M;VYT:"!P97)I;V1S(&5N9&5D(%-E<'1E;6)EF4Z(#$P<'0[(&UA M28C.#(Q M-SMS('-T;V-K(&]P=&EO;B!P;&%NF5D(&EN('1H90T*("`@9F]L;&]W:6YG('1A8FQE M.@T*("`@/"]D:78^#0H@("`\9&EV(&%L:6=N/3-$8V5N=&5R/@T*("`@/'1A M8FQE('-T>6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M M6QE/3-$)V9O M;G0M&5R8VES93PO8CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\ M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R M87`],T1N;W=R87`@86QI9VX],T1C96YT97(@8V]L6QE/3-$)V)O"!S;VQI9"`C M,#`P,#`P)SX\8CY686QU93PO8CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\ M+W1D/@T*("`@/"]T6QE/3-$)V)A8VMG#L@=&5X M="UI;F1E;G0Z+3$U<'@G/D]U='-T86YD:6YG(&%T($1E8V5M8F5R)B,Q-C`[ M,S$L(#(P,3`-"B`@(#PO9&EV/CPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO M=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&%L:6=N M/3-$6QE/3-$)VUA'0M:6YD96YT.BTQ-7!X)SY'6QE/3-$)VUA'0M:6YD96YT.BTQ-7!X)SY%>&5R8VES960-"B`@(#PO9&EV/CPO=&0^ M#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO M=&0^#0H@("`@("`@/'1D(&%L:6=N/3-$6QE/3-$)VUA'0M:6YD96YT M.BTQ-7!X)SY&;W)F96ET960@;W(@97AP:7)E9`T*("`@/"]D:78^/"]T9#X- M"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@;F]W"<^)B,Q-C`[ M#0H@("`\+V1I=CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@ M("`@(#QT9"!N;W=R87`],T1N;W=R87`@8V]L6QE/3-$)V)A8VMG#L@=&5X="UI;F1E;G0Z M+3$U<'@G/D]U='-T86YD:6YG(&%T(%-E<'1E;6)E"<^)B,Q-C`[#0H@("`\+V1I=CX\+W1D/@T*("`@("`@(#QT9#XF M(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@8V]L#L@=&5X="UI;F1E;G0Z+3$U<'@G/E9E#L@=&5X="UI;F1E;G0Z+3$U<'@G/B8C,38P.PT* M("`@/"]D:78^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@ M("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!A;&EG;CTS M1')I9VAT('-T>6QE/3-$)V)O"!D;W5B;&4@(S`P,#`P M,"<^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@ M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@ M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X- M"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T M9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[ M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q M-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^ M)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\(2TM($5N9"!486)L92!";V1Y M("TM/@T*("`@/"]T86)L93X-"B`@(#PO9&EV/@T*("`@/&1I=B!A;&EG;CTS M1&-E;G1EF4Z(#$P<'0[ M('1E>'0M86QI9VXZ(&QE9G0G(&-E;&QS<&%C:6YG/3-$,"!B;W)D97(],T0P M(&-E;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4^#0H@("`\(2TM($)E9VEN M(%1A8FQE($AE860@+2T^#0H@("`\='(@=F%L:6=N/3-$8F]T=&]M/@T*("`@ M("`@(#QT9"!W:61T:#TS1#0P)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W M:61T:#TS1#4E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$,24^ M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0U)3XF(S$V,#L\+W1D M/@T*("`@("`@(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^#0H@("`@("`@ M/'1D('=I9'1H/3-$-24^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@] M,T0Q)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#4E/B8C,38P M.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X-"B`@ M("`@("`\=&0@=VED=&@],T0U)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W M:61T:#TS1#$E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$-24^ M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0Q)3XF(S$V,#L\+W1D M/@T*("`@("`@(#QT9"!W:61T:#TS1#4E/B8C,38P.SPO=&0^#0H@("`@("`@ M/'1D('=I9'1H/3-$,24^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@] M,T0U)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T:#TS1#$E/B8C,38P M.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$-24^)B,Q-C`[/"]T9#X-"B`@ M("`@("`\=&0@=VED=&@],T0Q)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W M:61T:#TS1#4E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$,24^ M)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\='(@6QE/3-$)V9O;G0M&5R8VES86)L M93PO8CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T6QE/3-$)V9O;G0M&5R8VES93PO M8CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF M(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@86QI9VX] M,T1C96YT97(@8V]L&5R8VES93PO8CX\+W1D/@T*("`@("`@(#QT9#XF(S$V M,#L\+W1D/@T*("`@/"]TF4Z M(#AP="<@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`@(#QT9"!N;W=R87`],T1N M;W=R87`@86QI9VX],T1L969T('-T>6QE/3-$)V)O"!S;VQI9"`C,#`P,#`P)SX\8CY286YG92!O9B!%>&5R8VES92!06QE/3-$)V)O"!S;VQI9"`C,#`P,#`P)SX\8CY/ M=71S=&%N9&EN9SPO8CX\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T* M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N M;W=R87`@86QI9VX],T1C96YT97(@8V]L6QE/3-$)V)O"!S M;VQI9"`C,#`P,#`P)SX\8CY06QE M/3-$)VUA'0M:6YD96YT.BTQ-7!X)SXF;F)S M<#LD,2XP,`T*("`@/"]D:78^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T M9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX] M,T1R:6=H=#XT."PY-3(\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T* M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!C;VQS<&%N/3-$ M,R!A;&EG;CTS1&-E;G1E65A"<^)FYB6QE/3-$ M)VUA'0M:6YD96YT.BTQ-7!X)SXF;F)S<#LD M-"XU,2TF;F)S<#LD,3$N,3$-"B`@(#PO9&EV/CPO=&0^#0H@("`@("`@/'1D M/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@ M/'1D(&%L:6=N/3-$"<^)B,Q-C`[#0H@("`\+V1I=CX\+W1D/@T*("`@("`@ M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@ M8V]L6QE/3-$)VUA'0M:6YD96YT.BTQ-7!X)SXF;F)S<#LD+C`Q+29N8G-P.R0Q,2XQ,0T*("`@ M/"]D:78^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\ M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XR+#$R M-BPX,#0\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT M9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!C;VQS<&%N/3-$,R!A;&EG;CTS M1&-E;G1E65A#L@=&5X="UI;F1E;G0Z+3$U<'@G/B8C,38P M.PT*("`@/"]D:78^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@ M("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!A;&EG M;CTS1')I9VAT('-T>6QE/3-$)V)O"!D;W5B;&4@(S`P M,#`P,"<^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@ M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X- M"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T M9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[ M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q M-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`@("`@ M/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!A;&EG;CTS1')I9VAT M('-T>6QE/3-$)V)O"!D;W5B;&4@(S`P,#`P,"<^)B,Q M-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^ M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\ M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO M='(^#0H@("`\(2TM($5N9"!486)L92!";V1Y("TM/@T*("`@/"]T86)L93X- M"B`@(#PO9&EV/@T*("`@/&1I=B!A;&EG;CTS1&QE9G0@65T(')E8V]G;FEZ960@:7,@ M,2XY)B,Q-C`[>65AF5D(&YO;BUC87-H(&-O;7!E M;G-A=&EO;B!C;W-T(')E;&%T960@=&\@=6YV97-T960-"B`@(&]P=&EO;G,L M("9N8G-P.R0V-C$@:7,@=&\@8F4@28C.#(Q-SMS(#(P,#4@4&QA;BX-"B`@(#PO9&EV/@T*("`@/"$M M+2!&;VQI;R`M+3X-"B`@(#PA+2T@+T9O;&EO("TM/@T*("`@/"]D:78^#0H@ M("`\(2TM(%!!1T5"4D5!2R`M+3X-"B`@(#QD:78@3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R M=%]C,C1E-S,P,U\V969E7S1C-V9?.35D9E\S939D.69E8S8Y8V4-"D-O;G1E M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8S(T93'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/"$M+41/0U194$4@:'1M;"!054),24,@(BTO M+U&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L M+F1T9"(@+2T^#0H@("`\(2TM($)E9VEN($)L;V-K(%1A9V=E9"!.;W1E(#8@ M+2!U6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M2!I6UE;G1S(&1U92!U;F1E M'0M86QI9VXZ(&QE9G0G(&-E;&QS<&%C:6YG/3-$,"!B;W)D97(],T0P(&-E M;&QP861D:6YG/3-$,"!W:61T:#TS1#$P,"4^#0H@("`\(2TM($)E9VEN(%1A M8FQE($AE860@+2T^#0H@("`\='(@=F%L:6=N/3-$8F]T=&]M/@T*("`@("`@ M(#QT9"!W:61T:#TS1#@X)3XF(S$V,#L\+W1D/@T*("`@("`@(#QT9"!W:61T M:#TS1#4E/B8C,38P.SPO=&0^#0H@("`@("`@/'1D('=I9'1H/3-$,24^)B,Q M-C`[/"]T9#X-"B`@("`@("`\=&0@=VED=&@],T0U)3XF(S$V,#L\+W1D/@T* M("`@("`@(#QT9"!W:61T:#TS1#$E/B8C,38P.SPO=&0^#0H@("`\+W1R/@T* M("`@/"$M+2!%;F0@5&%B;&4@2&5A9"`M+3X-"B`@(#PA+2T@0F5G:6X@5&%B M;&4@0F]D>2`M+3X-"B`@(#QT"<^,C`Q M,@T*("`@/"]D:78^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@ M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H M=#XT,3`\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T"<^,C`Q,PT*("`@/"]D M:78^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^ M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XT,SD\+W1D M/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T"<^,C`Q-`T* M("`@/"]D:78^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@ M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XT M-38\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T"<^,C`Q-0T*("`@/"]D:78^ M/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q M-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XT-34\+W1D/@T* M("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T"<^,C`Q-@T*("`@ M/"]D:78^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\ M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XT-38\ M+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@/"]T"<^)B,Q-C`[#0H@("`\+V1I=CX\+W1D/@T*("`@("`@(#QT9#XF(S$V M,#L\+W1D/@T*("`@("`@(#QT9"!N;W=R87`],T1N;W=R87`@8V]L6QE/3-$ M)V)A8VMG#L@=&5X="UI;F1E;G0Z+3$U<'@G M/B8C,38P.PT*("`@/"]D:78^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T M9#X-"B`@("`@("`\=&0@86QI9VX],T1L969T/B9N8G-P.R0\+W1D/@T*("`@ M("`@(#QT9"!A;&EG;CTS1')I9VAT/C(L,S$Q/"]T9#X-"B`@("`@("`\=&0^ M)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\='(@#L@=&5X="UI;F1E;G0Z+3$U<'@G/B8C,38P.PT*("`@ M/"]D:78^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`@ M("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!A;&EG;CTS1')I M9VAT('-T>6QE/3-$)V)O"!D;W5B;&4@(S`P,#`P,"<^ M)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^ M#0H@("`\(2TM($5N9"!486)L92!";V1Y("TM/@T*("`@/"]T86)L93X-"B`@ M(#PO9&EV/@T*("`@/&1I=B!A;&EG;CTS1&QE9G0@F4Z M(#@U)3L@=F5R=&EC86PM86QI9VXZ('1E>'0M=&]P)SXF(S$W-#L\+W-U<#X@ M:&%N9"UH96QD(&EM86=I;F<@9&5V:6-E2!B=6EL9&EN M9R!A9&1I=&EO;F%L('5N:71S(&%N9"!P97)F;W)M:6YG(&]T:&5R(&1E=F5L M;W!M96YT86P@86-T:79I=&EEF4Z(#$P<'0[(&UAF4Z(#@U M)3L@=F5R=&EC86PM86QI9VXZ('1E>'0M=&]P)SXF(S$W-#L\+W-U<#X-"B`@ M('5N:71S('1H2!E;G1E28C.#(R,3L@6QE/3-$)V9O;G0M2!H87,@86X@96UP;&]Y;65N="!A9W)E M96UE;G0@=VET:"!I=',@4')E&5C=71I=F4@ M3V9F:6-E2P@2!P97)F;W)M86YC90T*("`@8F]N=7-E6QE/3-$)V9O;G0M2!A;F0@8V5R=&%I;@T*("`@;V8@:71S(&]F9FEC97)S(&%N9"!D:7)E8W1O M2!A;F0@;VX@0F5H86QF(&]F($%L;`T*("`@3W1H97)S(%-I;6EL87)L M>2!3:71U871E9"!V+B!-14Q!(%-C:65N8V5S+"!);F,N+"!*;W-E<&@@5BX@ M1W5L9F\L(%)I8VAA28C,38P.S(P+"`R,#$Q+"!I;B!T:&4@&-H86YG92!!8W0@ M;V8@,3DS-"P@86QL96=I;F6QE/3-$)V9O;G0M28C.#(Q-SMS(&-O M;6UO;B!S=&]C:R!D=7)I;F<@=&AE('!E'0M=&]P)SXF(S$W-#L\+W-U<#X@#0H@("!034$@ M07!P;&EC871I;VX@;VX@4V5P=&5M8F5R(#(R+"`R,#$Q+"!T:&4@<&%R=&EE M6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@ M3F5W(%)O;6%N)RQ4:6UEF4Z(#$P<'0[(&UA2!D969E;F0@86=A M:6YS="!T:&4-"B`@('-E8W5R:71I97,@8VQA2!L:71I9V%T:6]N+"!W92!C86YN;W0@<')E9&EC="!W M:71H(&-E2!T:&4-"B`@(&5V96YT=6%L(&]U=&-O;64@;V8@=&AI M2!T;R!C97)T86EN(&QE9V%L('!R;V-E M961I;F=S+"!I;F-I9&5N=&%L('1O('1H92!N;W)M86P@8V]U2!I;F-L=61E(&-O;G1R;W9E2!B92!M871E7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A3QB6QE/3-$)V9O;G0M6QE/3-$ M)V9O;G0M28C.#(Q-SMS(&-O;6UO;@T*("`@&EM871E;'D-"B`@("9N8G-P.R0Q,BXU)B,Q-C`[;6EL;&EO M;BX@4'5R28C.#(Q M-SMS(&-O;6UO;B!S=&]C:RX@5&AE('=A&5R8VES92!P28C,38P.S4L(#(P,3`@=&AE M($-O;7!A;GD@7,N($%S(&$@28C.#(Q-SMS(&-O;6UO;@T*("`@&EM871E;'D-"B`@("9N8G-P.R0Q,"XW)B,Q-C`[;6EL;&EO;BX@5&AE M('!R:79A=&4@<&QA8V5M96YT(&-L;W-E9"!!=6=U28C.#(Q-SMS(&-O;6UO;@T*("`@65A<@T*("`@=V%R&5R8VES92!P6QE/3-$)V9O;G0M&5R8VES92!O9B!T:&4@=V%R&-E2!H87,@ M8V]N8VQU9&5D('1H870@:70@:7,@=6YL:6ME;'D@=&AA="!T:&4@0V]M<&%N M>2!W;W5L9"!B90T*("`@6UE;G1S M('1O(&ET28C.#(Q-SMS(')E2!T:&4@4T5#(&]N($9E8G)U87)Y#0H@("`Q M,BP@,C`P-R!A;F0@4V5P=&5M8F5R)B,Q-C`[,3$L(#(P,#2X-"B`@(#PO9&EV/@T*("`@/&1I=B!A;&EG;CTS1&QE9G0@2!F:6QE9"!A($9O28C,38P.S(P,#DL#0H@("!M86YA9V5M96YT(&-O;7!L971E9"!A(')E9VES M=&5R960@9&ER96-T(&]F9F5R:6YG(&]F(#(L-#`P+#`P,"!S:&%R97,@;V8@ M=&AE($-O;7!A;GDF(S@R,3<[28C,38P M.S(P,#DL('1H92!#;VUP86YY(&5N=&5R960@:6YT;R!A(&-O;6UI='1E9"!E M<75I='D@9FEN86YC:6YG(&9A8VEL:71Y("@F(S@R,C`[0T5&1B8C.#(R,3LI M('=I=&@-"B`@($MI;F=S8G)I9&=E($-A<&ET86P@3&EM:71E9"P@<'5R28C.#(Q-SMS M('-O;&4@9&ES8W)E=&EO;BP@=7`@=&\@=&AE(&QE6QE M/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RQ4:6UEF4Z M(#$P<'0[(&UA2!I65A M<@T*("`@=V%R&EM871E;'D@)FYB'!E;G-E6QE/3-$)V9O;G0M2!A'!E;G-E2`F;F)S<#LD,34N,B8C,38P.VUI;&QI;VXN M($%P<')O>&EM871E;'D@)FYBF4Z(#$P<'0[(&UA3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C M,C1E-S,P,U\V969E7S1C-V9?.35D9E\S939D.69E8S8Y8V4-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8S(T93'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/"$M+41/0U194$4@:'1M;"!054),24,@(BTO+U&AT;6PQ+T141"]X:'1M;#$M=')A;G-I=&EO;F%L+F1T9"(@+2T^#0H@ M("`\(2TM($)E9VEN($)L;V-K(%1A9V=E9"!.;W1E(#@@+2!M96QA.E-C:&5D M=6QE3V93=&]C:VAO;&1E6QE/3-$)V9O;G0M6QE/3-$)V9O;G0M6QE/3-$)V)O"!S;VQI9"`C,#`P,#`P)SX\8CXR,#`W/"]B/CPO=&0^#0H@("`@ M("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D/B8C,38P.SPO=&0^#0H@ M("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!A;&EG;CTS1&-E;G1E2`M+3X-"B`@(#QT"<^3W5T M#L@=&5X="UI;F1E;G0Z+3$U<'@G/D5X97)C:7-E M9`T*("`@/"]D:78^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@ M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H M=#XF(S@R,3([/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@ M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@ M("`@("`\=&0@86QI9VX],T1R:6=H=#XF(S@R,3([/"]T9#X-"B`@("`@("`\ M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@ M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XF M(S@R,3([/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^ M#0H@("`\='(@=F%L:6=N/3-$8F]T=&]M('-T>6QE/3-$)V)A8VMG#L@=&5X="UI;F1E;G0Z+3$U<'@G/D9O6QE/3-$)V9O;G0M6QE/3-$)VUA'0M:6YD96YT.BTQ-7!X)SXF(S$V,#L-"B`@(#PO9&EV/CPO=&0^#0H@ M("`@("`@/'1D/B8C,38P.SPO=&0^#0H@("`@("`@/'1D(&YO=W)A<#TS1&YO M=W)A<"!C;VQS<&%N/3-$,B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)V)O"!S;VQI9"`C,#`P,#`P)SXF(S$V,#L\+W1D/@T*("`@("`@ M(#QT9#XF(S$V,#L\+W1D/@T*("`@("`@(#QT9#XF(S$V,#L\+W1D/@T*("`@ M("`@(#QT9"!N;W=R87`],T1N;W=R87`@8V]L6QE/3-$)VUA'0M:6YD96YT M.BTQ-7!X)SY/=71S=&%N9&EN9R!A="!397!T96UB97(F(S$V,#LS,"P@,C`Q M,0T*("`@/"]D:78^/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@ M("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H M=#XS-#8L-S@Q/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@ M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@ M("`@("`\=&0@86QI9VX],T1R:6=H=#XR,#`L,#`P/"]T9#X-"B`@("`@("`\ M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@ M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0@86QI9VX],T1R:6=H=#XU M-#8L-S@Q/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^ M#0H@("`\='(@#L@=&5X="UI M;F1E;G0Z+3$U<'@G/B8C,38P.PT*("`@/"]D:78^/"]T9#X-"B`@("`@("`\ M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A M<"!C;VQS<&%N/3-$,B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)V)O"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]T9#X-"B`@("`@("`\ M=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@ M("`@("`@/'1D(&YO=W)A<#TS1&YO=W)A<"!C;VQS<&%N/3-$,B!A;&EG;CTS M1')I9VAT('-T>6QE/3-$)V)O"!D;W5B;&4@(S`P,#`P M,"<^)B,Q-C`[/"]T9#X-"B`@("`@("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@ M("`\=&0^)B,Q-C`[/"]T9#X-"B`@("`@("`@("`@/'1D(&YO=W)A<#TS1&YO M=W)A<"!C;VQS<&%N/3-$,B!A;&EG;CTS1')I9VAT('-T>6QE/3-$)V)O"!D;W5B;&4@(S`P,#`P,"<^)B,Q-C`[/"]T9#X-"B`@("`@ M("`\=&0^)B,Q-C`[/"]T9#X-"B`@(#PO='(^#0H@("`\(2TM($5N9"!486)L M92!";V1Y("TM/@T*("`@/"]T86)L93X-"B`@(#PO9&EV/@T*("`@/&1I=B!A M;&EG;CTS1&QE9G0@28C.#(Q-SMS('!R:79A=&4@<&QA8V5M96YT M(&EN($%U9W5S="8C,38P.S(P,#<@=&AE#0H@("!#;VUP86YY(&ES28C.#(Q-SMS(&-O;6UO;B!S=&]C:RX@070-"B`@(%-E<'1E M;6)E65A M6QE/3-$)V9O;G0M9F%M:6QY.B`G5&EM97,@3F5W(%)O;6%N)RQ4:6UEF4Z(#$P<'0[(&UA2`F;F)S<#LD,2XW)B,Q-C`[ M;6EL;&EO;BX-"B`@(#PO9&EV/@T*("`@/"]D:78^#0H\'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQA'1";&]C:RTM/@T*("`@/&1I=B!S='EL93TS1"=F;VYT+69A M;6EL>3H@)U1I;65S($YE=R!2;VUA;B6QE/3-$)V9O;G0M'0M=&]P)SXF(S$W-#L\+W-U<#XL(&%N9"!T:&4@0V]M M<&%N>28C.#(Q-SMS(&)U2!E:71H M97(@<&%R='D@8GD@<')O=FED:6YG('1H:7)T>2!D87ES)B,X,C$W.PT*("`@ M<')I;W(@=W)I='1E;B!N;W1I8V4N#0H@("`\+V1I=CX-"B`@(#QD:78@86QI M9VX],T1L969T('-T>6QE/3-$)V9O;G0MF4Z(#$P<'0[(&UA28C.#(Q-SMS(&%C=&EN9R!#:&EE9B!/<&5R871I;F<@ M3V9F:6-E2!R971A:6YE7,F(S@R,3<[('!R:6]R('=R:71T96X@ M;F]T:6-E+"!O2!U<&]N('1H92!M=71U86P@86=R965M M96YT(&]F('1H92!#;VUP86YY(&%N9"!$F4Z(#$P<'0[(&UA ZIP 31 0000950123-11-095253-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950123-11-095253-xbrl.zip M4$L#!!0````(`-5S9#_'GBZ@,T<``#K\`0`1`!P`;65L82TR,#$Q,#DS,"YX M;6Q55`D``U(OM$Y2+[1.=7@+``$$)0X```0Y`0``[%U;<^,VLGX_5><_8+65 M;*;*DG@1*S%A>R]E)SDL*)B$)%8ID>+&M_/K3#9`2J0M%2>1, M=FM34[%-@NBO+VAT-T#PZN^O"X<\LR#DGONNH;:4!F&NY=GT3#7XC0\]?!GPVC\AWPS?D M:4D>'LBUY[K,<=B2-)MI)Q]H",]ZKNQ-:ZG)O=>GP"&`QPW?->91Y%^VVR\O M+RV\W/*"65M3%+W-W3"BKL4:LN6EP]W?"IKC[2>@ES9_W6K_HHO6:K_?;XN[ M:=,%<^BJ)?X!H@#9L+!E>0OH7565OJZDK7GH=32U6X1RC0[M!VJD)#3TW8J\1F3`K`LM-#,A*KG+[7>,#=9#T(!Q/ M?]75L15A3PCDBKD1CY;X&[?Q]REG`1&P6(ZG5`+#VQ\;[Q7@3#%40^U/ M82?M=7\^"[AGBYX%Y]%[(3E5`X,`]'KLWLKZ`$@!M$US!1 M)&KH@@^Y:J^O"AAVIH'44WKM3#Z_G+)R?"J'^%1.X_..NW\R=:IUJ',?FU]/ MF\5LGJC-'=Y%Z7\%[P+@3_(NN[S[UYJ=RGIWB!M^G0_D:$*N;+Y,P"1?Q#9ZBY>8-CK!>E5N+Y@-(P#]CZ)[2ZADZMV>I&D3[=W M/BXZO6:NM^#NGFY%P'<9SFG`PGW];O5PU5Z#ETWRC$Y$=RFCQ:1$W+;J(R^M MI(<#0LCUD$1O(P>LP=V,WN#.M6?%XLZM._6"!5WIZ0K"T,N1,(4'-N-A%("N M[^B"D43!#Q@Q%OC(3Z./`S(9WH[NAJ/)!;F]&[9(^^Z7J_:^CO-$AP`JH,XM M=/OZ(R0S):EF[7IO9RFE81P$<.>&AQ9U?F$T&$F74I98,QW*19WEV?H,J=F/ MKO?B3D!;GLOLVS",8;R6I'CG9=G:TUF>XK\\)W;!ERYON`-9YVF4-CK94)7D M_('Y7A!!&CN):!27)O0+6O^ASO($!8@AR';F!:4M8V!9S$FR:-%!EFJNQY18 M.C8>(6$J2P7SO;E(@T`^?G*X M=>-X-,J1V)T4$IM9?`%Z>=>`/]#5BL;"1:NFKJB&9O2R]I7I?F/L>(N%YTXB MS_I-SA+C.,)I%<#U\8?H]]C_DP=?&X0#6D0+*'K M?U$G9@7"3767EV=.U"#_&M(DM0BRKAB: MTE.U,R#?!\RGW!Z]^LP-&3PZCN8L&(0AB\+$7YXIUY[1[RJ]-<02%(\%N)*H M=JY$#4TWN]K)8*N4F]KM&;U^K[L&4Y+L2AKZV?:E*IU.I]$^\"!0!V\$ M-"*0$UJ?CZ/[CITO",TP52.KE/VT2F-:2:ESKI0TI:N;BG8\OEL(>]P9?W*8 M%"O<'KU:3HS.\GO/LU^XXYPI.U-3>_H:61F*1R-<2=(X5Y)=52UGJ^(9J:WE?7\`Z2.P[;2HSFN6(\!V?&OZW;G"DW MHV=V^AF][J1Q&,1*0-VS_9K>[2K&$8#DO3/%H"E:WS"[6]YT!Z$5J[WS685) M1.LKA40MRX,4++RG2PJ#K9KIR]0@G#(S9'<2*0%C)8O^N;)0E;YI9/5>"E,0 M,_LCIT_]WC2.17M)ZFJ%L.(IB4>S#L5;1V6$_N!%]TYT6@ZI<+JJN M]I1>!L31]-?R.#MH5\V>J:BEP:3SX0-<'\)/'E4VTZE:OYM531&ITI#6DCH[ MH(=X7EVD<1C$6CIG!_*;TCD&T;G"Z'2Z/ M:K>OZ)IVD#R6=W@DBC9890":$(HSUT(X^>Y?0W[I6CKMTPBM MI6"6I[H62GNCUB#'@RA@G5A4VL!PD,":@5/BVO+4[FDP#K#DS6Q!^)X%HD1W M+(>XKK91&WS?4I5(G86GO(RJP7.NUST>U,;:YGG(*A77'F0#&S(\[KG4 MN:?M!:MW)C)9M$@<`K.5S_HH]9-J]OED:328/ MASRX.OX_O1P^#Q=GRWN>'D M@86,!A;NI;AFS\SQQ/IML@T@QTK!UOQ"R7?T;D_-#9,"BA5#.U1>UDVS6R^T M_=NK"M>'3;W3Z>M?!5FQS,SNZ<@(R^?Z=`^T&]H*[8M-JQ)]9A;:FF[U^ M/[LB?(!FY?`.[9_0P2UJM<,[S>9Z6E]5N\I70W=@J5\WM$[_--F-?=RR"E/R MK6MY"_;1"\,JK*UIJEJWE]T/LX-0)3@.A"*=OMGO=?3*<)QF/TW5Z&N&:=:/ MXX`XU(ZIP11:7B^W[C,+10U>WK\%")!;1%48B:ITMP4?-V%V\>&+!>%I<[BUEDMLU7R5;\3T'S)=AIKB`+9C!0T`PH_K3,%/& MV/]=%%-F9.SF13=UL],QS^?E4-5M.)C\\.O-Q_'GS:K;-?,#@"3>%,8,=H'O M:?XA_JPBKE8-(YLJ%U"K$M2!NF;?['5[1X-*G16SA]X"`Z.JA(35#LW,S"^[ M*56$Y[MB^?QHB+?,V5B&M?')F M!0Q07S/Y\]9-WBI+=U_N?+NL`EWJNJGH9C9W.P7(%V+E0)BH=2&!J9F7C=IO4JQ9G70,4.0]5Z MA6CW$J\3\P''H$.P=3;F.Q;AJ^SW@8=GX-@?EC_!Y`_/KBS=BOAS=6+6L41N MZ+E21$GZ-:(^Y(%UHZ5I MUXCXT,LAAM;3C;,Q!Y[%F!W>!-YB0ATVGL(5.T:-L,HF#-PSE'L=_0#)$L8K MZ_Z5#[D-.RA/O$;(A\:;8JAZUA!.`YW3"FY>&?N80(2C5Q98/#RMWK4Y'9M* M=Y\A["*Y*D1D6Z9W(=G'9S[3`$_5JL1,3=Q]IR<%AQ(T]\D/=X=BL>$6:''J MR!-QQE.8PD^ICNP":FR]]E"2^BY_E7"5/B=>R*\"I=;IZ-E5U2)Z.U4MW[J* MF"UW4,D#`X")&VKAY%SN/*Q#<4'7D*(\FOIN4:Z:525&LZMV=\DP3ZB$_UD] M4*G_T92N:II&]Z#_V4'^\%E%\KBLS6BMFN#*T%1#S[YU<02"6I$?L`<%DH5. MIR[AI=PS#-@T+=`5.XC?R1)NF8 M',YI,&,V!&2[-W%7,?IP`V_BNTX#D1;(/[`9=\D'![>T/](9/$+NO(AM5,3' MP8RZ2?UW"%.UYW`[K0W?!RP$(5%9=TQ04$>\AR-\UC4/+1\H\/[5?L2\6'DU^;4>;)EAW9#9#!M[/HK3B0-`&R M5UPJ:9*ZA+4!P^;/A#I\YKYK.&P:-4@8+1WVKC$%$3:G=,&=Y27YVR-?@)^_ M8R_DP5M0]V\7XL)%".YAVMAB"P]JO7##71S+6Z^;MS(H+(:;;_(X0OX'NR2J MXD=OR0(LD;O-R/,O"5P0U+&+I_27]E.N:SQJMI#CTJV+D>T#\I_4Z[:%[-., MJFU245MD_/#]X.[V_\3>=#*XNR8?!I/;"1G?D/N'T61T]RCNG*+#4IC,!)(\ M:#?Y4L8%@=FM=4$HN0;W]R)?*@Q\+Y#K/=]%XAH-=9>K M*^K;-Q>$A_#X@MG<`G=LLV=N82>B(9GBV9GB6R("/'9GLQ"07V#+=`LUH2ZF M1HL%9@C`6+(2YTVA8]=SF]Q]IB%DMA?$]SBPZ$V;%D+]#MR'Z-*S(B](4:G= MMZ&@YDVG@.4-P9.G`WEL<>01<-PD?8Y%R0''0(K1P%D2G`5<&.0M\@@--OC% MGLG4H;-PSGWBRXS[0M#Z!,^!![)1/6'L[]!(S_CF+7[()4(Y-87Z+@GZ;52/ M-!9!1NUVI"5"-WCU@DP9C<"'H9CG(*GFG#G`PH+.,!-*!![-:408Q-HA<<07 M7H"C1>Q$W'>8`/A"0=S,G<',@%*PJ(]]BFZ@9V@=QJ'/+>[%(?'Y#*4%>@M_ M`U$Y##\^$PHM`=Z`6A$!)YS("'\CH(U4P2ZTH\X2W[6,(PCR_T"4@@Q*#&PN M%`F<0^$7T(]4-75F7L"C^0(L,,O+'K])X<8!=^0%G>,:P((PH M\#,R@N]$AQ+Q$W-!U"D3%\B\+\-J,(/5(=;",@!1&*7&`8X>,`NK@3[ABJ#C M0VNXE+,(&[):(`TCP4U.LLOU#`-@&CMKFX,D.#&YESG#BBG2?N*>'RY%"XFT M5=/P1Y7AZ/1?("FP7B=%V+.8Y/;?E]I.3OT*=6^O<^60E6$K:V)\8H(,^)R)'=O;U8 MGN,%E^2O\@7AM^2)6K_-`B]V;1`6QD0^Q0-GUIV3E("=0FQ"F.5SFT] MT%QPVSC:`MJ$L/W-%B/R[V!#F;M$LZW2U/+VBVEW[_\U%6$(&1>]=L]K.P%E M[IYG4@-Z8>"['0YA@G"03#I'S,363OJGUJ3U%HVIC&;:PG,<#JW^O$[HOW9; ME]VNK%8:X2H^84&X[=HP]@P]?P[1`@8P8+\PU>-7T\3DF`EFDK`LB9F2KI-P M3H#(Q@DB")9DE^E8R$0!%1GWR8'#V(7L_)GA'D&B7A"L*5R(,9@$R01LB9]19!$9I)QEH=Y_RD,%]ITDOJTSF*N3XT\#R!M"2`V>9!4? M'3&*'[2"'O@?L)@MF&6O/AY&")T$$#&P%_S^ M9-)7BPQ@+GCVL)X7!5Q6]3"WDA3!WX-M\W`NVH=TRJ*E3$:F4R:6/%W(*L`T MZK8`E(7/`ARRF-VX-L;N`(F*U$FF411">;F#]S[P(@^\)1G,`B82"9BI'$>` M#*/87A(&/(B,-H3)#GS*@D4M(I(JR/8@_DG36$$D%9!\5+3W8R$6MDIH5UYL M$%ASD(M`=,W0PX#7GBTSTR\\,8:L&49S5H.J0KZ#A-N!K.N-$/$->PKB-,G" M,4^^@TG=C=[(Y`\M)&/G8D-PS0J0U@,\K^TGYP:2MV4%^GMPIT!$@)_$$#E` M*'(MXM60W%.7;0Q@O)(;PCSC\T"2*)^$;_$P*`1P3.FS%X"!+HE(9,&$<1\] M^3W&I6+PX3)O],(CVBJ=1A^J4844R&I!L-F`I9(^Y, M2H[&+94MMW]#=IL1?V+<20$6HG6@@EW5:!/@(``#BM9>&3K,)1!&/J6?L84$ MW8I#6<3`&5GZ(U><=63'8D$Y6BEUP1A";A$0Y2=:*,4I=X0$0X;^JD"0LC82 M)'_"W`&.<2'$9\%0XQ:G&/92+&U$./9D<4`$P>AR9)T;246[@`Z^@IK8*D_CU@TH*%^R'0P8#,\0D:F`-P550J'1:EVDEDC\?*5%2VJ-\CL'V`2 M+5+CY+\5>X$-)<$)YBTQZ!\?.%K_(JK<=MR:1:6I9-4=0V3B02';D![9C M'[`)/GQ18T2TJYBY_L+/'#X78`XPTKRH4N0SI!\:'Q3&@(ODCJMB;C M_XST<@)+#2+/A^]05Q2\'1J[X$]KE.=Z`0-"@;0^X8J(5RQ)RD`@,]],>1!& M$"?0(%K%%UJ-@<$@GL5AE!#:-YSPHC@`0!;B0+#9)5CYQA>^%T8#.[V6C:%N M)^-L!"6]@*IW>@:Q4*:KBG]!(H>./V!SF*`!4;8.GY224^44US\Z9)[OF`\+$0F6W?&!(3R41FA5H!O MF2,:*5#PWS!*DOH'3OM`!@(EXHFE$?&F21&8BHQ+1HQ@:D&]#9"AFV9KM)[<*"]3A>>ZC*Y4A*8_(ZGM:'#"A MZC@>ZD]?(+61N_\QK8&D'-3*G642'0=>/$OK)8YPAR`D`0AY!_KXL./]]= MQ"()-!J-?G>#N^/R0QOT]"PK67?/H9W9?S;,8 MLVHY6\#2*:P6Y["R#JWRPRR=1UN4"1\^%*0"J4=_($Q7L>]=PU[*]+5/:"'G M#AQI24[=8,(GOGE$(!$OH)F+_*!)9JHKT]*6R#`\#'.9E$O[AS+B.]!+*F"K MWSK=1BO'PPP.E*_3-:K(R""*(J;*A,`6+&9@B3*V6>@VGX.I@T:`2;I2JL1^ M\HW-3>#P_!LE\>:.?6EMXXX01P8BC2G06=0G9%P2Y\#O@0I1(X+7)%\!%$]@ MAUG@VJ;DC:X($OG>F`G!Q@^,;!3D&`_Q!Y2BMY:9=P9',,,')EU;S)`N]%2HU M:%%1@)8:ZS9XUPRSG#"*X3\NJ!H4G4$8E#+BRA$E%2KI"V.@M$24&!((9:R+ M02X4#.Z"Z";W:A:(!3^L^F@D0*GF:A=\8_B=Y0F-G_N$"RK0:'A7YH?0"S&K!S\'=6\LN1\!`SP3V=P(V6"#P.I(*KT9'[B44UXC1Z M?#HC@`K)0X'GLF&#%AB?'K1PN+#+X4EYWN4 M;RY@(9+JI+D#20;:A]X"N6]Z&Q2&X+3XL^IE)M,H"S#J"M^Y$BWAOX#3$T*U M=TY2&QM%5>,HU"?,-MB@TJA>=K`'88AZR07MK[FY?RC3BV:\PV0M@74)U@DH MIR5![#R;3EB`W?`O^:C')7/`.%E)VFI<>2`)+?"E%XTIQY@V2YV,A=E6;B(J M7)HC--@-!^_*8+#!_BT5A;L1IEVJ7B06BF_#F\C)*)"N5H.;L$00:[4$HYBN M]Z^,NX*2^I#X'MI8-$\H,(T7\[I(Z(.*[<=*;S:-Y>0>HLT/B,8FTI]*)I;Y MWWCL)6/"^_HHZX\R:%902OZ#T81RPZ4DJNIG"*`MJ_FYORJ(RHZ^8EGL,$E) M>TQ>;V5/RSJP5BVXYNJ<#=5RM!K6U]$0"S>&H\O3SX/+X:CVJ@WD7BS*]`%; MPI:0:-AES5$<0Z29XFQ1]DG!6B'EI%[.&E7&2?9";1X?6=`I9UQYCI%X@Z>R MCDF).I)'H8S`DSZC)D)TRKE)`@X4&!U+\&]3`V`G%M\:F2[]*-7Q87)H2@UF MJ;#CT/(B3-K-R54/U'@J,=RSQF((LU0JRH)Z%H$%9-HI.:[`*B8O:\0.E`-. M41B;/=:H+IZ1EYO_+C=8TH"`<<"N`,7RQR3^/1]]+UH3A)W24]<:B&,DZD!F M*C.#5D2B9626,W,6(L)%L>1AYH"'WEX8[HI-'.7^I6477)?2[:7"FZ4,1#/X M77O"X$+P=T`**-!+<&=;;QW[\/`(3QS6.)&%7R`$N=4!#_3OD@"A)IX47?V#VL\EV` MA$6^EQ(?Y-M<0=4HASZ`C(^J!-2[RB>58WP9?!R^OQ@._JBJVGRB0#+5E%5R M<3.JAE*$!EH@'),9AW?M#.,XBH^C.&87Y"O60=I&=?&#,+'Y[=^0/M)N6!?# MX^'9I34X/C[_>G9Y>O;1^G)Q?@;_/AY^A@?UZR=GP#X>IHX_"/>;/0#E#M&O ME]@[!K$O7?6N$79'4W;#.AM>6I_.1R/KR_#".C[__/G\S!K]-K@8UD[1U"Q9 M!Y)1<.K8%UV^*KZ3R8KEGT&FZS_Q$!X^H"3JFKOHW M/KE=:2XW36/_*DN5V]B,NO^9IRRCGM'@#CA":U2JD9V""@93LI7"RG<6BT/`HBZ718!A4H M%J#]8:B$79E7]^Q<@G%UTE*,W2JNQ=PQ#$C`2P?Z(>ZS<$&A4IGY!*V1I]NP MOBRL%_>.7G.OTNIY&-< M+?WE`'^BX8[-]"0I1!?$XC,2A$0&)>H0@"W;:?7LPV;G^8!X$K!]QV[UVQOF M1.NQG(W1@5*@=HH0NIV>W3]T7@(9])R.?=3LU2Z.'+EY&Z:%'+(:"&"!Y9L\ MOH#)$L=GF[>:W6]CUW=R'>OQCV>6,9>8$+A3O*1E]_IMNWO8?0G" MY6C/3PKO;>HLMN$L>E&&*MKVF,K.+^9^';A*OUVGRTJ5LWNI[W6SCNT\2^5\ M8MZG=<%!/6IFF]^XI6\[>+7N[Z[A_GXB;G;-2:Y-PF[#&EV>'_]Q\'XP&IZ@ MC_S+\&ST/+U$S3H+S+C%&/+2Q`:LKN/`/E8#6=2_'MN/HJ,4X_7PN)!/26_A MKV92):HVAK4!#CU3T1+E MP<,H1'/5V[%/.GBR]`OO%2TJU<-CS0:&P&XG5\H8#\0L8I M(Z\T.Q;.&A[YJRSES`E^.8RL$.CZFIW1,]EMX@J+1+Q5R7A/(K&1@0*CY4Y5 M;J6Y&%G+F6<8RE9$F%(PCZD!3.Y-AX4%(F'S,)VZJO\GM7JZH=;HTM,O9P@7 MTHMH](8E+]_0D^7P:F*F22B6HA.P,+U!'AB,(.49&OPCU].H%(D;-Z:H1)Y) MDD^KII,!)MIS\7WN?2MGW0#%OBAV79D6@SQ#3.%1J?.)-PNZ:US5/C8:2W[DF8V/K&>/BVOJBJERFPM(4E]L8%3WJ&(\FQDZI7\53$?;L>HD[%XX>LG,]'D.J-I MY=;ACJF]8I0:^4D*4+TPC4[59Z,FROT@$\A";-7#I4TRK=W`NTEY]L8(/2=A M@D1S[B()'V&?K@()=X_6)N%NKUWXN+V;)*QR,'>`A"=KT(-.U-M-DN:JMENJ M^.=J0UT^3!M3&8\6^EXKECP84J<0NY1F> MIK@"Z7*$I0,`"H\+*Z/):UK>?;1`T/C6SR!/!0HXX=Y;( MV1UG,-"P>![WF0P[$9??S_+#9C*TBDX&I?&@4\ABKU#N7-ABD&*;X+^BO7Y< M,L)P4:SE6+7T:Z\V&:-B_=8^0>.>X,E0U:,&_F0Q8WP#NZZWM5W><7R[U^BR MQZ/VF;H'H-M53K6$<=2?%*%Q?Q-A97F@NAD]ZP[TFXUNYZ#?:[1;?ZE_NYV# M7G]AFO4VX)D/QH6??#N8H$U$-=-XR04V77O^#7(:[<.#=J/=J7][6HU6#Z;J M]AZY135LPPEFXF-C]CM?!-[S8[]9/]87I[A?WCPV&/IDLU68\D)YD)2Y#K;J M5=Y*-S5?IYI!:HL4!`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`\ZCQZ*Y-N_[>>D?GV;.;92;!3ATLG5W0VIG=V[^W6^]M31!]B.*) MH,MFL*LR-2NH)>MVB5:O-:?'G:R?NDW,[UO1=ZL\,;[R\S:90:_1?1%:WP_` MM)8R&S)B=N)AH+[]U[W>SNI%9;\&2LR.7=*;=Q"J^*G.30ZC?:+$&T@ M@E\*2AV[L_'NSWOYMB--.O?OO;SWUA-PBL3)W1^XX3=K-,<+]0Q/_PLY9OOW M]N^]`C?'GWP[9D5UWDO1!@_[';O9><;["IZJ"W9>A(>^^YP>^J>AM-=YM"7P M2C5!`UM[;7#_WF[(LXTW;GBU]:"=YFY4T>UGV<^RGV779EE;9]E7:50C^I&I MSZJ;O>$UITF>.0]TU]][P*6D]>D:^_-0RWE8DEC<7)U8K.IA#_;'Y4G'Y7%I MW8IM#7/WSM/W87_FMB.#7F`)[3:KX7?]O:?B=`,<=7^2M[.%+ZJR?`?8SZZ_ MMW64[OI!?EHY\DLZ)2^T-/XE=B%X><2Q.2QO^L"O3$5_G.UQ@?UWLEOT]M:_ODS_9]3/_N(41K;W*E6W4EM_!]6UHYZHXY"LI1:?& MV_DB=R`/IW-H'W5;SPC!?;=%M#9VH3):^_4> MW^>6QW"HX6C3+1@[=;8[G9;=>\[F%?><[,X&+SI[$@GV&]T=[$%14>W6[-C= M9]W`)Z+U\8V&EISLEYZ-*U&UKSO>O[>G@Q>GLY/*OGMR?1M%T,]WA>D/46[] M`U4NO5+);J!K7V?SH[^W)X8:9/P.W/8ZH$OQ5EX$*2_-XPO]\HLUU3U^QCV8 MMN78K6[+[O?:UM2]$7BS*(%Y0X6X#>LW73U/7#&3!`NM)3Q/@GS3'S`W@S"D5B\Y6S\/:5&[CA6!@# M17@1*CZ*Q?]E?N*GPDI$?"/[J_N1Q_>LEB]^U*O`;C+\HKYU,8S"`SVY37^J M==VZLX48>\,V[QE;3+'3;9ONPNWR"53MN7,SJ=&N[RO;^L'?.,N4!W?NLO7CB:`<(]72)!6W6W9:C:[UA457$\%WED\HQO@P^#M]?#`=_E-\V%!O"V,2%;;S[Q?K/2W\&*SP3 MM]9%!+O\GS;]8,,F^88WLSCA?[W+DH-KUYW_(4SX.-\@2+T/HO&WO\%8B@W3#\",KZ^!;,ZB%#MWJ.<<,UWV MA@(&`)CY*!6)`PWOQ-HO;D_/CRGU^&UC2=!=:7K^\_G1Y;;P[>O?M'^_C=NY/+$^N_ M?[O\_`GX2M.Z!,H`2@ZKU9'D!>1$;/.K`>AXK-T\JC3JO3DL<51[ABN\\Z/O_\ M^?3R\_#L7IVGI\1B5[5**POC6N] M@=5%5S`0L5UF`:[DT,`HF5=$P.!<$EF!P%NQD7=$DPFP/MN"-UA.NDD"+"FX ML[!2F'D(=03%SQ:;P`-%]EA$\I!T">[5O\0X10B_,CO"P=SY/(Z^T[W1EJMNL0$^'_JS;*;XW5P>7LO+A.9Z``!# M9Y7[U^\5FRQ!YZXS[PB7@=7CZG^1F M.7IT#[XE3I;Z?:2`WM9..4<[3LW)(<]/O^W=0O#C/:S;I-+.;B'Q\0'H7:72 M[HXA^$7RTMZ.(7'35/K2O?X24SL9Q]U)QE#O/CQ)VVK9;>?1$;A72M^;HO': M`AGW6RI;"11%G=!/X*4V7:6U%HN3!^["("#P(_1&=\@DX+ MY8Y%%Z_T.1.$9,77YGX=_7%Z?L9.\(^SJ]^LGY2#M-64#_4/SJ\_VU80CV=;MU!]/K60NQCZ`\V_V;(\3&QTC+@/:DFQ>5=K6_$,5AK#;N&6<%P"=F>=+U M:66AG]+K*OR`SR-TT9O8A1?=<>K?P%=".N)I>$8(A4=PB`M>2[-]^.L)(1L+ M:).Z:-WP$MH`":`I]F&5*LK!>V9;(KQVKP'J8S<.K/\1?I)8OXO073P>],P\ M'11C09P1703DRM-Q&.E.]"D,EUBW(@CPOX"1&]\3*F('6SV>\LX`/I(L2"E\ M*&FM;AKBS57T8AR,0M1D!0T9E$*P\H!7`HD$N$0VP0+I6%`P$4B-SA3\EX\= MA\GTF<,UU[=6`SPCS-6JB_9.0VL`)!<8,:VI_=&91FP2+F0+KN=2P$<3-F3'$DIK@KO MCJ?HF<9P:4#PN_$=2`$@JH/H.YR&@\2?S4>',)7#,`#KVO>-3^0L) M&FL<^T09/+$;ITK*5!%VC2`&-P()T$T1J(070+#*97&$ M_DK`CF-\PA>,XID0Z=)EA(!K9+JI#QP&&&T`Y!6ZP(TI*C%!Q?\96"P()&0) MEH`]CD@W*I,KGKTO(#M]CQX"]SB>^H+*QL<9@7M.,9G8MDYBAOAC%DPBI6I( MULD1%5QH&&;`C3`4;B5N`#1E`_`8BU-Y$S@'T/DX%L2CXD(,G2:XBL(,`S`< M?%'P5L\(1V4&:!V#3B<.,%$!-3UQBPP1=")@\[DDC;.0)8'B-;AW`J`!:D2& M4-=^G(?6&2B6Q="/<\3W%>.IA[,XCV)DO0D@/69Y/0Y`6)$`IS0&V$"03+!I ML*$3/\B%P]?&B`$_(=XQ3F'O,SAB2C,:11DJ!F'^'):+,'-UPX/[\W MK"\"=)`D"FU@AX!2WP-2"7@*6.1[,76#"4XP")A7G"/DB37R9SY0$KPY\M., M--^;AO5Y^&E@C?`TCE&<(X.UK=^C1,RGUI\-1:470#)N[%FG#6N4@@B$/U(. M+;Z/A9M]IWF.@<4##W0!,-I^@OLL:N3;U?_%:1Z,;PZ:A_U^Y^#W#Y^!.&\C M*V'(\OU).$4")''$VV0C8>+J*J*5QHW52@=F)0Y>_QT$-9P-,[:IQ);<^,0% MD53<]"KT#V9WM/)K6IZ)=SUQ&?>;Q3M-4XG['.\YUFVK&N]'S1;A_5?Z7J_N M,PP)^!@%<,#HR2<0'2[_K03O/93VE-6:_/`^2EN#RIQ?'(=6V^RTCB25D43B ML%G.'=@P,CB$I#M45]&U):U#$%)(?9*)P/]]$%=QD:RQH%R+5!^D9::_0D3JH7!-P0L"?%OI?%:O$J M-3&.9E64V$9*;!YI\5PA-'M::$I3&6S^;Z!ED<-CX@/Q>NX,#<>&!5+WLWM7 MYK92ZU\F9PTB8B$++_M,`,!M,?6I>,0TW\]))Y<)\&!&*7\T"!J[D2DI",3? ML\"$\8B)@`%E*B.28F!<:Q81F#`F:%!(8K2:`D@YG$IE`/Z(NX[G&W2N.V9: M7]1*"SL7S><1)UA)N"MFS#40^+TBJ:75M@UU"GA(@%ZV52H_*`_"G^M7!DR, MZ,KY)%)0XYAB\!'2JE)LZK;#&4V?!PA/`!\K'JJ7;+4*-(6*4VJLD]>=9 MH#]CA0:T)/Q2:G\.[@UKM7H_+.(D?%#1.15$2I_J M[6^`YJ&Y%:K\7@S*'^D:QAV42PB+=6<>>R`)ZSC716$T&`3]B__*/,Q9A>]) M_080,.7)M3#-,;:0,E]X=N?&++*BP0EX0A-M!A."_NQ'F=3#,2N-V#52@$=< MY,:_CH`Q)J"@,&<`TPBV(4FU4VH)5_O5FD:W,&7,/B^T^A"00`MML*Q@K\%R MBV@O/=0GZ36I]Z=W>@H8)L3N>D@\0&*"SRRFN>G1&M8`S$`/YDN$?FT<98'' M:?=`PD@4/KHGY5MB,L$`>4UH[R=9(^VV5U*%;Q7*C M7V;`TSR`-T`<`)7(_6,&)#^4RU+(M7,.-0:Y3RLG;\C,_89B%!:/N9">3II5 M:8R4SQZOW)2JA.F')>9N-C]Z9&@[0X`^O<.7?H34Z+Z1&KTV%G:$QRYF1??! M-KD\/_[CM_-/)\.+D:%J6,._?SV]_"<17YVIT*#824EOY/HZI-[V5KB=#?ZM MW;/:_25=^VA/H,U/K)9/&JI72=FOIYB1.QXC1V=[$&M?T)^I5"A026_P^((\ M'PM5MH1Q>?C?H2[OB";K:_L(XZT;<^U'FAL,%NAF\&>[T[,/N_U\Y'M&9;%& M(Y.W3R=?7X,)DR@>2P,92=H@$=XZ[48K1SZ08J#B7:%(EW]($[YU6HWNPL<- MZXOA7R]9$17[Q0$C-W\TQ]9Z../;;J/?M(0[GLH0+.\+Z\$WI%@+1M']&#+P M[BK,%Q#?;#A=6B:/J$3-.J/*:C.UG0C/!.!C-ZO^62H4ZA)+,/98-`OG2(D;3:G*:L6\?P48VV$% MP.&$M)OYT)Y[!X)WD-`YP\"?74W-3K]M'_4X,71=6F:#QO- MIL$::SJ,Y1TP.*THG*>%LY04CRL[-H!RW4`L'D3#`3I&$T4Y_22QPV&\BM+I M(@6Q=03F3?F#!*!&'Q!65Q>8GX+=X(]*BHR&QR1A*+)W0W%:&=;-5^'Z`1U. M+$GA;`]EVY(5"KM(=B9/DI109*Q2LQ'R:J+=GHQC_RJ/S%7@MDCJ$K_:P:HL M6^V)-XQ*H#Q!$7KEX*R)6GY3K@(39SZ7B>?2-@+%%UJ^G/28^!M8#_YN@Q*'2_BHL%JQ0=DS- MT"L%KVBHX5=VLYFB`0E$6M6:1,A_:I('@"J>?`TG))T&;Q8*,U#9 M/*QB'&Z^Z&0J@LD2]*A$`DRYY4)[I)Z0;AM0RFLN0(NJ5:7LK7Z9D,>I1^@^ M][EY`C)\F70XN\*9?>[L$`MX,G5O2&4+#:KV803T9$6P<<3RF++QM)#FB7+6 M>MMI+E&]/KLA'&9:=I;Z`26KD@*\$D-`D&5YBTA'FN%L'E8MY>="J<4@BH;20G^#W"MW$J+$MZ"A%9?9G-B!D@AMYITHA ME&93!E%F.6XE5H170$HU0CJHI(%>WT1!!D@* M$->N[+'BZH)YH))O2,]*\66>R>%ISG]1WFR<7$5Z@:PQFA;%VM@G8=JP?NRX M4BQ8.\.DARPFG\JB2H0.>VP\DDSNR..`#]?<=M:,0]#$R==`%).A89X[+O`` M$EN&H4+!@72ID0-H^+2L3289L6*#[,MVDZVT?3(!7*+]Q7R`/F<,V`B4>7H7 M3>]6%5=?JK\5%85TB?D&/+/=-_U#YM=DXH3C/(BF#-%;2L<#`E<]AUQN9*0\15)@/4<"J>=[I,TDE"H//S!2 M2@@O<=>\ZP]MOS*(0BRT,6K_.9Z\HB]&P_I:&,@VLTGRT51BB6#GV?(!FW;9 MEX,)T0N+*E5X6.JB9[7:&_EV,VCKMUVNLMH M(*86%J565V3EE3I<$9F"XA]D"=IQ4I`(N-KN'8)56_`*DT MQQ,ZVAS8)8.#4T99.2B0P"UI0!.A3BM)K7G)L5L!-.>PR71/S"TB1E&Y#>4R MS,+:C2%&6/4DZ9].B^E\M:2K=LEVHB)05A)=*W6_"2^Z#0T>4@%"3EB+9[+H M@&8%6`8F%LS=GJ(Z1/+JP)F&A_B\H3.6M`-0!O#L.+W*J/%@0BEPS#RE[J*) M0<2)L M(#=+IZ!]_5L>V5;7;O5:=K=]:$8XY$-#+>`"!Z=9/2?@5D\I]3\EQ:6PR&>E MXP66H?'*JHD?F*FU=I[09I*T9L#0?P&C"HY1(,XGU;/_0TK5UYNI=6@=6(]# MQ8ZX+A;3M<`8_L?@XF)P=CFJ/3&+O*3`B$".W9<(D\=V5[=NI!Z3,RQCEYTF M]@T<<8I>9S=:*^YG^9%GJ6I7\Y2+NC?31,=82-W7^6(<..>J3P=XEQ9V]"H7 M=HGFQ--75D7YKZ2EK'$K/`KGQ<+JMF-45IL2^!G)9/'>S4[/[A\^XY5#CP=5 M^D5>`JC=IV%UB7RHO]?D4"7R[A2-:@6XM3,WT^S!W?D>DQ^B>"+\=$_+>W!? M".^=ZU*1/;7NP7T*M;[TAK,28SO94'F_CMU:QTXJ'R5C<(6G=J?X_=X:K`/4 M>JS!E\[C-\57=N)VU/UB]NW>,8@_C\6-+[OA^,DX2V2_Y,45E`[X/MIU[^&4,L1(,>SG4)F!?4IUH<>5Z8=NL;@\O\@3 MDVWH[EH[RI@I%=SATWJ6*^ MG&>>W)^XKI+I"&+CSCLC4WWE`,V&=5*5Z7[_U!*!>H6Z2EE1`V8^]MIVMW/T M4%(H(8M&QF`53;BJ&4%5.X'EFVLF&STNU66S;:'D7;U?L,T79?W(CJL_0F.H M(Z,QU`/PL"-,>C'7Z*AA70P_#2Z')R!2+B[_B3?FCKY^PDMSK<''B^&0+M(E M*JP[#:RZ>1ZR49/P=QQ#LN@V&NE MLI=SG=BKJCAOWU-2NHC(:N#E,%/7QW[T!.\*]O@^PH;/\,))W@!]0DU>]7SR M-O?$O(0^E9U,5===51E6=^_?9IN^+Z+J_"\DL-+&SK-985&U9N`VINO2<4$/M6U@68GE$CAV<@N\DT4#29'Y(74@Y777N^J727:IW MJ=I?VWK;H[84.*'>0'*@E:R=$#2]VIDE+A=UE? M@JKY%9"W3UG@W'D2_N8K$5A=\/$W[&-E;+&4T%@0C$GGJ0BQ[@,0OVD=ZR%\ M`V^N"CSK'^YUB/U&ODP;)\_".A8;ZV.KC!.3D$V8&E2Z7+@<:UU6D(M>09G6 MBIW@1L<1U[4N&\_E8@&^C.-<7TXN+^/@_IZE6AC5^3FOF):MA`VBTGU"R\:Q M66I9Z!!D]+VF+RM1Q2+$)J1872!;9O[F1;5_,HT603?Y)2 MJ5SQ/%6>)1N']F$%76Y"D-9[(*C66!A(['Z M;X$3%N;`.J02HUIBD*QKTN0LL-5:&+N""3Z0NVZ3'0W`<+>&H/K&M7,AP]^V MYK^H*#FD"M MGJ.Q.[XK7=?#?>)5A235'C+QZ9L5\YO@63U!33C)KA+Q?YF\^@Z/'B@W3$#8 MPBG#`\6W`U1UGF]B:R0<=O*0N5-R2B9`>E$:/_"?$XRK&HTKM^3S"/N#>?85^BS)(UEJ5"OZ:[(-Z M+),IZH#,VZ5>U%2E_H]G,?>Z-@I-K3;#)P\9_$[7,MK!/=KOLVH%!>C7\X$\ MPO[>K`.$[L6&N*@M&)RQ> M\.LJ5;<^WX%V15?<8*;ZF1<"9.6VOE@\3?:*;HH1@(`-DPK5A,;YP_TS@LGH MMH2%^U[QH?Y3WIH9"&X[)6]8P)X5C"WCMM.X\OI`F@KW(XM3X_9&P)KQ[E9BU1R>(/0OVC>3<67!/IAWN)4OFET48]/8^++!2[*GE M2FMW)12+"LO+CI56Z24/DHF;U4QP,V(Q15YR(Q@$?.L5*R..H8S+X6_#L]'IGT/KT_FH_JC+*C[T&#^(>:[ME8;9V-PI*\">(\#(J6L( MZ@#(?O''A]^5LW+_-WP[CK;,A]A8^Q7W6'!:YG4XRY:]NZ>K!?K$U_>CX=^_ M#L\NK>&?SQ+2/)H0F.ZU@_<9@QR,/.D6S=@3._!0 MG]#=9+9S@?B76!Q\YNZE`P4X*Q/Y%8%Z'QKKX+RRL\HRDEOS0`/RTA!_&7$F M$C\(_/#;+Q/YZ!/\87VGG]*[.6!'>=G>R%\Q//%7\[1]OXH#.F\8;'V'C]_A MBV_TT`!/843J+AC%:D#@N<`>_N,4V.J!HWX,W"L1_/4-__B_P57PQGJW`.L@ M+@[LQF/U/?SS'D#E&^_0"CA0(ZK/D>:*L\MYHK^^44A$8&4_#<>$[@'+;54M MM[75Y;9J7&Z[:KGMK2ZW7>-R.U7+[6QUN9T:E]NM6FYWJ\OMUKC<7M5R>UM= M;J_&Y?:KEMO?ZG+[-2[WL&JYAUM=[F&-RSVJ6N[15I=[5.-RG6:EGM'I'!UQ%Z34]$3)YP[?AV,[ZH^,H-Z%*@ M9"J$:I:N4B^LO+7A?[TKK.)O"[]\@C_@5_P=@89__C]02P,$%`````@`U7-D M/^P[V)=Q"0``?V$``!4`'`!M96QA+3(P,3$P.3,P7V-A;"YX;6Q55`D``U(O MM$Y2+[1.=7@+``$$)0X```0Y`0``[5U=;^,V%GU?8/\#UWW8%EC'=M).FT&S M1>)D!@;2<9#L[/9M04NT38Q,NJ24Q/WU>TF)_I!(B;;',5WL4Q*;ESSWG,NO M*U+Y^9?768*>B9"4LZM6[ZS;0H1%/*9L;Q''PDC`JK/?L7B"^KS^4+0R31%W_:_0Z,%>GQ$MYPQDB1D@=IM M4\D-EF#+65[;^5FO^"ZA[,L(OD.`B7E[/7D4C.N)ATSKO= MBXXIV,I+OG^5=*/TRX4IV^O\]NO]4S0E,]RF3*:812LK58W-KG=Y>=G1WT)1 M2=]+;7_/(YQJEAIQ(6<)]5?;%&NKC]J]\_9%[^Q5QBW%@>`)>21CI)M_GR[F MY*HEZ6R>*-CZLZD@XZO6C"08['N][N5%5UE_<\NC;$98>LWB.Y;2=#%@8RYF M&G,+J7H_/PZ6X)4]2`M:$WD6\5E'%>C4U]%1`".<1%FB/[D'.!M`R6M*6$QB M`U75N5>+1>4T5?5TNZB-3/GU7S&+46Z,JG@-H7X$W.!$AM,%6,+)#LD>\1X_8X*8(:!C^T1`*_]SGT(*8&R,(,V>)KV=/TN,FC MC2\3-5)QL>E_@5`/1V,L1WI,@@%^@O&\HWCID"25YA/-5+O;*X:F;XJ/_WLM M)6#I9T(%EVD@P2.2Z&;+WW?>&)Z2$482]>/N]XP^XT3)>YWVL1`+F-+^C9., M6&![VI7#X%IL>H9%9"J'7S M3EZP"Y7.0U(IA^CLZ4?ENDRRGLRCOW_8.XV$3D#8>:`MAWH4DS-K;WN7JP@&W"):?0@H6P"HR$GO%3$W9<)5P(2[$N`Q)##W(>$GA+!FH$$Z\ M9K_9#4F'-:#U0^?Q^2X37<=Q4)OZ-:"U2P-'N6,M,1^A]3[\I&DMZOKBQPZ: M*O3R.M..VP12<]XAS!YA\R6H3?\:5M@:/Z4\^C+E"0"5:IN<+NK[A\/DV(+4 M>F)1::5-4&D`+S6<_+]MNC3OQ!J,*Y%M+7644&D.#BM6$R1!92+Z?#;CK);X M:I%`6:\"-90'E6.XCF&6TC`>,(T'K(_G-,7)&GK;5L;#*%!9?*`;H8+*2SR2 M%%-&XCLL&&43"9NS;*:X)3$L.VA$;0LI'Z-`A?*!;H1JS@F$/H';2ACOFC?9 MG=(C\[V>HC<<(2@>IY\['Z>O[!$?HU4-Z-O/#&?0^TC\71@/V0ML;#)@X#VY MY]*V8;66>OO>+PG$GGH&?4N>2<+U0Y_B,:>UX]>6/TJ?J*%[U>EK89L'M^YT M1_L((W-^3"\!S-?QC#(J4^7F,W&KTV@1JCZ-P(U"[F3),13Z1-+:+E[Z_BCL M6S$N$X`V:0S709UC&+!G(E/5:W.H`Y82`9]8'_&ZBH8G@!NK42&H3(A.&'_B MC&_&C7M$:C((3Y$FQ$:7YBS(P59/U<..Q>+IPG/QI"I`NH;P%D\@CH+W(/@S MA>9O%I\!_X`M1ZKK""8&UT.`;8S_/UE8>\:6Y)MN4T)O>DE0::!;,A+5J/-EM7U[M5=&(B[^JF4=^=7`M#_=)I*#4I5$[E>*GO5]') MJ^_GICFR'M2YF:HS.F)7-/AW=;OAR8MK=\N(&5;.J8K>C$C;]ERKW_CD!509P7PVR'E[8P#FE$JI%M M>=9I"]=,Q+IS7\=8-P#@B)!8?@`VGJ"S#L?P29PICXES!>AC=&I*>KAD%&S. MB/T)1ETK9X:!H-).#@?RVW<[CKI6XZ/V375B9ZCIEG>O1$14KE[(XNJ:=IN0 M>F:-2-:>:??(A.57NJQ5?:>(^F0#B&E\.-:0_H.%@`&_'&#^9B>DB;]31I:@ MKFVM(Q](F:D;N@,&7N+D(1LE-!J.8:<(WC=TK@;;$Q)T2\_,K?^@DEEF(5;$ MH'%!7[VN69+:BY^:=K7.&+F^5KK*8W!4IYMIFI(X/UJZ=.$#CM3VO'P58P?[ M$U)H!^^,9.ZTU%%V"LLP6T)N[E[EHBJG])]H,6*DR%.QTY&FO M=R(.Q02SXJ`">'J#)95JPT8D>%H\(?=[PYQ/38=X/Z)/NT43Q2&N=UW]3KE; M*J.$RTP0^&.]%OVZ1%T/&HZ1Q8/=Z?ZLUG9WL!F$L%/"^U%;MCH$C>4V*I2= MERD#"W74K8QK=W(>2:3>`EV'P:]1?JS.EZRF6@Y!7E.;%3(ORF3F M-:!5%W=R83A21RI@["IN3*GC,+Z<.HP/0:6CJ0J#WY<9!$.D+!&8HMP6 MK>/H>9K_)5EQZ5G8(:CV;KC#]KLST6D7_0!M5(:@+5?S8,VY+5].VB-F& MZ_1?+5[MU^M6#/YHC=7"ZN]H`]_N9*UR+7X4N1-.7X.8X@(WFEE0I)E0W$R@9M M0%O^EP#XXW]02P,$%`````@`U7-D/Q3]Y.OL&P``,'L!`!4`'`!M96QA+3(P M,3$P.3,P7VQA8BYX;6Q55`D``U(OM$Y2+[1.=7@+``$$)0X```0Y`0``U5UM M<]M&DOY^5?(X\:/P^V=7+RZ? M(1RZD>>'=]\_VR?G3N+Z_K.__?"?__'7_SH_1W]_N[I![W&(8R?%'OKLI_?L MNP]._`E-HMU3[-_=I^AL\AS=/J'5"EU'88B#`#^A\_-O7U^P7PEIXK])&/]- MY#HI>TM:7$A*0?\ZS\G.Z5?G5R_/7UV]^))XS^@[B*,`K_`6L<>_29]V^/MG MB?^P"RAL]MU]C+=B#$$<7U#^BQ#?T>:A\E]3^5??4?E_RKZ^<6YQ\`Q1RH^K MF52=UQ59&=.%)8R;*'6"5D#+G!0MM2OZUPW!54&,OZ0X]+"78Z9"%&W+GL%L M(A,:N15Q`36/*,ZEL6=^_^P!!\[OUY&[?\!A.@Z]:9CZZ=,LW$;Q`[.F\6V2 MQHZ;5M\<92-OYNKJ\O6K2_9>&@AB;<2>/XZK&)W8S9]#/FH4SB@NW(CXS"X] M#_@[Y>S;.'IHH5T:-6#Z/;@-RMI45(EQ$NUC%[=]WUPXZ0@()^WJ<'C^<=W( M%-CK^"%_%G)"#_&GH=+CT#_R!_[SKYS%R'HJ_L,>OG626X:`],EWCK.[H-9Q M@8,TR;]A]G)^>97U)G_*OOY]G"0X38Y;(GM?,B)[-J2&20U&3)%;!S(R#Y,6 M):/@;93@FS)&Y6L2V]`/X_5ZNED?FKLG>$%G7(Q(:)'V[7&RCV/JHB9F6:.% MLDX)Z+J1'A$"VJH02=X`V*X93DX[0CE>:%N>.,D]&67H?],_]OZC M$Q!4R3B=.''\1*;0OSC!_GB(:LAKW]8;*56V?2/&1J-Z3Z[0`%C=-0@3&]Q= M^@$?V*TZ22\:L`\E]A%R4I1+0$P$U"1E&>.=XWO3+SL<)IAHNDCO<5SI&B1O MQHC3OA,U4*CL0@9L$`YD#*MF?!DGPIPU888846[D9IVXP\18=:?N^F2L3!W& MC([&IJHG]:)1BN,!-1/@K-%D)@$^2]3.#B$$<#-"LYG@"#'4 MIW"Z4C[I1*_4]E`;[7"A6JHZJ<'F8X MU>$1=-"K'^RCR/ON![#V8L=IWC28JE5W$A`_"5W.26F4P^PMC1T//SCQ MI\2^RW10XX^Q,F77T3)!^(TAJ)K%Y7QHRQBIB;F4UZK'=`:?,2+&27RFX`4=;DK1 MV`&1Y!5(:.V[A!)TV0V$A!"FKP!2LQ@>N@-D()J#+`:`@APBQ=#]Y4+D#92A M&URF0)XB@,L-*"-8L&2`)@L`'/PW>F=V[?_&=V[]P$]]G)!H;9U&[J?[*/"( MF],0+'W2+,":L]OWH::JE;W,E!=DY;89N)K9WE!&C':>V.T-KA32CEJR76C7I>(^]NG_*M971@QBV&OR1;8N)@(FL%SV_[12E71"`"6Y=WC333>;@D>\J[5'B*A!X MJ-0B!0:&P4U3*F&R`G-(8K M\CS`7'&?KQG,]PZ+/N;9+A$/J$?*E9`X9YT!.NTE0U1W@BB\0QL8K`B8";D?S_5+N6K6>"*7%0JB.I;1/20I2UR//+"D.KDRV(I M2QNPE`=Q)NAE__[>^0!&KB;=U&!&*N,1"G@&J;4+/KL1#DOPHU*ST6@8D\E^ MWCB87^H5!/9!C>%]R\2CAN!%S=^CY:WFT<.#GSZP;;^A-XG"U`_O M<.C*/4C)`;"M7*]`93.YG!QD"[D.3KWD8/'APVSS83K?K$=HLIAO9O/WT_F$ M5N70*A9:H/-^O)DMYNAL'J48?6=W5:J%0@<.OIV\S`/E%HTKVH95P]:L:FU@ M=6J-*[G*#-]D=5Q6C;X7Q&B/""E! MSDB0`3XZ$^&8#.@,!#$,T6;Z+/1-*"DZ1W]^<75)%V31(V7["W+VZ7T4^_\F M)%>7H\M+]@\E]\20DK\@/TGHPB[;@K]/Z:&%=*O7&Q1&H=W*GC8J,](1/TUD MA&9,%2<<)[EQJ9SN%& M!U<#=)?6.F0>1/A1%",N@?L3(C(0$S(,CV)0DG'1F1F]ESH3M`?)U)![SC$' MO,>($>D]A8\YI0$)T&,:ZY!Y"N=#8X$.\-[!1\`&^N<,P_"**GR=1W#JH7A# M&8VQ)_A',Q8@+S#$7O6`(WAD$Y>OGMZ.5W+T??OOK?8BJ5"G8<,+YK[&;?7K%O+ZTG?,W?TI#" M^!+RAC&\$2>H8S6)W@W8@-VO8HIYA$Z0IR M8,\PC&VK'@$;G+=&/[2PO*:(,B:74@_`^N71N(1T$%:OC&6%%@\0A+="7;'T M`4V33(-O->,(!`>^QY/KV"R0F6CN_- MPHFS\U,G**DH>0DFC`!;_8W5J>SYUW*!;/XW1%7?\UPP(GI<_;D?(I?SVMW1 MWP-^RHD(_HQWA,J.!.4S*YPZ?HB]J1.'Q'63L>ON'_9L/_DUWOJN+ZNJ,F&T M[S/FZI1]1L\%X3.FJ$3G!.2$R..45IVE-?"<$>6&K,A22ZO(!ED5V+X<$K.KO]?4/Z[A.B<9ZMN$= MSRER7QT/\%X;!2;]QA&V!`3NZBVU$9_!.8R=.Z=N%ID4I'=XJ6[ MN5=!#W`2D0Y\Y2PB&3'(9@8-FOH!.3E]<0"7W4,5VN/-&<`W+*QP@HEQT8LM MK_$C#B)V(U`&3SKS5O)`Q)@&2E3#2P4#3&2I!22(S3@/ZSZ]`Y?ER+(C\!)7 M[A50W?Y['!+_#(@J8^_!#WWJF*G_B-7>H.6R[P^&BI0]0L,"X1-&D&K&E7$Q MVW(J?%;]HCOX*I_8-^QD6D[7$$#3NEGH1@_X)DIDV[:%E(!3N3I@X23N0`9R MF*0,AF(>%!`BF"E;`Y"<%)U1XI.D.G6!5O-;ZE,D46&6:)%F1@I@]M7NQ=GTH M7\3.R]W?.HGOTIR*'^Q3:9FLELN^GQDJ4O8\#0N$+QI!JAD1H^+9.$Y'AQ9F M5FA'#W+/J@RKFQ$L.'`[;8J*CV('Q0@=-,QXF_O+`PXTH?*U(6ZR.G=KT0FV!V@PLLR M>2@7B#*)B(MD]PXI]IR>OCLYJ?9Y'_,YU][)M`\+[YF[*;^(U]65Z\[MQ$$,O5NJ>[1 M_+RA%)`E[+8PZS7]1`K:!M'G!-'7B0YQGU.(L+O:W9MJ=++-U,M%H=LG=$:E MD9C\.3KD,`\2)>OD=M8_OH8`8NS]:\^S9,DF6F'JEGZ`*\@W43^]SFD>!;&; MXW2OK+K_H__G@/1MIU-$L$FC>!2_3R][V"&B(M_2SR[M1_:\ZQA`'PGWBHJ' MH7HNAOS<3W]K\XZ7'6ETG\TGZ<+S0Q2G_K]%TTLC#H@;7K0*5"]XD9+#W.^B M@2.X:N3`P=?\2SR6KWOI@GV$R%\!+M0HL[-[)W9QY.W=JE:6=XUD21SL3:(' MFOM7N86,&&#WB!)V90>)D!)D%XD"27T.2-X![6;=$JG=/21-T#+B\UM*C29" MQ):K[QP_I,/5(KSVDUV4L$V:B^TX27`J6U;2\`!4WIDH4:F[4S&`5-WI`=5+ MO1PZ^0J1QSB<@&9=MOX7FHUA;'8K[]HJD$V6B!XE1JK*^$B)[FJ\YFJ$^([N M0H1K#MME06Z,27]SC?G_I5EOM@-;$WDV$0!1.M14O6HQD2DW2.S7%%X]GW5/ M_J+'RE3"-&:/;)Y5NM[8;LC66;-<`#K+13RG6A["JDP,>$Q5UW098WJ&0WY- M8%9)0B;-K-Q$.?2V%38$OVRBMMI'323!E`.V1UHS\+-^XQ&+O M%3^7LW)G.<#PWZOF$M?.).8U^4QQ7J`%.548:)M#]W%CUXWV89HLG2=:BT0S M`JX;[\F[U-Y_V%;8$/JX)FJK^S@32
-%)@(\L@9A%M-#@*")@RI=660FTAZ)XAG_&T&>*%O$/H%Q1*J;L% M`>,P>@4I,*7)>>)+[4%ZA18:5#N%7,#7,,*V\2:%A"'XE%;!)@/NX/Q+`T\Y M":X&=8'(.@.]<>#KO"5=2MF',#;4MKA$Y8 M&:FMTAIH(6M_!:Q`&]^L-MT@^A2^7;R'*GJEH,'T,0;J&O0U"BE#JJ+7PM16 MT?NYA*%5T3=73=,)%0*'5-6Y=)ZRVMBQ^\?>CS'!3KJ4]&E)5$O'H4?/?61G M@4G>7A,!`)=6-E:OG8E`N8P18E)&Q4&M1_K9S/79;3G+'4H4@Q*08/I8PS4->AK%%*&E&+0PM2F&+:YA*&E&)JKINF$"HC&4 MIS;T3HG%CFZ92*9?<.SZB?0L+0,^X'A`I8PT'!`Q@4<#SM1JXPRE[[8LJ?^ZL0Q"?V/9\+F;)9/RFJ@2G$J ME@&/O1.PC,%H;&9:LG]N/SF[]6.M^E*I[M*?3Z62]I`JFSK!C8KTAFPR;N-9 M2$9L)UCN;P/?76RW.*X?J->"'W:4-%).-EHJF:%'30-P&K/<,19BE)P';,SL MKDDN`64B$)>!%C758-:WLDXCASF)$GDB6LD"MX:E4D&T:B6BAURGDN.IGW2: M;V:*,;\5-HU@?:6Y"L5:5#$Q*%R$L<&N/)VJ+7J<(=.;O_V4/)#?/%B$MN\< ME];.'5_ZV8(?<,YLJIQP\JQCAIE%FZ'2#".%D/P:W4-&(Y<#.J_^:I5L--.V MKZ6-/G`@:D+,?0I,9O.>8W+(.8\8NGB^4Z6%G>N(L!B-K1"]@]GU;J'KCT*/_T7[OT0EH/[HD(5_D'6^/DKRD9B+L]R]M5"SW,$WX(?J8 MYOB$9GKFE7;J'7:U,>NE5:?L`SX\P&J'TX..DUP1]J$D982X'"38M`C1Z8"W M9V^J[ACF=>K$:7.%QZ3KC>,GTDW^X@1[;:L>JX.<%-WB.S^DURFQ$FH&YF1: M3D/E#/5D.F)Z%)18.XMG(^]WNP"SW$-`T;X+HL^S#0G;6I2@9UE:2 MY<1Y-X6+%'H[,?:2Z5WP"0X?R$XQ.VR)52$14))T!9$*MY]A/H_LA MF'*9[NY!=^>@.ST^\9S-?DZCNS;U/DCE[4X2%O&=$V9W.DRB,(D"W\NOBUB2 MEYZ_OB*)YP1DZIBRGC>Y]A,WB))]C#?X2_J6P/PDZ>S[?PS`'>$G>E656\5[ M?@;(/>0GT:%^#?CJ_7@^^[_Q9K:8H_'\&KT=KV=KM'B'EJOI>CK?L%_L7F=N M2?/28T:H\B`VM2L_JK0:0.>%Q=/0X7'H'_2!B#WQGU]E/Z0)97J2_97U.*HP MJ!?!($%2C\B5?L4<>8ZB,M*YZ2L)0$;3B1 M32/4I):C(@WD(NR1T-F+:Y0`:C;PD1=I%_228<%27-(0^WI*!_[I>C/[,-Y, MU_9#B;[P]NI.DG%120GJ3*(Q2T%F3+]0'[H?XQ231[[4.@@`^4W6+$CG:@85)(S MB'C21&'=Y=Z-1`S3#967<3?@A[EDNS'`NA-BEY[[6S+=91R%Y+.;I4&`@CDH MU>PZX=2)Z4(_+9-@5ZSJ1CX%O7WWTH(O^Y*4&&+TTH"I%Z9,-^AFL5ZCY72% M)HL/'Q9SM/YQO)I:=8FFJ'-Z6BB$&,<@!IYC-32#C)P,%F2@4(,1 M%F+1BV29Y=`2\RC,#0AF-#@I?KOF?UA66&S+5VFO>%$_6V`]W,U=G,>I&1@Z M2[7O3#V]B++/=10),13U`KE>_+-93'XZ?SM>3Z_I>+6PG;E<25"HAZ+/G'H^KA!15!3(0!;5%JI6=FD MTD@"R#:5%@CKI?`D9)QM6%)S1,9CENRSZ9K5Y=S,-K/W]L?G?E0[".'; M5,IBAE9#8Z2Q9IQM*&.@7JD:11L)`!DT6R!4&>[HR&JI'=_XJ7\'.FC"*VEY M-PX=S^^CP,-QPC>SSZ,4FX^7#?@!=N0T5:ZR)\>4&6*`;`A.'*K^N+BYGJ[6 MWZ#ISQ]GF]_L;K/IJD")_YO\&`8J8FBC'X>F2[<>$0$D684P*ZG5"@5,0E4` MP<@R+FBH$N-[$JW0:SU8EA(JJ7IJ'3J6:N5[]+(3X6HNFA^SJJR);"'$KU?@493#:PK+3:6!W MP,MQDNGSRK^[3Y/JP*X9"8VY[0^1#14KCYV&K""#:B-L=6LKO!]F.#TA>KMN MDV5EETZHCC%37@JP*RLCA#5U]<*B8%NBD4!48$\.!F?^< M!+?>W#,4'O9_'Y,HWJ.1_+O`N9.[0X+=%W?1XP5AX9Y`/AP[@$"X/* M)=MM6YV&>3/+Z-JVN%I>]\;/Y"/^`$2?@,@C$'U&*U.XSE9[E_EYW_W8@42L M72-0ZI9;@)"H;?,KA'5O^UQX?K)_+^V^(73]-3>7!M/*94V.&Y?^UK5-#S)Z M;$HJM%7[3;EEGY#=L8E2SV:9(ZH5>ZF;JS$2B?`6(1!EH?F8>"HZ.M M:"7W9SC9#G7ZK&S;:H)*C^MB1WPZL<*[**8K=?3`RWW2FP5)I(/8CE+3(ZL1 MTG:T%X7,_BPEFQT63T'\,1TLY)T?X'A"9AEW4=S;^'(D%,(>A'I5S:!"TJWU M!:)Z:W0F&^7".S3U"M_Y-#L0IG/GH8=)H5@J1&.+-:NV=I6F6W.+9/76W@?A MB$KOT."_1,$^3)V8FV=OW7Y-+$232W2KMOD14;=&%PKKK=4+Z=S?NW3IO^(@ M^"F,/H=K["11B+U9DNRQ(KG=K/FEXB',0*-KU1PDQ-W,0BFT-_.@3SG_1!^# M\N<@_J`.AK+&IM+1DQTI^0/ MSR+R=-([\ET/0X!"-$Q:2*KC<8ZH1M@U8201V&/V*,L"9_E`]HP>[($FE4]B M#27!D+90TT]L"059/W9P)*Y_*V!K`4INB=?S]?_TK=R[=@8D:!D*/1HI1V]UH3\X&*TOL"+Z7CY4J&:QLBD MU/;M2@.\;$H24KO6HP2A,)C2A5G1%BUV.':R,\[!;:?D$/GUJ=KB&R4+:.\D M54'2*]7HP7HC"1)CHRHNKY4:%?]\0V#\P/XB'^BY<.2/_P=02P,$%`````@` MU7-D/X)`CU2Y$```6.L``!4`'`!M96QA+3(P,3$P.3,P7W!R92YX;6Q55`D` M`U(OM$Y2+[1.=7@+``$$)0X```0Y`0``[5U+<^,V$KZG*O^!ZQPVJ5I9ECV/ M>"JS*8ULIUQQ+)7LR61/*8J$)&PH0@.2MI5?OPV^10(@*$KB8WVR+*'![OZZ M&T`#;/ST\\O*TIX0=3"Q/YX,3L].-&0;Q,3VXN.)Y_1TQ\#XY.=_?_O-3__H M];0_/DWOM%^0C:CN(E-[QN[2_^XWG?ZEC+.OFD.T!+[*"W\]-!^)N%[;]F\)L&/-G.AQ<'?SQ9NN[Z0[___/Q\ M^GQQ2NBB?WYV-NC_\=O=@[%$*[V';4<,W?4%2I&_S*@5 M=7#1CY\E;,'^ZT7->NRKWN"\=S$X?7',DX!%A?Y/(F'8%SQQ!I>7EWW_UQ.F M`THL-$5SC?W]/+V-*5;(8E``-L@Y-.'BUME#TW9*B^<<3UB<(-AB<75Z<,;&^D_?73S-8OO,Q M7>@V_MOO#!X`5H"=\7Q"D0-/#!^A)K9*3Q69_>R@\?S:<3$(CQQ5QK)4%9F8 M(H.!81C$`S3LQ802&SX:B&&DS%11+Q69O$?N'7&<":(CLEH1^V&I4Z3*FX"X M(DL/+C'^\J,,]+I&ME/*ND34%9EB`F+7U_F(^$#`EP2RX3QX?JK!_&@E`XSE!69^:)3JIOU4!J(\G<_(.C6RW,%SPZ#AS7*H;;M21I<^0%?2D2-=79B_4JC^I MG9Q^T$:H]UZYE>L_QGRC^_,B*'WF4"7F#'4.W_H-T*@XUXJ:M4;]8A`2!'VLQ M_2_(LGZUR;/]@'2'V,B\=1P/4:$+"-NW!HL".1)`+FL!Y'=B>:!!NKG!%JQ; MA4#DVK4,@!S_L>('9_4,`H&/3M&:4+8F?@`M>F+]BYJW#`:1&`D:]0S)OE6, M($0N"!4/R)E6+=-]AOM$Y<<>C$-3")*?+&GF9T"=L>>R;0VV#2-V`RE1RP"1 M"Y/@4\_:8.+-+&S<6$3/)C\$;5JF_2W>$V4?.\40"1!,UH+UX0U\QQL*)&U; MHWR)#,EK M,T05<^9;O4U\72^1BPTF\@[\9'JHO!,%8[6_2S*>C]?L]`&H73VM+Z#>(U,C MW5E"_'S>B:<4L6R_(9/J5]^%R!C*]K;#0.MI,3/P>42@=YN=T`C)M)!NIZ@S MUYV9[\J>TUOH^CH(/B;;`P*O_XSYFD\O\$V,((A1!('2W8B@!M%LMU" MZ.["#!T'5"AA.]O@V"%4775)!.7Q'0;.P6DN;((PPI34.X$I4C85;B?L0[#?[!=M%M#:H MBT!M"WQ\H-[N&2CBZE9M/DE@ZNUN)C"I]!=I$)/6;+9QC_C.*&O>O"%5SF\( MY[LN!=E;4+V]P#,+!9H!0:]?#,MC*;M?"#&?L65Q@%4C:Q[`:GR'0+_O$M!7 M(:O!H@"-B`/2$]L(8A7??15HF@>Q`M,AOC]V"=_41"&1EH.IH%WS9`G;0MB2%UB2)+&'0K M[9!20''F2-:X#L3+FC('=5%V:7!^FM]D;S'.X8M5SD3?Z#`YE*Q$!0UKQK=H M72K@.D*S4WDC$)9ZP&E..WPX16T;CZB(\0C4/>>'&C"]58)4V++9@`K9CN#< M=Q:IQAFO$H[M@U"&WIZ31@V9(2<+,[5I$:]]2V=&/%$BL-]W:Q(<952F(.P( M_F)7FF&0-Z\9;K'%9O-'?/8CB/><.VI(-);B*FC7>$`%?$=([CN3U(S(+,>O M=M1VC;K)\88.I9Q2=2#85G^Z%`3O1(.L=9M@E0H2P6N/]#6&L3TE/2\/J$#4;'15)(CPWG,JJ5Z\I\C5 ML8W,:YW:,(%PAH;AK3R_2A,LY;"!>8.K"E&S\5:1(,)[W\FG&A>KO)ID"E.G MIJ/)XSA";\_'D!JR0.7.(7?85&_79+A8F@CU?2>8LJASWWT[Z#M+F9?)PJZC M%YA4WV#2OM_JYX<3[?65IM?3+IS0^WK:Y?6TR^MI%_Z&CH<>R7`^!['!2\1; ML()VS=Z%%3"=G(IX32@V(T2_)A1W3"C"!&A,_0'.]!,Y$T3#DML%.48Q8;-7 M1ZI2))G(#OGXMO!!79VAYRY!FK^3R;@0\SQ!F[#._<6<0''V(JQ9(ZN/)FE;AV,5:#M^,T?,=5PHK5/;`%-` M`33(ZDY=H2=D$;\$2B@]]S"%M'T=T!9:97*,0LI[7$RM0P=F@IL_+9!X:*ZP M[=\DXN(G)`:XD*+1$!=R?YCB:76>DHEU$X2XX#HV<3A.MVHTE%R.#U0.K<9C M,K?V$W+\D_&!G+$05,WV8BFD->'7YGMADVWC%X;:(H,'( M%K'>Q1)J]\B5AMG,[PU&+\/I8E-JIUE5#0:XFU&$JJ34A M'90JQ;^=#;I0S`:Q#C2_ASJS0:DSC+%$:B=,.B@XS&/::5.'T46E=2\48B]&&R:S4?FPY70\@+:;E?=&PSI8WM*^RLPU>#QG-A->:"]ETUB0*Q]YS0NPPLPT8+=I"LMO2[ M01$XP14*_J;T%;Y5+]^85R;NJLV4T4&<9.S4K".O@4EPLT]478Y[PX^2.:EU M5%/&JJ3?B`U&3C3J/2@C$#XYN5=R_DW;2TOT[J4SRXA.M M7>7"##M,)`R-KQZF2'A_)L/(.CN$HC2%NMHHR$R04C79]G MA$7;JLTSI)VT=)XAE2FYG:1;\XQTX&1OMXY]J9SK%T0-[`BJI!32-"A>*)@[ M=Q3A"W:@JTWV?+`W+4C$_'CNB_1%IQ2F2-D!09VL?="JRW:@&U#JKI232,[* M$;"*K[L M+/G-6VH"4IGD90^/OGI4"/C!Y3_0>5#1(M;$C6ZPG&NV$O@.].W#>0`/"X!/NL5<8P(S'6)F-^\X]E&.O.GI@'+2'.KFE\99PQ`\A-(-.(/PFBXU MNG;BGQ/C0)?&K'T[`WZIVT7X_QQTQ`"8(`>Z028P@6N[KKG"@[=>6[ZR="M2 MUJT])W2E%UV]HDK9=!-0%B0R@TU.D"F8]$<*<=;VVX M:T^U0%[.DN.EX:XR1B_V'3YA>)0W_<=TH=OA^VD0$%G]`X=MI29/B347OO;_ M[NR,72]UA1W#(HY'$?R3[D73;7;-%/2CC>?:5D_'KA64XFI$;(=8V(P$3?.5 MNM4HJ5P@J[RXGWZ/7CJI"ML)W(]@99\L_LV?^W]$+174]FDW<3&GO:LFKF/0 MB4#TF6W.7#LNAKB=9"A20><\&W2`@I4726BJIE2W61`$`&G+REG=[8Y%KB9O M>FR74=!=/.H*F>Z6,4^1`=V%[\[`W&)"B0T?C<";.<9]D37NH`M4-!>YDPUY)^EK>5-T!O[A" M1CGQNN7*]\AEK_%.$`T+PJ=I M/J;(OR/>3QWX&/JL1ON.$D>KVN&QW5&9WT]I?F5.6[G'.EQ[/W80EPJJJH)N MA8G@@(8O(RR0V70#&@3WF=YA%R]$4>-=-FJD.OJ7MM65!GUIJN$C-ZTK0UC*=+GE_M9#Y;CE3]E1_RH5^ MS+I0W/;(5AD]%V+=E!72=K:QD?B3,F7EC.N#L42F9T5O!N1,*>)$FHO=H9,Z M7*DD'G'6=@?QNN5LX8Q\HE-WPS9O/,M_F7!!D3"C>YG/Z/I]:'XG6M*+ENKF MR/Z9%NL1$'3TPD1N,79^0]"%#40$QNF9FY MM`]4?25#F=XK-IT9\FKXFHSOR>4E.9)"`.=P3X*@(#FD&K%2>+:M;C_/T]$, M$DK0(Z$'G9DQZ5X8WM[>=F^WNU)-PZU>KQ]^_G!VY>PZ+U\0_#GKO;NQXJR& ML2D%:CMD0ALJ(JB!.!-?'\#8[#&Z6B]H`90[U]_=W0U=;FYOJ)J".:<)Z)1& M,,DARN$4+LP\?+T_9:L`;AD8PR*_Z!B(^%8>;^%,E4XN@[A,6#SH,6 M^S8,7W`,$R:8R+RN[H>4VPY]-0,PV@M=3VI1%@<;IO:KWK9;\EIDWVI5O>0AF[?N]A6V,A1&/VT0=[2I` MP0P7`NP&["IL/N,UDMLU7=@:UL!N:;>)REYE8PW?,@SG^*8<&A92VW5=V`J6 M6.+!/[FLA;#VSZY)+V%"W!70GKUS&'0T2U*.W=NGS11,!AVK=5#YN46#%1%"R0+-U1AJF0*RN!R+2Q\+P@,,Q8^+$LAMAA< MYE&.?H;[Y/E18W4^->IF"_A.85>/?O[YN#D=/S5NA`#_C@&?6?XED8:5:[&P M?F&&84IEB%BXV7S@VI7XN]TS&3F:!R#V+2AP@4T*^EO!=K][IV/KW-,<**-^ MF@,%[CD.+-P]KN1#$V4]V+4>]'<*#\@:+E1O3I_FAA3GZWDRH7KLN)9>_K8X MX1RH(J>4I@X8`C=ZSA647$]V9D[Y?%]LRE-=J5V,Q\!6=J6)L0\MA=O/+/*O M`G3^=47^ZAQZ^%+Z8*R-HI'Q$[X=PKZL9N['0?<;!B,KYV-'&F\A,,FA,9[A]N,3V`]3(#ZX`46G@$UZ#&HT<<=T>I09.][8CUXJ,:_- M4)/!9:\L0S.TAV0)%VOU0LD((-8G2B;'=Z`B9H_MW%J)]'/9OA1TI MB%OB/H()*,R>>SN4VNCAS'YG%%_+@SAVJUW*+RB+3\60ILP4-_>^$Z])\!_4 MHGX==0UWYI!CLZT$VVKAH_'?&^V9(OU']="Z6TM&VC:#YB#XC+'VF2'8S^_B MC!=#1>U`\UP:*,:.9;6R!O9'UU?HIV!\_!M02P$"'@,4````"`#5`L``00E#@``!#D!``!02P$"'@,4````"`#5&UL M550%``-2+[1.=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`U7-D/Q3]Y.OL M&P``,'L!`!4`&````````0```*2!/E$``&UE;&$M,C`Q,3`Y,S!?;&%B+GAM M;%54!0`#4B^T3G5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`-5S9#^"0(]4 MN1```%CK```5`!@```````$```"D@7EM``!M96QA+3(P,3$P.3,P7W!R92YX M;6Q55`4``U(OM$YU>`L``00E#@``!#D!``!02P$"'@,4````"`#5`L``00E#@``!#D!``!02P4&``````4`!0"_`0``*X4````` ` end